













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 




Utilising Stimulated Raman Scattering 
Microscopy to Study Intracellular 





Doctor of Philosophy with Integrated Study 
 
Optical Medical Imaging with Healthcare Innovation and 
Entrepreneurship 
 







This thesis is submitted in part fulfilment of the requirement for the degree of Doctor 
of Philosophy with Integrated Study at the University of Edinburgh. Unless otherwise 
stated, the work described in this thesis is original and has not been submitted 
previously in whole, or in part for any degree or qualification at this, or any other 
university. In accordance with the dissertation regulations as specified by The 
























I would like to express my gratitude to supervisors Professor Alison N. Hulme and 
Professor Valerie G. Brunton for their continuous support and guidance. Alison, you 
welcomed me as a keen undergraduate student to do a summer project in 2015, and 
it was your infectious attitude towards research that inspired me to pursue a PhD in 
Raman imaging. Val, I have learned an immeasurable amount from you over the last 
four years – thank you for always challenging my thought-process. I am extremely 
grateful for all the advice that both of you have given me throughout the last four years 
- it has been a privilege to work with two amazing female leaders in science. 
I thank the EPSRC, MRC and the OPTIMA doctoral training programme for the 
funding which has allowed me to undertake this interdisciplinary PhD. As part of 
OPTIMA, I was extremely lucky to receive bespoke training in healthcare innovation 
and entrepreneurship as well as an opportunity to carry out a three month internship. 
The training provided by OPTIMA has broadened my horizons and positively 
influenced my future career choices. Thank you also to everyone at Swedbank for 
welcoming me for an internship and introducing me to the world of banking and 
financial analysis.  
Special thanks to the Brunton/Frame group for welcoming me to the Cancer Research 
UK Edinburgh Centre from day one – you helped a taught medicinal chemist become 
a cancer researcher. Biggest thank you goes to our resident microscopy expert Martin 
Lee, your support through the good and the bad times has been invaluable! I would 
also like to thank Henry Beetham for all the help on spheroid work, and for always 
being willing to discuss my research. Thank you to the ECRC lunch crew (past and 
present members) that turned into QuaranTea club (Martin, Henry, Robb) during the 
pandemic – you made my PhD experience a lot more positive!  
My gratitude goes to the Gammoh group for explaining all things related to autophagy 
to me whenever I had questions. Jane Fraser and Agata Makar – I appreciate all the 
help you have given me! Joanne Simpson, you have been a beacon of light in daily 
lab life – thank you for always listening, giving advice and making me laugh!  
I would also like to thank all the past and present members of the Hulme group for 
their support. I might not have done experiments in the School of Chemistry during 
my PhD, but I always felt included in the group. Special thanks to Marie Bluntzer for 
your help with the DFT calculations.  
IV 
 
My thanks go to all support staff in the Cancer Research Centre whose hard work has 
made research run smoother. Thanks to Elisabeth Freyer and Stacey Riddles for 
helping me with FACS and Dr Jimi Wills for LC-MS.  
A huge thanks to my family and friends for always supporting and encouraging me 
throughout this time. Thanks Mum, for being my biggest fan – I would not be writing 
this here today without your unconditional support. Speaking to you daily has kept me 
sane and got me through every hurdle on this journey. Jaanika, Margus, Kristin and 
Nora – thank you for helping me re-charge my batteries in Estonia whenever I needed 
to take a break from it all. Thank you Resa – you checked up on me daily, proofread 
all my chapters, and always reminded me of the light at the end of the tunnel. I can 
always count on you to be there for me and am forever grateful to have you in my life! 
Finally, to Lindsay. You have been my rock throughout the PhD – providing a shoulder 
to cry on when needed, but always believing in me and encouraging me to keep going. 
Thank you for keeping both my caffeine and blood sugar levels high throughout the 























Despite advancements in the drug discovery process, drug attrition rate in the late 
stages of clinical trials still remains high. Better understanding of drug efficacy in the 
pre-clinical stage would potentially translate into increased clinical trial success rate 
and reduce the economic burden of failed trials. However, visualising intracellular 
drug uptake and distribution at high resolution to improve the pre-clinical drug 
discovery process is still a challenge for scientists.  
Stimulated Raman scattering (SRS) microscopy represents a powerful imaging tool 
for visualising drug molecules inside cells with high resolution, without the need for 
additional labels, or nanoparticle sensors as used in many other optical imaging 
technologies. It provides Raman imaging with minimal spectral distortion and a 
quantitative output, allowing accurate determination of intracellular drug 
concentrations.  
Ponatinib is a clinically approved tyrosine kinase inhibitor that targets BCR-ABL and 
is used to treat chronic myeloid leukaemia (CML). Drug resistance is a widespread 
problem in CML treatment, where ponatinib resistant patients have very limited 
treatment options. Ponatinib has an alkyne moiety in its structure that makes it 
inherently Raman active in the cellular silent region of the Raman spectrum. In this 
thesis, SRS microscopy was used to image intracellular ponatinib label-free with high 
sensitivity and specificity in live human CML cell lines, in the context of ponatinib 
resistance.  
SRS imaging of ponatinib was optimised in Chapter 3, enabling ponatinib imaging at 
nanomolar treatment concentrations as well as determination of absolute ponatinib 
concentrations in both ponatinib sensitive and resistant CML cells. In Chapter 4, it 
was determined that ponatinib is sequestered into the lysosomes, with a higher 
lysosomal concentration found in drug resistant cells. This was associated with 
increased lysosome biogenesis. Target engagement studies showed that treatment 
with chloroquine reduced ponatinib accumulation in lysosomes, but did not re-
sensitise cells to ponatinib, confirming a BCR-ABL independent resistance 
mechanism in this CML cell model.  
To demonstrate further utility of SRS microscopy, it was applied to spheroid imaging 
in Chapter 5. CML cell lines formed three-dimensional (3D) cell ‘aggregates’ rather 
than spheroids with tight cell-cell contacts, and could not be used for SRS imaging. 
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However, spheroid growth was successfully optimised in a breast cancer cell line 



























Before new drugs are approved for use, they go through rigorous regulatory pathway 
in clinical trials, where the safety and efficacy of the new drug is tested on volunteers. 
This process is lengthy – an average drug takes up to ten years to get from discovery 
in the lab to being approved for use. Clinical trials are expensive and many drugs fail 
in the last phases of the process, leading to denied approval. To increase clinical trial 
success rate and therefore reduce the cost of drug development, it is important to 
gain a better understanding of drug effects in the pre-clinical phase. One way of doing 
so is studying drug uptake, metabolism and localisation within cancer cells. However, 
imaging drugs in cells with good definition is still challenging for scientists.  
In this project, we demonstrate the utility of Raman microscopy for drug imaging. 
Raman microscopy enables visualisation of specific bonds inside molecules, and it 
allowed us to study ponatinib, a drug used to treat chronic myeloid leukaemia (CML). 
As drug resistance to ponatinib has been reported in CML patients, we imaged 
ponatinib in both drug sensitive and drug resistant cells. Ponatinib imaging provided 
insightful information on its intracellular localisation, uptake, metabolism and its 
resistance mechanism in CML. To demonstrate further utility of Raman microscopy, 
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Chapter 1 Introduction 
1.1 Drug attrition rates  
Drug attrition rates in the pharmaceutical industry are an increasing problem due to 
the high cost and long timescales associated with the drug development process.1-5 
Despite increased investment in drug research and development (R&D) in recent 
decades, the annual number of drugs approved by the US Food and Drug 
Administration (FDA) has not increased proportionally.6 Although significant advances 
have been made in the development of tools used to identify drug targets (for example 
computational modelling and screening) and molecules that interact with these targets 
(for example high-throughput target-based screening for key proteins such as G-
protein coupled receptors and kinases), drug attrition rates remain challenging for the 
pharmaceutical industry.4 R&D spending increases annually due to multitude of 
factors such as inflation, increased regulatory control as well as higher failure rates; 
as a result, the cost per new drug has been increasing since the 1950s at an annual 
rate of 13.4%. Thus pharmaceutical companies need to increase their output of new 
medicines in order to secure a sustainable future.6 
It is a common occurrence that promising pre-clinical drug candidates fail to translate 
into clinical successes, demonstrating the ineffectiveness of current disease models 
used in drug discovery.7 The major causes of attrition in late stages of the pipeline in 
recent years have been lack of efficacy and safety concerns (Figure 1.1a).8 Failure 
due to lack of efficacy could be decreased by improving existing pre-clinical models 
that are used to estimate drug efficacy. The greatest attrition rates by therapeutic area 
are for oncology and the central nervous system (CNS) (Figure 1.1b).8 This could be 
attributed to a poor understanding of the underlying mechanisms in these diseases 
as well as a lack of reliable and disease-relevant pre-clinical screening models. 
 
Figure 1.1 (a) Of the 148 failures between Phase II and submission in 2011 and 2012, reasons 
were reported for 105; the majority of failures were due to lack of efficacy. (b) The 105 reported 





Standard cell-line screens and in vivo xenograft models fail to mimic key 
pathophysiological features of complex diseases such as cancer and Alzheimer’s 
disease. Cell-based disease models still largely rely on cancer cells or immortalized 
cells grown in artificial environments. These cell lines have been cultured for many 
generations, resulting in altered genetics and lack of similarity to primary tissue cells.9 
The use of high oxygen partial pressure (approximately 20%) during experiments 
does not represent the true microenvironment of the diseased tissue, which fluctuates 
between 1% in the dermis and 14% in the arterial blood for humans.10 Differences in 
culture conditions, however, can affect cell metabolism, mitochondrial function as well 
as cell differentiation.11 It is hence necessary to improve pre-clinical models used to 
study drug efficacy in order to better understand drug uptake, distribution and 
metabolism prior to moving on to clinical trials. This would enable elimination of 
unsuitable drug candidates earlier in the pipeline, lead to safer clinical trials, and of 
course better use of time and financial resources. 
1.2 Visualising drug localisation  
In addition to lacking high quality pre-clinical models, scientists are still unable to 
monitor intracellular drug distribution and concentration accurately. In drug discovery 
and development, it is vital to analyse the drug candidates’ uptake and distribution in 
order to evaluate their potential efficacy.  
1.2.1 Currently used techniques and limitations 
Drug distribution has traditionally been investigated in target cells/tissues by utilising 
positron emission tomography (PET)12, magnetic resonance imaging (MRI)13, as well 
as whole body autoradiography (WBA)14. The majority of drugs do not accumulate in 
tissues at high enough concentrations to be detected by MRI, so it is mostly used to 
study the effects of drugs on tissue morphology, physiology and biochemistry. MRI 
spatial resolution is about a few hundred microns and 50–60 µm for human and rodent 
imaging respectively.15 PET allows drug distribution studies of radioactively labelled 
drugs in both animals and humans, and has been successfully used to determine the 
pharmacokinetics of radiolabelled cytotoxic agents, such as [18F] fluorouracil in 
individual cancer patients, before initiating full-dose treatment.16 However, PET has a 
spatial resolution in the order of 2–5 mm, which is less than MRI. WBA enables 
radiolabelled drug detection in whole animals.17 Although it allows imaging with higher 




range from days to weeks.18 The major limitation in applying MRI, PET and WBA to 
the study of drug uptake in tissues is the use of radioactive labels. These techniques 
only provide data on the concentration of radioactivity, while the actual molecular 
identity of the radioactivity is not known and the parent drug cannot be distinguished 
from metabolites.  
Recently, matrix-assisted laser desorption ionization with mass spectrometry imaging 
(MALDI-MSI) has been applied as a label-free imaging modality to study 
pharmaceutical uptake and metabolism in tissue sections.19-22 MALDI-MSI combines 
the resolution of WBA with the molecular specificity of mass spectrometry, enabling 
the detection of both the parent drug as well as its metabolites in parallel. MALDI 
requires matrix application on the sample to desorb and ionize compounds with a 
laser. Matrix selection and the method of application influence the sensitivity and 
spatial resolution of MALDI, and need to be optimised for each drug. Unfortunately, 
MALDI-MSI has a relatively low spatial resolution of approximately 20-100 µm, which 
prevents drug imaging at the cellular level.23 
Secondary ion mass spectrometry imaging (SIMS-MSI) offers a complementary 
method to MALDI-MSI for the acquisition of higher spatial resolution images.17 SIMS-
MSI can achieve submicromolar spatial resolution reliably, and is suited to detecting 
small molecules with under 1000 Da molecular weight.24 Therefore, it is unsurprising 
that SIMS has been used for subcellular studies of drugs such as amiodarone and 
boron neutron capture therapy drugs.25,26 However, like other mass spectrometry 
techniques, both MALDI and SIMS are destructive imaging techniques. 
Unlike MALDI and SIMS, confocal fluorescence microscopy is compatible with live 
cell imaging and has enabled imaging of compounds and biomolecules by attachment 
of a fluorescent label to the molecule of interest.27-30 Confocal fluorescence 
microscopy has a spatial resolution of 150 nm, allowing subcellular imaging and 
detection of cellular organelles such as the nucleus, endoplasmic reticulum and Golgi 
apparatus.29 This imaging technique is highly reliable, sensitive and widely used in 
biomedical research. The use of fluorescent labels to study drug uptake and 
localisation, however, is limited by the relatively large size of an average fluorophore 
in relation to a small molecule under investigation which can result in perturbation of 
the molecule’s intracellular behaviour. In some cases, drug molecules are inherently 




1.2.2 Raman scattering effect 
Raman spectroscopy is a non-destructive analytical technique that is used to measure 
inelastic scattering of light from molecular vibrations. The Raman scattering effect was 
first described by C. V. Raman in 1928, who observed modified scattering of light 
when irradiating samples with sunlight.33  Raman scattering is a rare phenomenon - 
most of the light absorbed by the molecule is elastically scattered at the same energy 
(ʋ=ʋ0) (Figure 1.2a). The elastic scattering is known as Rayleigh scattering. Inelastic 
scattering has an extremely low probability of occurrence, only ~1 in 108 photons 
undergo Raman scattering (Stokes and anti-Stokes scattering) in comparison to 
Rayleigh scattering (Figure 1.2b).34 
 
Figure 1.2 The principles of the Raman scattering effect. (a) Incident light (ʋ0) is used to excite 
a chemical bond within a molecule (for example C-H bond). The majority of the light is 
scattered at the same frequency, but a small proportion is Raman scattered at a higher or 
lower frequency. (b) Energy level diagrams showing Rayleigh (ʋ=ʋ0), Stokes (ʋ<ʋ0) and anti-
Stokes (ʋ>ʋ0) scattering. Rayleigh scattering is the elastic scattering of photons during 
interaction with a molecular vibration. Raman scattering is the inelastic scattering of photons 
following interaction with a molecular vibration, and is detected as a Stokes photon, which has 
either lost energy (Stokes scattering) or gained energy (anti-Stokes scattering). 
1.2.2.1 Spontaneous Raman spectroscopy 
Spontaneous Raman spectroscopy is the original form of Raman spectroscopy. It 
utilises a single laser to excite all of the bonds in a molecule, producing a molecular 
fingerprint of the sample. In contrast to infrared (IR) spectroscopy, Raman scattering 
of water is very weak, making it an excellent tool for studying biological samples.35 




2850 cm-1 and 2953 cm-1 lie the CH2 and CH3 stretch of the cell which are indicative 
of cellular lipids and proteins respectively. Between 1800-2800 cm-1 lies the so-called 
‘cell-silent’ region where there are surprisingly no diagnostic peaks from the cell 
content. In the fingerprint region, below 1700 cm-1, there are a number of smaller 
peaks present from the cell content, including the C=O stretch from the protein 
backbone (1665 cm-1) as well as the sharp aromatic ring peak from the amino acid 
phenylalanine (1001 cm-1). The laser detection system for spontaneous Raman 
spectroscopy can be combined with a confocal microscope, enabling spectral 
acquisition at each pixel of the sample by raster scanning.36 The spectral data can be 




Figure 1.3 Raman spectrum of pelleted CML cells. Pelleted K562 cells were analysed by 
spontaneous Raman spectroscopy using λex = 785 nm. Characteristic cellular peaks are 
shown: CH3 (2953 cm-1), CH2 (2850 cm-1), C=O (1655 cm-1), phenylalanine (1001 cm-1). The 
cell silent region (~1800-2800 cm-1) is highlighted. 
1.2.2.1.1 Raman microscopy application to drug imaging  
Raman microscopy has been applied to drug imaging. A number of chemotherapeutic 
agents have been imaged intracellularly. Examples include studies carried out on 
paclitaxel, topoisomerase I inhibitor (CPT-11) as well as theraphthal and metal-
carbonyl complexes.37-42 All of these studies were carried out on label-free targets, 
where characteristic Raman peaks intrinsic to the molecule of interest were used to 
detect the molecules inside cells. Table 1.1 summarises the parameters used in each 




studies shown in Table 1.1 has enabled further understanding of how these molecules 
behave intracellularly, and hence proven that Raman spectroscopy is a valuable tool 
when it comes to label-free drug imaging. As Raman scattering is a very weak effect, 
the majority of these studies had to use drug concentrations that were in excess of 
clinically relevant levels for the Raman signal to be detected. More specific examples 
where Raman microscopy has been applied to imaging targeted cancer therapeutics 
are discussed later in Section 3.1.2. 
Table 1.1 Comparison table of different chemotherapeutic agents that have been imaged by 
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1.2.2.2 Bioorthogonal Raman labels 
Bioorthogonal chemistry transformed the field of chemical biology by allowing 
scientists to carry out reactions within biological organisms with excellent selectivity 
and no toxicity or perturbation to the living system.43 The term bioorthogonal has also 
been adopted to describe Raman-active tags, which vibrate in the cell-silent region of 
the Raman spectrum, typically at around 2100-2300 wavenumbers, enabling 
chemically specific imaging with minimal background.44 Raman tags are used to 
enhance Raman sensitivity of the small molecule of interest. Raman-active tags need 
to be exogenous (i.e. cells do not have a naturally high concentration of these 




Two main strategies are utilised: the first is the use of bioorthogonal Raman-active 
groups (e.g. C≡C, C≡N, C≡O) which are either inherent to the molecule of interest, or 
are introduced chemically for imaging purposes.45 The second is the use of 
isotopologues, which means compounds that only differ from the parent structure by 
isotopic substitution (e.g. C-H to C-D).46 The advantage of using Raman tags 
compared their fluorescent equivalents is that they are generally smaller and show 
greater photostability (i.e. the intensity of the Raman signal does not decay with 
prolonged exposure) than their fluorescent counterparts.  
The most widely studied Raman-active tag is the alkyne moiety.44,45 Compared to 
other Raman tags like nitrile and deuterium, alkynes have the strongest Raman signal. 
In contrast to deuterium labels, which often produce multiple signals, alkynes have a 
narrow band width, which makes them more suitable for multiplex imaging. Figure 1.4 
shows examples of Raman imaging using alkyne tags. 5’-Ethynyl-2’-deoxyuridine 
(EdU), an analogue of the nucleobase thymine, has been used to label cell nuclei, 
and can be used to visualise cell division (Figure 1.4a).47 Hu et al. synthesized an 
alkyne tagged analogue of glucose and successfully imaged it in a number of cell and 
tissue types; Figure 1.4b shows uptake in mouse neurones.48 The Raman signal of 
alkyne tags can be further enhanced by the addition of adjacent aromatic groups or 
alkynes, creating bisalkynes. Tipping et al. utilised this and added a bisaryldiyne 
(BADY) tag to the bioactive small molecule anisomycin (Figure 1.4c).49 They 












Figure 1.4 Raman imaging with bioorthogonal labels. (a) Cell nuclei labelled with EdU 
(100 µM) and imaged at 2125 cm-1 in HeLa cells. Scale bar: 10 µm. Reproduced with 
permission,47 copyright Springer Nature. (b) Alkyne labelled glucose (3-O-propargyl-D-
glucose, 3-OPG) (8 mM) imaged at 2129 cm-1 in primary mouse neurones. Scale bar: 20 µm. 
Reproduced with permission,48 copyright John Wiley and Sons. (c) Imaging of BADY-
anisomycin (10 µM, 30 min, orange) at 2219 cm-1 alone, and multiplexed with EdU (100 µM, 
18 h, blue) at 2120 cm-1 in HeLa cells. Scale bars: 10 µm Reproduced with permission,49 
copyright The Royal Society of Chemistry.  
Further development of Raman multiplex imaging has recently seen the application 
of polyynes. Polyynes are a linear chain of conjugated alkynes, which have sharp 
Raman peaks, a large intensity enhancement compared to terminal alkynes and 
natural frequency separation with increasing lengths. Hu et al. took advantage of the 
superb Raman properties of polyynes and developed a Raman multiplex imaging 
palette.50 Through chain-length modulation, bond-selective isotope labelling and end-
group substitutions, they achieved 20 distinct Raman colours in the cell-silent region, 
and named it the carbon rainbow (Carbow; Fig. 1.5a,b). Carbow dyes were applied to 
cellular imaging, and 15-colour tandem-fluorescence-Raman imaging in live cells was 
demonstrated (Figure 1.5c).  
Another Raman dye palette was developed by Wei et al. who used triple-bond-
conjugated near-infrared dyes, where each display a single peak in the cell-silent 
Raman spectral window.51 In combination with available fluorescent probes, this 
palette provides 24 resolvable colours, with the potential for further expansion. In 
contrast, fluorescence microscopy can only differentiate between a maximum of six 




dye palettes will undoubtedly enable more complex studies in biological systems than 
was previously possible with fluorescence alone. 
 
 
Figure 1.5 Raman multiplex imaging with the Carbow dye palette. (a) Chemical strategies for 
Raman-frequency expansion of polyynes: frequency modulation on the polyyne scaffold by 
conjugation elongation, isotope swapping and end-capping variations. (b) Carbow dye palette 
with 20 well-resolved Raman peaks. (c) 15-color tandem-fluorescence-Raman imaging of live 
HeLa cells with corresponding Carbow and fluorescent molecules. Reproduced with 
permission,50 copyright Springer Nature.  
1.2.2.3 Coherent Raman scattering  
The use of bioorthogonal Raman tags is not the only strategy to overcome the 
inherently weak signal in Raman spectroscopy. Technological development has also 
led to the use of coherent Raman scattering techniques. Coherent Raman scattering 
describes non-linear techniques where two incident lasers are used to excite and 
image a particular vibration of interest to enhance the Raman signal. Coherent anti-
Stokes Raman scattering (CARS) and stimulated Raman scattering (SRS) are both 
coherent Raman techniques that have found use in many biological applications.53,54 
CARS utilises two lasers, the pump laser (ωp) and Stokes laser (ωs). These interact 
with the sample in a four-wave mixing process and generate signal at the anti-Stokes 
frequency, Ω (ωas = 2ωp-ωs) (Figure 1.6). When Ω matches a molecular vibration of 
interest, contrast is derived from the chemical bonds in the sample.55 However, the 
process can also occur in non-resonant conditions, which leads to issues with high 
background noise and prevents quantitative imaging by CARS microscopy. In 
contrast to spontaneous Raman, CARS allows up to video-rate imaging of biological 








Figure 1.6 Coherent Raman scattering. Energy level diagrams showing the signal generation 
process of CARS and SRS. In SRS, the sample is excited with a pump and Stokes laser to 
create an image when Ω matches a specific molecular vibration. In CARS, a four wave mixing 
process is used, where Ω is tuned to the anti-Stokes frequency. 
SRS signals are also generated using two lasers, the pump (ωp) and the Stokes (ωs) 
laser (Figure 1.6). The energy difference (Δω = ωp - ωs) between the two lasers is 
tuned to match a specific molecular vibration (Ω), leading to stimulated excitation of 
the Raman active vibrational mode. This causes an intensity loss in the pump beam 
(stimulated Raman loss, SRL) and an intensity gain in the Stokes beam (stimulated 
Raman gain, SRG). By using an acousto-optic modulator (AOM), the Stokes beam 
can then be modulated to enable the measurement of the change in the pump beam 
only by using a radio-frequency lock-in detection, which provides the contrast to 
generate the image. SRL and SRG do not occur when Ω does not match a molecular 
vibration, so there is no non-resonant background in SRS.  
1.2.2.4 Stimulated Raman scattering microscopy 
Stimulated Raman scattering microscopy was first described in 1962,57 but its 
potential for live cell imaging was only realised in 2008 when Freudiger et al. 
developed a high-sensitivity detection system that allowed biocompatible SRS 
microscopy.58 The last decade has seen the further development of SRS microscopy 
in order to overcome the disadvantages related to traditional Raman scattering.59 
There is a lot of interest in utilising SRS for biomedical applications and drug 
discovery.60,61 
The main advantages of SRS imaging over spontaneous Raman spectroscopy 




stimulated Raman scattering, making it both a more effective and more sensitive 
technique for 2D/3D cell imaging.59,60,62 It is also important to mention that SRS has a 
linear dependence on concentration (Figure 1.7a), like spontaneous Raman 
spectroscopy, and it has good data correlation with the spontaneous Raman spectrum 
(Figure 1.7b).63 This makes SRS an excellent tool for quantitative imaging which is 
especially valuable for drug screening studies.62 For other Raman imaging 
techniques, such as surface-enhanced Raman spectroscopy (SERS) and CARS, it is 
more complex to quantify the signal in a concentration dependent manner.58,64,65 
 
 
Figure 1.7 (a) SRS contrast vs concentration plot of phenyldiyne (PhDY)-Cholesterol 
solutions. Reproduced with permission,66 copyright Springer Nature. (b) The non-distorted 
SRS spectrum intensities of Alk-16 mapped against the spontaneous Raman spectrum. 
Reproduced with permission,59 copyright John Wiley and Sons. 
1.2.2.4.1 SRS microscope 
A schematic representation of a SRS microscope illustrates how SRS microscopy is 
carried out (Figure 1.8). The pump and Stokes beams are synchronised, spatially 
overlapped using a dichroic mirror, and co-lineated into a beam-scanning microscope. 
An objective lens is used to focus the beams onto a focal point in the sample, 
generating a stimulated Raman process at its focus. A high numerical aperture 
condensor is used to collect the transmitted beams, a filter then blocks out the Stokes 
beam, enabling the subsequent detection of the pump beam by a photo-diode. A lock-
in amplifier is used to extract the SRL signal from the laser intensity, providing a 2D 





Figure 1.8 A Schematic representation of a SRS microscope. Reproduced with permission,60 
copyright The Royal Society of Chemistry. 
1.2.2.4.2 SRS application to imaging pharmaceuticals 
As discussed in Section 1.2, imaging pharmaceutical compounds in living systems is 
important to better understand their mechanism of action. SRS microscopy has been 
utilised for imaging pharmaceuticals using both the label-free approach as well as 
small Raman tags.60 
Label-free SRS imaging has been applied to study drug formulations in tablets67 and 
implants,68 and used to study dermal drug delivery.47,69 Liao et al. imaged vitamin E, 
a fat-soluble antioxidant widely used in skincare products, in mouse skin.69 They 
imaged the α-tocopherol form of vitamin E (Figure 1.9a), using the C-H stretch of the 
molecule at 2911 cm-1 to detect its diffusion into skin. To distinguish the overlapping 
C-H stretch of vitamin E and the skin tissue, SRG spectra were acquired each pixel 
and analysed by multivariate curve resolution (MCR) analysis. The SRG image was 
decomposed into vitamin E (in pink), lipid (in yellow), and protein (in green) as shown 
in Fig. 1.9b. Vitamin E molecules were found to be enriched in the sebaceous gland 






Figure 1.9 Label-free imaging of vitamin E (α-tocopherol) and terbafine hydrochloride (TH) 
using SRS microscopy. (a) Chemical structure of α-tocopherol. (b) MCR concentration maps 
of α-tocopherol (magenta), lipid (yellow) and protein (green) on anesthetized nude mouse skin 
after 5 min treatment at 20 μm and 50 μm depth. Scale bar: 100 μm. Reproduced with 
permission,69 copyright AAAS. (c) Chemical structure of TH; Raman spectra of a drug cream 
(1% TH) and mouse ear skin tissue. (d) SRS imaging of mouse ear tissue (z = 88 µm). SRS 
images acquired from alkyne on (2230 cm-1) and off-resonance (2300 cm-1), protein (C=O, 
1655 cm-1) and lipid (CH2, 2845 cm-1) stretches. Scale bar: 20 µm. Reproduced with 
permission,47 copyright Springer Nature.  
Wei et al. imaged FDA approved antifungal skin drug terbafine hydrochloride (TH) in 
mouse ear tissue to a depth of about 100 µM using SRS imaging.47 TH has an 
inherent alkyne with a Raman peak at 2230 cm-1, which was detected in the Raman 
spectrum of Lamisil, a cream containing 1% TH (Figure 1.9c). SRS imaging of TH was 
achieved in mouse ear tissue by treating the ears with 1% TH in DMSO solution. TH 
was found to localise in high fat regions of the tissue (Figure 1.9d), suggesting it is 
penetrates into tissues through the lipid phase. This is consistent with the molecule’s 
lipophilic nature.  
When drugs do not have characteristic vibrational features, small Raman tags have 
been used to allow SRS imaging with improved sensitivity and specificity. Saar et al. 
used deuterium labelling to visualise the penetration of non-steroidal anti-
inflammatory drug ibuprofen into mouse skin.70 The drug was applied to the mouse 
ear as a propylene glycol (PG) solution, and uptake was measured over time. It was 
found that ibuprofen forms crystals on the tissue surface, while some drug penetration 
into the skin via the hair follicle was seen. Precipitation of ibuprofen was likely 




evaporation of PG from the surface. These factors probably increased the local drug 
concentration above its saturation solubility. The diffusion of pharmaceutically 
relevant solvents into nails has also been studied via deuterium labelling.71 SRS 
imaging of deuterated water (D2O), DMSO (DMSO-d6) and PG (PG-d8) revealed much 
faster transport of water through the nail, relative to PG and DMSO. 
Alkyne tags, which are more Raman active than deuterium, have also been utilised to 
study the intracellular distribution of small molecule inhibitors using SRS. Diyne 
Raman tags were applied to imaging anisomycin49 (Figure 1.4c), antimycins72 and 
ferrostatins.73 SRS imaging of these Raman-tagged inhibitors revealed both 
anisomycin and antimycins localised in the endoplasmic reticulum (ER), while 
ferrostatin-1 accumulated in lysosomes, mitochondria and ER.  
These examples demonstrate the widespread applications of SRS microscopy for 
studying pharmaceuticals. Additional examples, where FDA approved drugs have 
been imaged by Raman microscopy, are discussed in Section 3.1.2.  
1.3 Chronic myeloid leukaemia (CML) 
Chronic myeloid leukaemia affects approximately one individual per 100,000 
population per year, accounting for 15% of all new cases of leukaemia in the Western 
hemisphere.74 Although the median age at diagnosis is 53 years, all age groups, 
including children, are affected.75 The common symptoms of CML patients are fatigue, 
anorexia, and weight loss. However, approximately 40% of patients are 
asymptomatic. For these patients, diagnosis is based on an abnormal blood count. 
The development of targeted therapy increased the 10-year survival rate for CML 
patients from about 20% to 80-90%. Tyrosine kinase inhibitors (TKIs) have profoundly 
affected the prognosis for newly diagnosed CML patients, where the overall survival 
rates are now only slightly lower than that of the general population.76 
1.3.1 CML development 
Chronic myeloid leukaemia (CML) is a myeloproliferative disease of hematopoietic 
stem cells. Over 90% of patients with CML have an abnormal Philadelphia 
chromosome (Ph), where chromosome 9 and chromosome 22, which contain the ABL 
(Ableson leukemia virus) and BCR (breakpoint cluster region) gene respectively, have 
translocated (Figure 1.10).77 The Ph is found in cells from the myeloid, erythroid, 




chimeric BCR-ABL oncogene that upon transcription and translation leads to the 
formation of cytoplasmic fusion protein BCR-ABL, which is a tyrosine kinase.78 ATP 
binding activates BCR-ABL and leads to uncontrolled cell proliferation, differentiation 
and cell survival, which results in the CML phenotype.  
 
Figure 1.10 Characterisation of CML. The hallmark of CML in patients is the formation of the 
Philadephia chromosome upon translocation of chromosome 9 and 22. The molecular 
consequence of this translocation is the generation of a BCR-ABL oncogene, which in turn 
translates into BCR-ABL oncoprotein.  
The majority of CML patients are in the chronic phase of the disease at the time of 
diagnosis.79 Treatment in this phase of the disease gives the best prognosis for 
patients. Chronic phase (CP) is followed by accelerated phase (AP) and blast crisis 
(BC), which are characterised by additional chromosomal changes, increased BCR-
ABL levels as well as increased genomic instability.80 CML treatment during 
accelerated phase and blast crisis is associated with poorer outcomes. Therefore, 
early diagnosis and treatment is critical for patients’ long-term survival.  
1.3.2 Current CML therapies  
CML treatment has changed dramatically over the years. Therapy was restricted to 
the chemotherapeutics busulphan and hydroxyurea before the 1980-s.81 These 
improved patient blood count and gave symptomatic relief, but did not delay the onset 
of disease progression, which occurred at a median of 4–5 years after diagnosis. 
Allogeneic stem cell transplantation and interferon alpha became the treatments of 




these treatments prolonged patient survival, however, interferon alpha treatment led 
to multiple toxicities in patients.84 Allogeneic stem cell transplantation can be curative, 
but also has associated risks of morbidities and mortality. 
The era of targeted therapy started in 2001 when imatinib was approved by the FDA 
as the first tyrosine kinase inhibitor for the treatment of CML.85 Imatinib targets the 
BCR-ABL protein-tyrosine kinase, inhibits its phosphorylation and subsequently leads 
to inhibition of cell proliferation and the induction of apoptosis.86 Imatinib was 
welcomed as a revolutionary anticancer agent in terms of its target specificity, high 
efficacy and low toxicity.87 However, point mutations in the ABL kinase domain of 
BCR-ABL quickly led to the development of drug resistance due to impaired inhibitor 
binding.88 Up to 30% of patients developed intolerance or resistance to imatinib within 
the first 5 years of therapy.89  
Nilotinib was then developed as a second-line therapy for CML patients that had 
developed imatinib resistance.90 Nilotinib proved to be effective against some 
BCR-ABL point mutations, such as E255V, M351T, and F486S, but failed against the 
T315I point mutation which is located at the gatekeeper region of the ATP-binding site 
and is crucial for drug binding. While imatinib and nilotinib both bind to the inactive 
BCR-ABL (type II ATP competitive inhibitors) (Figure 1.11a), dasatinib and bosutinib 
are two other BCR-ABL inhibitors that bind to the active BCR-ABL (type I ATP 
competitive inhibitor) (Figure 1.11b).91 Unfortunately, dasatinib and bosutinib were 
also ineffective against the BCR-ABLT315I mutant.92,93  
The T315I point mutation is the most frequently detected mutation in patients who 
have developed resistance or intolerance to imatinib treatment as well as in patients 
with resistance to dasatinib or nilotinib.94,95 The mutation from a small threonine to a 
bulky isoleucine inhibits the drugs from binding into the allosteric pocket and hence 
reduces the binding affinity of the aforementioned inhibitors.91 Computational 
modelling has demonstrated that the T315I mutation eliminates a critical hydrogen 






Figure 1.11 Inhibition of BCR-ABL by TKIs. (a) Imatinib (cyan) binds to the kinase domain of 
BCR-ABL in its inactive state where the activation loop (red) is in the “closed” conformation 
and the DFG motif is in the “out” conformation. (b) Dasatinib (cyan) binds to the kinase domain 
of BCR-ABL in its active state where the activation loon (red) is in an “open” conformation and 
the DFG motif is in the “in” conformation. Reproduced with permission,97 copyright SAGE 
Publishing. (c) Ponatinib (green) binding to BCR-ABLT315I mutant. The side chain of the 
mutated gatekeeper residue Ile315 is shown in red. Hydrogen bonds are highlighted with pink 
dashed lines. Reproduced with permission,98 copyright Elsevier. 
As a third-line treatment for CML, ponatinib was subsequently developed by O’Hare 
et al. to combat the BCR-ABLT315I mutant which could not be treated with imatinib, 
nilotinib, dasatinib, or bosutinib.98 These original ATP mimics all form a hydrogen bond 
with the side chain OH of the T315 residue in native BCR-ABL. Ponatinib was hence 
designed to avoid that binding mode and instead accommodates the T315I alkyl side 
chain by having a slim alkyne linker in the molecule, hence bypassing the additional 
steric hindrance found in the mutant (Figure 1.11c). While ponatinib has one less 
hydrogen bond with the target, it still forms five hydrogen bonds with the protein in 
addition to the favourable van der Waals interactions with the I315 residue. Ponatinib 
demonstrates high efficacy against various BCR-ABL mutants as well as the native 
BCR-ABL, which is why it was approved by the FDA for treatment of CML in 2011. 
However, the risk for serious toxicities and thrombotic events with ponatinib treatment 
was found to be significant post-approval. For that reason, ponatinib is now only 
considered as a treatment option for patients with a T315I mutation, as there are no 
other options for these patient. The risk of side effects is reduced when a lower 
ponatinib dose, 15-30 mg daily, is used instead of the standard 45 mg daily. 
Research is ongoing to find better treatment options for CML patients who have 




mutation. As of 2020, three novel third generation TKIs are in clinical trials for CML 
treatment, including asciminib, HQP1351 and K0706.99 Allogeneic stem cell 
transplant remains an important treatment option for CML patients with AP and BP-
CML, and it is considered for patients in CP-CML who have failed treatment with at 
least two TKIs.99  
1.3.3 CML drug resistance mechanisms  
Despite the early success associated with TKI treatment of CML, not all patients 
experience long-term durable responses. This is a consequence of TKI drug 
resistance in CML, which can either be primary, when treatment fails, or acquired, 
when the achieved response is lost.100 Before a patient is declared to have TKI 
resistance, it is important to assess treatment compliance as well as drug-drug 
interactions. A lower rate of imatinib adherence to a treatment plan has been shown 
to correlate with poorer outcomes.101 
Primary resistance, where treatment with TKIs does not yield desired results, affects 
15% to 25% of CML patients. Mechanisms of primary resistance have two potential 
causes: unsuccessful BCR-ABL inhibition by the treatment (BCR-ABL dependent), 
inadequate number of normal hematopoietic progenitors in the bone marrow 
environment (BCR-ABL independent). The main causes of acquired resistance, 
where initial successful treatment response is followed by relapse of the disease, are 
BCR-ABL dependent; but a number of BCR-ABL independent resistance 
mechanisms have also been identified in CML.  
1.3.3.1 BCR-ABL dependent resistance mechanisms 
BCR-ABL dependent resistance can be caused by BCR-ABL mutations or BCR-ABL 
overexpression and/or amplification, which can negatively impact the effectiveness of 
TKI treatment in patients.102 BCR-ABL mutations, which inhibit drug binding, are the 
most common cause of drug resistance (Figure 1.12a). Over 100 mutations have 
been identified to date. Point mutations in the ABL tyrosine kinase domain of 
BCR-ABL have been found in more than 50% of CML patients with clinical resistance, 
and are more common in patients with acquired resistance rather than primary 
resistance.103 Although the majority of reported BCR-ABL mutations occur in the 
kinase domain, mutations outside of the kinase domain also exist. In addition, 




of separate BCR-ABL proteins, and compound mutations, where there are two 
mutations within the same BCR-ABL protein, also contribute to drug resistance.104 
Another BCR-ABL dependent drug resistance mechanism is BCR-ABL amplification 
as result of TKI treatment (Figure 1.12b). In this case, drug still binds to BCR-ABL, 
but due to higher levels of the target in the cell, not all BCR-ABL is inhibited. Both 
genomic amplification of BCR-ABL gene as well as overexpression of BCR-ABL 





Figure 1.12 Major resistance mechanisms in CML. BCR-ABL dependent mechanism: (a) 
BCR-ABL mutations, (b) BCR-ABL amplification. BCR-ABL independent mechanisms: (c) 
drug transporters, (d) alternate signalling pathways, (e) CML stem cells, (f) autophagy. Image 





1.3.3.2 BCR-ABL independent resistance mechanisms 
Although less prevalent, approximately 40% of relapsed patients have 
uncharacterised BCR–ABL independent mechanisms of resistance. Therefore, 
investigating these mechanisms for further improvement of CML therapy is crucial. 
BCR-ABL independent mechanisms of resistance include activation of alternate pro-
survival signalling pathways, drug influx–efflux activity, inherently resistant stem cells, 
as well as increased autophagy.   
The activation of additional pro-survival signalling mechanisms overcomes the 
dependence on BCR-ABL signalling in CML cells (Figure 1.12d). A number of 
signalling pathways have been found to be associated with BCR-ABL independent 
resistance mechanisms. JAK2/STAT5 and RAF/MEK/ERK signalling pathways have 
both been associated with BCR-ABL independent resistance in CML.106,107 The PI3K 
signalling pathway was found to be upregulated by a number of independent 
studies.108-110 Elevated levels of FOXO1 were found in imatinib and dasatinib dual-
resistant cells, while increased mTOR was found in ponatinib resistant cells.109 In both 
cases, PI3K inhibition was proposed as a novel treatment approach to overcome the 
BCR-ABL independent TKI resistance mechanism. 
Drug transporters, which control intracellular drug levels, can also confer resistance 
to TKI therapy in CML (Figure 1.12c). Both membrane influx pumps, such as the 
human organic cation transporter 1 (OCT1), and efflux pumps, such as ATP-binding 
cassette (ABC) members have found to play an important role. OCT1 is required for 
imatinib transport into the cell, where low OCT1 levels are associated with a 
suboptimal treatment response, requiring a dose increase.111 Overexpression of ABC 
efflux transporters P-glycoprotein (Pgp), ABCA3, ABCC2, and ABCG2 has also been 
found to negatively impact treatment efficacy in CML.112,113 
CML stem cells have been found to be the cause of minimal residual disease in 
treated patients, hence driving relapse and disease progression.102 Leukemic stem 
cells (LSC) are CD34+/CD38- and BCR-ABL positive, only accounting for less than 
1% of CD34+ cells at diagnosis.103 These cells do not require BCR-ABL activity for 
their survival and as a consequence are primarily resistant to TKI treatment (Figure 
1.12e).114 Leukemic stem cells possess multiple features which promote TKI 
resistance, including the deregulated expression of BCR-ABL and a high degree of 




remove the current need for indefinite therapy with TKIs and increase the possibility 
of obtaining a cure for CML. 
1.4 Autophagy 
Autophagy is a term that describes the delivery of cytoplasmic constituents to the 
lysosomes for degradation.116 Cells use autophagy to mitigate metabolic and 
therapeutic stresses, remove waste and manage toxic by-products of anabolism and 
catabolism, including reactive oxygen species (ROS).117 As such, autophagy 
induction can happen under various stress conditions such as nutrient or growth factor 
deprivation, oxidative stress, and drug treatment. Increased autophagy has also been 
found to drive BCR-ABL independent resistance in CML (Figure 1.12f). The specific 
role of autophagy in CML is discussed further in Section 1.4.2. 
The molecular mechanisms of autophagy are described in Figure 1.13. Autophagy is 
initiated upon inhibition of mammalian target of rapamycin (mTOR), leading to 
activation of Unc-51 like kinase (ULK1/2) complex which in response starts 
phagophore formation.118 The class III phosphoinositide 3-kinase (PI3K-III) is critical 
for further expansion of phagophores. Maturation of phagophores into 
autophagosomes, double-membraned vesicles that are the main mediators of 
autophagy, is mediated by microtubule-associated protein 1 light chain 3 (LC3). LC3-I 
lipidation with a phosphatidylethanolamine (PE) to form LC3-II on the surface of 
autophagosomes is facilitated by ubiquitin-like enzymes ATG7 and ATG3. Complete 
autophagosomes then fuse with lysosomes to form autolysosomes. Lysosomes have 
an acidic lumen containing pH-sensitive digestive enzymes that can break down 
waste materials and cellular debris inside the autolysosome. Degradation inside 
autolysosome removes unwanted cellular materials such as damaged proteins, and 






Figure 1.13 Molecular mechanisms of autophagy. 1)  Autophagy initiation starts with the 
activation of the ULK1/2 kinase complex. 2) Phagophore formation and maturation dependent 
on PI3K-III complex 3) Autophagosome completion upon LC3-II incorporation into the 
autophagosome double membrane. 4) Autophagosome fuses with the lysosome to form 
autolysosome. 5) Inside the autolysosome, the inner single membrane of the autophagosomes 
and its cargo is lysed by lysosomal hydrolases, including cathepsins. 6) The degraded content 
is recycled back into the cell. Image created with Biorender.  
1.4.1 Autophagy as a therapeutic target 
Modulation of autophagy activity is implicated in a number of different disease areas, 
including neurodegeneration, infectious diseases, and cancer.119 In 
neurodegenerative diseases, autophagy serves to help eliminate misfolded, toxic 
protein aggregates through a process called aggrephagy; and damaged mitochondria 
through a process called mitophagy. Pharmacological stimulation of autophagy is 
being investigated as a therapeutic strategy against neurodegenerative diseases.120 
Autophagy is also involved in a variety of immune functions, such as removal of 
intracellular bacteria, inflammatory cytokine secretion and control of inflammation. In 
a process called xenophagy, autophagy plays a key role in fighting off invading 
bacteria.121  
The role of autophagy in cancer is multifaceted. Prior to the onset of tumorigenesis, 
autophagy has a cytoprotective role, where loss of autophagy is associated with a 
higher risk of cancer development.122 In contrast, autophagy has also been found to 




suboptimal conditions.123 Additionally, autophagy induction is a side effect of many 
cancer therapies.124 As a result, the inhibition of autophagy has become a desirable 
pharmacological target, with an aim to improve the efficacy of existing therapies and 
to prevent resistance to treatment.125 
There have been numerous clinical trials for cancer treatment, where the inhibition of 
autophagy has been used in combination with other therapeutic agents.117 All of these 
studies have used chloroquine (CQ) and its derivative hydroxychloroquine (HCQ) as 
the autophagy inhibitors. CQ and HCQ both impair the autophagy pathway by 
inhibiting autophagosome and lysosome fusion in the autophagy process (Figure 
1.13). These drugs have been approved for the treatment of malaria and arthritis for 
decades, but have limitations as autophagy inhibitors. As non-specific autophagy 
inhibitors, they can exert anti-tumour effects via other mechanisms than just inhibition 
of autophagy.126 In that regard, it is not entirely unsurprising that clinical trials with CQ 
and HCQ have not delivered the required potency for effective autophagy inhibition in 
patients. More potent alternatives are being investigated in preclinical studies.127  
1.4.2 Autophagy in CML drug resistance 
Increasing evidence indicates that autophagy plays a critical role in CML 
tumorigenesis, progression, and treatment.118 Autophagy acts as protective 
mechanism in CML, where imatinib treatment has been shown to increase autophagy. 
The induction of autophagy in response to drug treatment is associated with 
persistence and recovery of a subpopulation of CML cells.128 Bellodi et al. found that 
combination treatment with imatinib and autophagy inhibitor CQ resulted in increased 
cell death in vitro, and sensitised inherently TKI-resistant CML stem cells to 
treatment.129  
The efficacy of HCQ and imatinib combination treatment in previously treated CML 
patients with residual disease was assessed in a phase II clinical trial.130 The results 
were published in 2020, concluding that combination treatment with HCQ 
(400-800 mg daily) and imatinib provided only modest improvement over imatinib 
treatment alone, and the primary end point of the study was not met. One reason for 
trial failure was reported to be inability to achieve adequate HCQ plasma levels to 
accomplish meaningful autophagy inhibition, highlighting the clinical need for more 




Combined inhibition of autophagy and mTOR, as well as autophagy and the 
Hedgehog pathway, have also been shown to be promising approaches to 
successfully induce apoptosis in ponatinib-resistant and imatinib-resistant CML cells, 
respectively.109,131 Both of these studies also demonstrated that specific inhibition of 
key autophagy proteins, autophagy-related 5 (ATG5) and ATG7, also sensitised drug 
resistant CML cells to treatment in vitro.  
Although progress has been made in investigating the role of autophagy in CML, 
particularly in the context of drug resistance, the exact mechanisms still remain 
unclear; and have not yet yielded a novel therapeutic option for CML treatment.  
1.5 Lysosomes 
The term ‘lysosome’ means ‘digestive body’ in Greek. Lysosomes were discovered 
by Christian de Duve in 1955, who described the discovery as serendipitous.132 
Lysosomes are mostly known for their role as the primary degradative compartment 
in eukaryotic cells. They degrade both extracellular material that has been internalised 
by endocytosis as well as intracellular components that have been sequestered by 
autophagy.133 
The defining characteristic of lysosomes is the acidic pH within the lysosomal lumen, 
which ranges between ~4.5 and 5.5, and provides an optimal environment for the 
function of pH-sensitive hydrolases. Vacuolar H+ ATPase (v-ATPase) on the 
lysosome membrane is responsible for maintaining the low pH inside the lysosome 
by pumping in hydrogen ions (Figure 1.14).134 Lysosome outer membrane is 
composed of a single phospholipid bilayer that is decorated with transmembrane 
proteins, including the lysosome-associated membrane protein (LAMP)1 and LAMP2, 
which together total 50% of lysosomal membrane proteins. Inside the acidic lumen, 
there are about 60 known resident acid hydrolases, which facilitate the degradation 
of a vast array of macromolecules and lead to the production of amino acids, 





Figure 1.14 Schematic of the lysosome. Acidic pH in the lysosome lumen is achieved by the 
proton pump v-ATPase on the lysosome membrane. The most abundant proteins on the 
lysosome membranes are LAMP1 and LAMP2. Hydrolases within the lysosomal lumen are 
optimised to work under acidic conditions, where each hydrolase targets specific substrates 
for degradation. Image created with Biorender. 
1.5.1 Lysosome biogenesis 
There are multiple endocytic and scavenging pathways that lead to lysosome 
formation in the cell, starting with the transportation of endocytosed material to the 
early endosome (Figure 1.15). Extracellular material and pathogens are endocytosed 
through macropinocytosis and phagocytosis respectively, while plasma membrane–
localised proteins such as signalling receptors are internalised via clathrin-mediated 
endocytosis.134 Early endosomes act as the sorting centre in the cell, deciding whether 
internalised cargo is retained in the cell or transported back to the cell membrane for 
disposal. The maturation from early endosomes to late endosomes involves changes 
in the external protein and lipid coat by progressive acidification of the lumen. 
Hydrolytic enzymes and lysosomal membrane proteins are delivered to the maturing 
late endosome via fusion with post-Golgi vesicles transporting the cargo. Through 
further acidification and a series of additional steps, the lysosome is finally formed.135 
However, degradation of contents delivered to the lysosome is not the end-point of 
lysosomal function.  
While lysosomes were originally thought to be simple cellular recycling machines, it 
is becoming increasingly evident that their role in cellular homeostasis is much more 
complex. Lysosomes are involved in a number of important biological processes, 
including phagocytosis, autophagy, plasma membrane repair, as well as cholesterol 
homeostasis.133 Lysosomes can also trigger cell death via cathepsin release into the 





Figure 1.15 The endolysosomal system. Early endosome formation can be triggered by 
micropinocytosis of extracellular cargo, phagocytosis of pathogens or clathrin-mediated 
endocytosis of membrane-bound proteins. The Golgi-apparatus delivers hydrolases and 
proteins to the endosome in the form of vesicles to drive endosome maturation, acidification, 
and finally lysosome formation. Lysosomes are involved in a wide array of cellular processes, 
including autophagy. Image created with Biorender.  
Lysosome biogenesis is a complex, tightly controlled cellular process. The impairment 
of lysosomal biogenesis pathways is implicated in a number of degenerative storage 
diseases, including lysosomal storage disorders and late-onset neurodegenerative 
diseases.136  Transcription factor EB (TFEB) is a major regulator of lysosome 
biogenesis that coordinates the expression of lysosomal hydrolases, lysosomal 
membrane proteins, as well as autophagy proteins in response to sensing lysosomal 
stress.137  
1.5.2 Lysosome biogenesis in CML 
Lysosomal function plays an important role in cancer, where disease progression has 
been associated with changes in lysosomal volume, composition and cellular 
distribution.138 Increased lysosomal drug uptake and lysosome size are also involved 
in cancer drug resistance.139 Lysosomal targeting has been investigated in preclinical 
studies. Treatment with mefloquine, an anti-malarial agent with reported anti-cancer 
properties, caused lysosomal disruption and selectively induced cell death in acute 




As lysosomes are involved in the autophagy process, and autophagy has been shown 
to be increased in CML, it is therefore unsurprising that lysosomes are also implicated 
in CML. Yi et al. investigated the effects of combination treatment using mefloquine 
and TKIs in stem cells derived from blast phase CML (BP-CML) patients that were 
resistant to TKI therapy.141 They found that mefloquine enhanced the cytotoxicity of 
TKI treatment, and selectively killed drug resistant BP-CML stem cells, including ones 
harbouring the T315I point mutation. In addition, they showed that the mefloquine 
mechanism of action is biphasic – initially increasing lysosomal biogenesis and 
activation in CML cells, followed by oxidative stress, lysosomal lipid damage and 
lysosome functional impairment. This study shows that lysosomal targeting is 
potentially a viable option for targeting drug resistance in CML. 
1.6 Spheroids 
A spheroid is defined as a non-substrate-adherent, aggregated, mutually adherent 
population of cells adopting a spherical (-like) shape.142 To grow spheroids, cells are 
cultured as aggregates with or without scaffold materials, or are embedded in gels.143-
145 Cell aggregates have many different names; ranging from mammosphere and 
micromass to spheroids.146,147 In this thesis, the term spheroid is used to indicate a 
3D cell aggregate (not necessarily constituting a perfect spherical shape) that does 
not adhere to any culture substrate (e.g. polystyrene).  
Spheroids can form different morphologies depending on cell type and culture 
conditions (Figure 1.16).148 When a panel of 25 breast cancer cell lines were grown 
in 3D on top of laminin-rich extracellular matrix (ECM) gel, four distinct 3D 
morphologies were identified – round, mass, grape-like and stellate. Round spheroids 
display organised nuclei and have robust cell-cell contacts (e.g. S1 cell line). Mass 
and grape-like spheroids both have disorganised nuclei, but mass spheroids form 
strong cell-cell contacts (e.g. BT-474 cell line) whilst grape-like spheroids form weak 
cell-cell contacts (e.g. SK-BR3 cell line). Stellate spheroids had distinct elongated cell 
bodies with disorganised nuclei (e.g. BT-549). This demonstrates heterogeneity within 
the 3D morphology of different cell lines, which will have an impact on drug 
penetration and distribution during screening. 3D morphology also influences their 
experimental handling - spheroids made of loosely arranged cells can be difficult to 







Figure 1.16 Schematic representing the various morphologies of spheroids. Spheroids adapt 
various shapes depending on the culture conditions and inherent nature of the cells. Image 
created with Biorender. 
Large spheroids (~500 μm in diameter) display physicochemical gradients similar to 
micrometastases and small avascular tumours (0.5-1 mm3) (Figure 1.17).149 Limited 
diffusion (~150-200 μm) decreases oxygen and nutrient availability at the core of the 
spheroid, and causes metabolic waste accumulation at the core.150 Oxygen deficiency 
induces hypoxia at the spheroid core, resulting in changed gene expression, 
increased aerobic glycolysis, lactic acid production and decreased pH (0.6 pH 
units).151  Build-up of metabolic waste also causes both necrotic and apoptotic cell 
death at the hypoxic core.152 The core is surrounded by a layer of viable quiescent 
cells, while the outer  layer consists of proliferating cells.153 Spheroid size and cell 
density greatly impacts the generation of physicochemical gradients and biological 
zones in the spheroid, influencing their response to drugs. 
 
 
Figure 1.17 Schematic representing physicochemical gradients in a spheroid and the resulting 
spheroid structure. Availability of O2 and nutrients (blue triangle) decreases with increasing 
depth of the spheroid. Metabolic waste accumulation (red triangle) is highest in the middle of 
the spheroid compared to the edge. There is a hypoxic core in the middle of the spheroid, a 





1.6.1 Spheroid growth methods 
Numerous different methods have been developed over the years to grow spheroids. 
Broadly, they can be categorised into scaffold-based or scaffold-free.154 Scaffold-
based methods make use of an external matrix, where the spheroid is grown either 
on top of the matrix or embedded in the matrix (Figure 1.18a). Natural matrices include 
hydrogels such as collagen, matrigel and gelatin. Synthetic hydrogels such as 
polyethylene glycol (PEG), polyglycolic acid (PGA), polylactic acid (PA) as well as 
peptides are also used to enhance spheroid growth. These scaffolds mimic the ECM 
and can provide both structural and physical support for spheroid formation, but also 
allow the cells to spread and migrate in 3D. However, automation of scaffold-based 
spheroids for use in high content screening (HCS) would be challenging as most 
matrices are temperature sensitive, requiring active temperature-control. In addition, 
variability in z-plane location of spheroids can cause problems during data collection 
and analysis.155  
 
 
Figure 1.18 Methods for growing spheroids. (a) Scaffold-based methods involve growing a 
spheroid either on top of a matrix or embedded in matrix. Matrices used are either natural (e.g. 
collagen, matrigel, and gelatin) or synthetic (e.g. PEG, PGA, PA, peptides). Scaffold-free 
methods include (b) the hanging drop method (arrow indicates spheroid growth over time in 
the droplet) and (c) ultra-low attachment plates. Image created with Biorender. 
The two most commonly used scaffold-free methods are the hanging droplet method 
(HDM) and the use of ultra-low attachment plates.154 In the HDM, the cells self-
aggregate in the media as there is no available surface for attachment (Figure 1.18b). 
Due to the limited size of the droplet, fresh culture medium needs to be added 




generally labour intensive and complex. In addition, it would be necessary to transfer 
the spheroids to a secondary plate for drug treatment and that is not optimal for 
HCS.156 
The second scaffold-free technique for spheroid formation utilises 96- or 384-well U-
shaped ultra-low attachment (ULA) plates (Figure 1.18c).157 Like HDM, it takes 
advantage of self-aggregation of cells in the presence of no attachment surface. U-
shaped ULA plates are often made of polystyrene and treated with hydrophilic or 
hydrophobic coatings like the non-adherent polymer poly(2-hydroxyethyl 
methacrylate) (poly-HEMA), which reduces cell attachment to the wells. It allows 
formation of uniform-sized spheroids within 1-3 days, where a single spheroid per well 
is formed.155 This method is compatible with automation and HCS. Rotema et al. 
successfully used it to screen 633 kinase inhibitors and FDA-approved drugs on 
spheroids grown in ULA plates.158 Furthermore, Madoux et al. developed a custom 
1536-well ULA plate for high-throughput screening and used it for a pilot cytotoxicity 
screen of 3300 drugs.159 Therefore, in this thesis, we also utilised U-bottom ULA 













High drug attrition rates continue to increase the cost of drug development in the 
pharmaceutical industry. Pre-clinical imaging of drugs in vitro and in vivo, which could 
lead to improved understanding of drug uptake, retention and metabolism, remains a 
challenge. Raman microscopy, in particular SRS microscopy, combines high 
molecular specificity with excellent resolution, and shows great potential for 
applications in drug imaging.  
Since the introduction of targeted TKI treatment in 2001, CML, a cancer of the 
haematopoietic stem cells, has seen a great improvement in patient survival. A 
significant proportion of patients, however, either have primary resistance to TKI 
treatment, or develop acquired resistance following TKI treatment for a number of 
years. Both BCR-ABL dependent and BCR-ABL independent drug resistance have 
been identified. Increased autophagy has been identified as a BCR-ABL independent 
CML drug resistance mechanism, and was targeted in a clinical trial involving 
combination treatment with a nonspecific autophagy inhibitor HCQ and TKI imatinib. 
Unfortunately, the combination treatment only marginally improved patient response 
compared to treatment with imatinib alone. Imaging TKIs used for CML treatment by 
SRS microscopy could help investigate intracellular drug localisation and its potential 
involvement in CML drug resistance. 
1.8 Project aims 
The aim of this project was to utilise SRS microscopy to study the intracellular 
distribution of label-free ponatinib in live CML cells. Ponatinib localisation in cells has 
not been reported previously. In Chapter 3, the ponatinib imaging protocol was 
optimised and SRS was used to determine absolute ponatinib concentrations in both 
drug sensitive and drug resistant CML cell lines. The sensitivity of SRS imaging was 
demonstrated by showing that nanomolar ponatinib treatment concentrations can be 
detected using this imaging technique. In Chapter 4, ponatinib accumulation in 
lysosomes was visualised and its significance in the context of a model of BCR-ABL 
independent resistance in CML was investigated. Additionally, SRS was used for 
target engagement studies with CQ and ponatinib combination treatment. Finally, in 
Chapter 5, SRS microscopy was applied to three dimensional spheroid imaging and 
ponatinib detection within these spheroids. 
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Chapter 2 Materials and Methods 
2.1 Materials 
2.1.1 Solutions and buffers 
The composition of all the solutions and buffers used throughout the thesis are listed 
in Table 2.1 below.  
Table 2.1 Solutions and buffers. 
Solution/Buffer Composition 
1 M NaCl 58.44 g NaCl 
1000 mL dH2O 
1 M Tris HCl pH 8 121.14 g Tris 
1000 mL dH2O 
adjust pH to 8 using 1 M HCl 
0.1 M NaHCO3 pH 8 8.4 g NaHCO3 
1000 mL dH2O 
adjust pH to 8 using 1 M HCl 
6X Laemmli sample buffer 9% SDS 
50% (v/v) glycerol 
375 mM Tris (pH 6.8) 
0.03% bromophenol blue in water.  
Before use, add 10% (v/v) β-mercaptoethanol 
RIPA buffer  50 mM Tris HCl (pH 8) 
150 mM NaCl 
1% NP40 
0.5% deoxycholate  
0.1% SDS  
prepared in dH2O 
Lysis buffer – Western blot 10 mL RIPA buffer  
1 tablet cOmplete™ ULTRA (Roche) 
1 tablet PhosSTOP (Roche)  
Tris buffered saline (TBS) 10X 200 mM Tris 
1500 mM NaCl 
adjust pH to 7.6, prepared in dH2O 
Tris glycine SDS (TGS) buffer  25 mM Tris 
192 mM glycine 
0.1% (w/v) SDS 
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pH 8.3, prepared in dH2O 
Blocking solution – Western blot 5% BSA (w/v) in TBST 
Blocking solution – IF 1% BSA (w/v) in PBS 
FACS buffer 10% FBS in PBS 
Phosphate buffered saline (PBS) 1 PBS tablet 
500 mL dH2O 
PBST 100 µL Triton X-100 
100 mL 1X PBS 
TBST 100 mL TBS (10x) 
1 mL Triton X-100 
900 mL dH2O 
Freezing medium 70% Media (RPMI or DMEM) 
20% FBS 
10% DMSO  





2.1.2.1 Primary antibodies 
The primary antibodies used in the thesis are listed in Table 2.2, with dilutions for 
Western blots and immunofluorescence (IF) noted. For Western blots, antibodies 
were diluted in 5% BSA in TBST. For IF, antibodies were diluted in 1% BSA in PBS. 
Table 2.2 List of primary antibodies used. 
Antibody Host Catalog Nr Company WB IF 
α-tubulin mouse 3873 CST 1:2000 - 
ATG7 rabbit A2856 Sigma Aldrich 1:1000 - 
CYP3A4 rabbit ab135813 Abcam 1:500 - 
LAMP1 rabbit 9091 CST - 1:200 
phospho-CRKL (Tyr207) rabbit 3181 CST 1:1000  
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2.1.2.2 Secondary antibodies 
 
Table 2.3 List of secondary antibodies used. 
Antibody Host Catalog Nr Company WB IF 
Anti-mouse IgG, HRP-linked horse 7076 CST 1:5000 - 
Anti-rabbit IgG, HRP-linked goat 7074 CST 1:5000 - 
AlexaFluor™ 488 anti-rabbit goat A11008 Thermo Fisher - 1:400 
 
2.2 Methods 
2.2.1 Cell culture methods 
2.2.1.1 Cell culture 
The cell lines used in this thesis are listed in Table 2.4, a more detailed description of 
each cell line is in Table 2.5. CML cell lines and the T47D cell line were cultured in 
RPMI-1640 medium (Gibco) supplemented with 10% fetal bovine serum (FBS, Gibco) 
and 1% L-glutamine (Thermo Fisher Scientific), and maintained in a humidified 
atmosphere at 37 °C and 5% CO2. Ponatinib resistant (Pon-Res) cell lines were grown 
in the presence of 100 nM ponatinib. SW480 cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM, high glucose, Sigma-Aldrich) supplemented with 
10% FBS and 1% L-glutamine at 37 °C in a humidified atmosphere containing 
5% CO2. Ponatinib (Synkinase) and chloroquine (Sigma Aldrich) stock solutions were 
prepared in DMSO and diluted in media before addition to the cells at the indicated 
concentrations. 
Table 2.4 Cell lines used in this thesis. 
Cell line Source Cell line origin Species 
KCL22  Helgason group* CML human 
KCL22Pon-Res Helgason group CML human 
KCL22Pon-ResCRISPR-Ctrl Helgason group CML human 
KCL22Pon-ResCRISPR-ATG7 Helgason group CML human 
BaF3-p210 Helgason group CML mouse 
BaF3-p210Pon-Res Helgason group CML mouse 
SW480 ATCC Colon adenocarcinoma human 
T47D ATCC Ductal breast carcinoma human 
 
 
* All the CML cell lines were obtained from Dr Vignir Helgason’s group at the University of 
Glasgow. CML: chronic myeloid leukaemia 
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Table 2.5 Summary of cell lines used in the thesis. 
Cell line Description 
KCL22  Human myeloid CML cell line (phase: blast crisis) sensitive 
to ponatinib treatment. 
KCL22Pon-Res Mitchell et al. developed a KCL22 cell line with BCR-ABL 
independent acquired resistance to ponatinib following 
exposure of KCL22 cells to increasing concentrations of 
ponatinib for a prolonged period. Ponatinib-resistant 
(KCL22Pon-Res) clones continued to proliferate in the presence 
of 100 nM ponatinib.109  
KCL22Pon-ResCRISPR-ATG7 CML cell line with BCR-ABL independent acquired ponatinib 
resistance, where autophagy has been impaired. Mitchell 
et al. used CRISPR-Cas9 in KCL22Pon-Res cells to knock 
down ATG7, an essential autophagy gene required for LC3 
lipidation.109 ATG7 knockdown inhibited LC3B-II formation 
and autophagy in these cells, measured by both decreased 
LC3B-II and increased autophagy substrate SQSTM1/p62 
levels.109 
KCL22Pon-ResCRISPR-Ctrl CML cell line with BCR-ABL independent acquired ponatinib 
resistance, with an empty CRISPR-Cas9 vector.109 
BaF3-p210 BaF3 cells are early precursors of B lymphocytes that were 
established from the bone marrow of MRL/LPR, CBA/J, and 
BALB/c mice.160 The p210bcr-abl protein is encoded by 
breakpoint cluster region Abelson (BCR-ABL) oncogene, 
and is the hallmark of CML in humans. p210bcr-abl was 
introduced into BaF3 cells through retroviral constructs to 
generate BaF3-p210 cell line.161  
BaF3-p210Pon-Res BaF3-p210 cells with an acquired resistance to ponatinib. 
Mitchell et al. incubated BaF3-p210 cells with increasing 
concentrations of ponatinib for a prolonged period. 
Ponatinib-resistant (BaF3-p210Pon-Res) clones continued to 
proliferate in the presence of 100 nM ponatinib. 
SW480 Human colorectal cancer cell line originally isolated from a 
primary adenocarcinoma in the colon.162 
T47D Estrogen receptor positive luminal A type breast cancer cell 
line derived from a metastatic ductal carcinoma. When grown 
in 3D, T47D cells form tightly cohesive mass structures 
displaying robust cell–cell adhesions.163 
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2.2.1.2 Cell counting 
Cell solution in media was mixed with Trypan blue dye in 1:1 ratio (50 µL cell solution 
+ 50 µL dye). The cell mixture was pipetted into both chambers of the Tali™ cellular 
analysis slide (Thermo Fisher Scientific) (25 µL into each). The slide was inserted into 
a Tali™ Image-Based Cytometer where the cells were manually focused. An average 
cell concentration was recorded from 20 fields of view that were captured. The second 
chamber of the analysis slide was recorded in an identical manner. The average of 
the two cell concentrations was used to calculate a desired cell dilution for 
experiments.  
2.2.1.2 Cryopreservation  
Freshly harvested cells from a single confluent T75 flask were pelleted by 
centrifugation at 300 g (3 min) and re-suspended in freezing medium (3 mL). The cell 
suspension was pipetted into three cryovials (Corning, 1 mL into each). Cryovials 
were placed inside a Nalgene® Mr. Frosty (Sigma Aldrich) filled with isopropanol, and 
stored at -80 °C for 24 h to allow for 1 °C/min cooling rate. The cryovials were then 
transferred into liquid nitrogen for long term storage.  
2.2.1.3 Liquid nitrogen recovery  
Prior to retrieving cells from liquid nitrogen, media was warmed to 37 °C. Frozen cells 
in the cryovial were defrosted by pipetting warm media (1 mL at a time) into the 
cryovial and aspirating the cells to a universal tube containing warm media. The cell 
suspension was pelleted by centrifugation at 118 g (5 min). Cells were re-suspended 
in fresh media (10 mL), transferred into a T75 cell culture flask and cultured in a 
humidified atmosphere at 37 °C and 5% CO2.  
2.2.2 Alamar Blue assay 
Cells were seeded onto 96 well plates on day -2 (Figure 2.1a) and incubated for 48 h 
at 37 °C. On day 0, Alamar Blue cell viability reagent (ThermoFisher Scientific) was 
added to the control plate at 1/10 concentration and incubated at 37 °C for 3 h (Figure 
2.1b) prior to measuring the plate fluorescence at 590 nm using a PerkinElmer 
EnVisionTM 2101 Multilabel reader (Figure 2.1c). Ponatinib was added to the 
remaining plates at increasing concentrations (0.1 to 5000 nΜ) and incubated for 48 h 
at 37 °C (Figure 2.1d). After 48 h, Alamar Blue was added to the drug treated plates 
for 3 h prior to measuring the plates at 590 nm (Figure 2.1e). 





Figure 2.1 Schematic for Alamar Blue assay. (a) Cells were plated onto 96 well plates on 
day -2 and incubated for 48 h. (b) On day zero, Alamar Blue reagent was added to the control 
plate and incubated for 3 h. (c) Fluorescence was measured at 590 nm using PerkinElmer 
EnVisionTM 2101 Multilabel reader. (d) On day zero, ponatinib was added to drug plates and 
incubated for 48 h. (e) On day two, Alamar Blue reagent was added to the drug plates and 
incubated for 3 h prior to measuring plate fluorescence. Image created with Biorender. 
2.2.2.1 GI50 of ponatinib in CML cell lines 
Ponatinib concentration causing 50% cell growth inhibition (GI50) in each CML cell line 
was determined using the Alamar Blue protocol described in Section 2.2.2. To analyse 
the data, control plate readings (day 0) were subtracted from drug treated plate 
readings (day 2). These absorption values from six replicate wells were normalised 
as a percentage of vehicle (DMSO) treated values and GI50 values generated using 
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Table 2.6 GI50 values expressed as a mean of n = 3 ± standard error of the mean (SEM) for a 
panel of CML cell lines. 
Cell line GI50 (nM ± SEM) 
KCL22  2.4 ± 0.1 
KCL22Pon-Res 593 ± 88 
KCL22Pon-ResCRISPR-Ctrl 339 ± 20 
KCL22Pon-ResCRISPR-ATG7 702 ± 55 
BaF3-p210 2.3 ± 0.1 
BaF3-p210Pon-Res 1017 ± 69 
 
2.2.3 Immunofluorescence (IF) 
2.2.3.1 Coating fluorodishes for IF 
Cell-Tak™ (Corning) was diluted in 0.1 M NaHCO3 (pH=8) to a final concentration of 
3.5 µg/cm2. An aliquot of diluted Cell-Tak™ was added to fluorodishes (550 µL/dish), 
which were left for 2 h at room temperature (RT). Fluorodishes were washed with 
sterile water twice, a drop of ethanol was added per fluorodish, and the dishes were 
left to air-dry in a sterile environment (30 min, RT). Coated dishes were stored at 4 °C 
and used within 7 days. 
2.2.3.2 IF protocol 
Cells were adhered to Cell-Tak™ coated fluorodishes (10 min, RT) prior to fixing 
(4% PFA in PBS, 20 min, RT) and  permeabilising (0.1% Triton X-100 in PBS, (PBST), 
10 min, RT). Samples were blocked with 1% BSA in PBS (30 min, RT) and incubated 
with primary antibody (LAMP 1, 1:200, Cell Signalling Technology; TFEB, 1:100, 
Invitrogen) in 1% BSA in PBS at 4 °C overnight. Samples were washed thrice with 
PBS, incubated with secondary antibody (AlexaFluorTM 488 goat anti-rabbit, 1:400, 
ThermoFisher, 1 h, RT) in 1% BSA in PBS, washed thrice with PBST and once with 
PBS. Finally, samples were labelled with DRAQ7 (1:60, abcam, 30 min, RT), left in 
PBS and stored at 4 °C before imaging. 
2.2.3.3 IF image analysis  
LAMP1 immunofluorescence was measured per field of view. Six fields of view were 
acquired for each sample and analysed on ImageJ. Background intensity was 
accounted for by setting the minimum intensity from 0 to 150 on each image. 
(imageàadjustàbrightness/contrast) Total pixel intensity of the image (RawIntDen) 
 Materials and Methods 
50 
 
was then measured. (analyseàmeasure) Number of cells on the image was obtained 
by measuring the number of nuclei on the corresponding DRAQ7 image, where cells 
on the edges were excluded. (imageàadjustàthreshold; analyseàanalyse 
particlesàexclude on edges) Total fluorescence intensity (TFI) per cell was then 
calculated by dividing the total pixel intensity of the image with the number of cells on 
the image. Welch’s t-test was used to compare the acquired data on GraphPad Prism. 
TFEB immunofluorescence was measured per nuclei in the field of view. Six fields of 
view were acquired for each sample and analysed on ImageJ. Background intensity 
was accounted for by setting the minimum intensity from 0 to 100 on each image. 
(imageàadjustàbrightness/contrast). Number of nuclei on each image was obtained 
from the corresponding DRAQ7 image, where cells on the edges were excluded. 
(imageàadjustàthreshold; analyseàanalyse particlesàsize(pixels)100-infinity; 
circularity 0.1-1.00;exclude on edges). Mean fluorescence intensity (MFI) was 
measured inside individual nuclei in each field of view. The Mann-Whitney test was 
used to compare the acquired data on GraphPad Prism. 
2.2.4 Fluorescence activated cell sorting (FACS) 
Samples were stained with Lysosensor™ Green DND-189 (1 µM, 1 h, 37 °C, 
ThermoFisher Scientific), washed with serum free RPMI-1640 by centrifugation 
(300 g, 3 min), re-suspended in PBS +10% FBS and kept on ice prior to immediate 
processing. Samples were run on the BD LSRFortessa X-20 (SORP) (Becton 
Dickinson) and processed using BD FACSDiva software (Becton Dickinson). Data 
was analysed using FlowJo software (TreeStar), where geometric mean values were 
derived for n=3 biological repeats.  
2.2.5 Protein methods 
2.2.5.1 Cell lysates 
Cells were plated in 10 cm dishes at 1×106 cells/dish, incubated for 48 h at 37 °C, and 
treated as indicated in the figure legends. Cells were washed with PBS (1×10 mL, 
1×5 mL) and lysed in 100 μL lysis buffer for 10 min whilst kept on ice. Lysates were 
centrifuged at 17115 g (15 min, 4 °C) and the supernatant transferred to new 
Eppendorf tubes. Lysates were stored at -80 °C. 
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2.2.5.2 Protein concentration determination  
Lysate protein concentration was measured using a bicinchoninic acid (BCA) assay. 
Micro BCA™ Protein Assay Kit (ThermoFisher Scientific) was used according to 
manual, with the microplate protocol used. Plate absorbance was measured at 
562 nm and each lysate concentration was measured in duplicate. 
2.2.5.3 Western blotting  
20 µg of total protein was added to RIPA buffer mixed with 6X Laemmli sample buffer 
to make up a total of 15-20 µL per sample, and boiled at 95°C for 5 min to denature 
proteins. Samples were separated by polyacrylamide gel electrophoresis using 4-15% 
Mini-PROTEAN® TGX™ precast protein gels (Bio-Rad) in a BioRad Mini-PROTEAN 
4 gel chamber with TGS buffer (180 V, 40 min).  
Proteins were transferred to a nitrocellulose membrane (0.2 µm, Bio-Rad) using a 
Trans-Blot Turbo Transfer System (25 V, 2.5 A, 10 min, Bio-Rad) and blocked using 
Western blot blocking solution (1 h, RT). The membrane was immunoblotted with 
primary antibodies at 4 °C overnight, followed by washing with TBST three times. 
Secondary antibody was incubated with the membrane (1 h, RT) before washing with 
TBST thrice. Bound antibodies were visualised by chemiluminescence using Clarity 
ECL Substrate (Bio-Rad) and the Bio-Rad Gel Doc XRS+ System. 
2.2.6 Density functional theory (DFT) calculations† 
For each molecule of interest, 20 sample conformers were generated using the 
distance-based algorithm implemented in RDKit and a basic energy minimisation was 
performed using the MMFF94 forcefield. The geometry of individual structures was 
then further optimized at a DFT level according to Becke’s three-parameter hybrid 
method with LYP correlation (B3LYP) using the 6-31G(d) basis set in the gaussian09 
program package. Due to the large size of the molecules, Pulay’s DIIS method was 
applied during SCF optimisation.164 Force constants, and the resulting Raman 
vibrational frequencies were computed with the same DFT method and basis set. To 
correct for the an-harmonic nature of bonded atoms, a scaling factor of 0.96 was used 
to re-scale the high range frequency values.165  The 10 structures with the lowest 
single point free energy were used for the data reported. 
 
† Marie Bluntzer performed the DFT calculations. 
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2.2.7 Liquid chromatography mass spectrometry (LC-MS)‡ 
CML cells were incubated with ponatinib (5 µM, 1 h) and washed with serum free 
RPMI media by centrifugation (300 g, 3 min). The aspirated cell pellet was extracted 
using MS extraction buffer (1 mL). The insoluble material was pelleted (21130 g, 4 °C, 
5 min) and the supernatant collected for analysis. Extracts were vacuum centrifuged 
to remove solvents before being adjusted to 0.1 % formic acid in a total volume of 
50 µL.  10 µL were injected onto a Dionex BioRS using a 100 mm x 2.1 mm C18 
Accucore 150 for separation over a 10 min gradient from 5% to 95% acetonitrile (with 
0.1 % formic acid throughout). Eluting molecules were ionized with 3.4 kV and 
analysed on a Thermo Q Exactive with a scan range of 150-600 m/z and resolution 
35k.  Ion chromatograms were extracted using RawTraces 
(gitlab.com/jimiwills/rawtraces) and analysed with associated Perl scripts. 
2.2.8 Spontaneous Raman spectroscopy  
Spontaneous Raman spectra of solid ponatinib were acquired using a confocal 
Raman spectrometer (inVia™ confocal Raman microscope, Renishaw). A 297 mW 
785 nm diode laser, or a 200 mW 532 nm laser excitation source was used to excite 
the sample through a 20× or 50× objective. CaF2 slides were used to acquire all 
spectra to minimise Raman background. The recorded spectral range for grating 
1200 g mm-1 was 100–3200 cm-1, while the total data acquisition was 10 s for spectra. 
All spectra were background subtracted using the background correction algorithm 
available on the WiRE 4.4 software. 
2.2.9 Stimulated Raman scattering (SRS) microscopy 
2.2.9.1 SRS microscope 
Images were acquired using a custom-built multi-modal microscope setup previously 
described.49  Briefly: A picoEmerald (APE, Berlin, Germany) laser provided both a 
tuneable pump laser (720-990 nm, 7 ps, 80 MHz repetition rate) and a spatially and 
temporally overlapped Stokes laser (1064 nm, 5-6 ps, 80 MHz repetition rate). The 
output beams were inserted into the scanning unit of an Olympus FV1000MPE 
microscope equipped with an Olympus XLPL25XWMP N.A. 1.05 objective lens using 
a short-pass 690 nm dichroic mirror (Olympus). Backscattered emission signals from 
two-photon fluorescence were separated from scattered excitation light using a short-
 
‡ Dr Jimi Wills performed LC-MS injections and analysis. 
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pass 690 nm dichroic mirror and IR cut filter (Olympus). A series of filters and dichroic 
mirrors were then used to deconvolve the different emission signals onto one of 4 
available photo-multiplier tubes (PMT). Lysotracker® Green and Lysotracker® Red 
two-photon fluorescence signals were filtered using FF552-Di02, FF483/639-Di01 
and FF510/84 (Semrock). 
For SRS measurements, the Stokes beam was modulated with a 20 MHz electro-
optic-modulator (EoM) built into the picoEmerald laser. Forward scattered light was 
collected using a 20× Olympus XLUMPLFLN N.A. 1.00 objective lens and Stokes light 
was removed by filtering with an ET890/220m filter (Chroma). A telescope focused 
the light onto an APE silicon photodiode connected to an APE lock in amplifier with 
the time constant set to 20 μs except for fast acquisitions where it was set to 4 μs. 
The lock in amplifier signal was fed into an Olympus FV10-Analog unit. Laser powers 
after the objective were measured up to 40-70 mW for the pump laser and up to 
70 mW for the Stokes laser. All images were recorded at 512 × 512 or 1024 × 1024 
pixels with a pixel dwell time between 2 and 20 μs using FluoView FV10-ASW 
scanning software (Olympus). Where SRS signal quantification was measured, all 
samples were imaged under identical conditions on the same day.  
2.2.9.2 SRS sample preparation  
SW480 cells were plated at 5×104 cells in FluoroDish Cell Culture Dishes (World 
Precision Instruments) and incubated at 37 °C for 48 h. Adhered cells were incubated 
with ponatinib as indicated in the figure legends. Cells were washed with PBS 
(2 × 2 mL) and either imaged live or fixed with glutaraldehyde (4% in PBS, 10 min, 
37 °C) or paraformaldehyde (4% in PBS, 20 min, RT). Following fixation, cells were 
washed with PBS (2 × 2 mL) and stored at 4 °C prior to imaging. 
CML cells were plated in 10 cm dishes at 1×106 cells in RPMI (10% FBS, 1% 
L-Glutamine) for 48 h at 37 °C. Cells were incubated with ponatinib as indicated in the 
figure legends and washed with serum free RPMI (2 × 10 mL). The cell suspension 
was centrifuged (300 g, 3 min) to remove the media, and 3-5 μL of cell pellet 
(depending on coverslip size) was pipetted onto a glass slide and covered with a 
coverslip before live imaging by SRS microscopy.  
For multi-modal imaging experiments with Lysotracker® Green or Lysotracker® Red, 
cells were treated with ponatinib (5 μM, 1 h) or DMSO (1:1000, 1 h) and 
simultaneously labelled with Lysotracker® Green (ThermoFisher Scientific) (50 nM, 
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1 h, 37 °C) or Lysotracker® Red (ThermoFisher Scientific) (75 nM, 1 h , 37 °C) and 
imaged live by SRS microscopy and two-photon fluorescence microscopy. 
2.2.9.3 SRS image analysis 
ImageJ166 was used to add false colour assignments, overlays and scale bars to 
images. Consistent brightness settings were used throughout. 
Background subtraction. For each field of view alkyne and off-resonance images were 
opened on ImageJ. The off-resonance image was subtracted from the alkyne image 
using the image calculator functionality. (process à image calculator) 
Cell segmentation. A recorded cell identification macro§ was used on ImageJ to 
identify individual cells. Image of interest was opened (IN_folder) and freehand 
selection was used to draw around an individual cell in the field of view. The selection 
was added to ROI manager (Ctrl+T). This was repeated for the desired number of 
cells. All the selections were saved in the ROIset folder by clicking OK.  
(pluginàmacrosàrunàidentify_cells.ijmàIN_folderàROIset_folder) 
Cell segmentation macro was then used to individually extract all the saved cells using 
the ROIset saved of the image. This macro automatically saves individual cell images 
into a separate folder.  
(pluginàmacrosàrunàextract_cells.ijmàIN_folderàROIset_folderàcells_extrac-
ted_folder) 
2.2.9.4 Quantifying total intracellular ponatinib concentration 
KCL22Pon-Res cells were treated with ponatinib (5 µM, 1 h), washed and imaged live to 
determine optimal imaging settings that would prevent pixel saturation. The final laser 
power settings were set to be 100 mW (the tuneable pump beam) with gain 1. 
Calibration curve of ponatinib solutions in DMSO was then acquired. SRS images in 
the range of 2176 – 2246 cm-1 were obtained for each ponatinib concentration as well 
as DMSO alone in triplicate. The average pixel intensities of each SRS image across 
the range were calculated using ImageJ. The average pixel intensity values were 
plotted for each concentration and a Gaussian fitting was applied on Origin. The 
 
§ Dr Bertrand Vernay developed the ImageJ macros used in this thesis. 
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resulting peak was integrated, and the peak height was plotted at each concentration 
to give a ponatinib calibration curve. 
KCL22 and KCL22Pon-Res cells were treated with ponatinib (5 μM, 1 h), and imaged 
using identical SRS settings on the same day. Z-stacks were taken for each cell line. 
Individual cells (n=20) were segmented from these images using ImageJ.  
The data from individual cells were loaded into Matlab and processed by Dr Martin 
Lee. Image data were converted from software counts to a concentration using the 
parameters of the fitted line in excel unless the intensity fell below the y-axis intercept 
in which case the value was changed to zero to avoid negative concentrations.  This 
could occur due to noise in the SRS recording but was mainly found in background 
areas that had been segmented from the original data.  
Each pixel was used to represent a 3D volume by multiplying by pixel width, height 
and z-stack spacing.  Using the volume and concentration from the pixel intensity a 
corresponding amount of ponatinib in that area scanned could be calculated.  The 
total amount of ponatinib in the cell was calculated by summing all the data from each 
pixel and each image stack across all recorded images for that cell.  
Cell size measurements were taken using the recorded settings for image height and 
the area from the manual image segmentation image to calculate the average 
concentration of drug across the cell. 
2.2.9.5 Quantifying relative ponatinib levels at biologically relevant doses 
KCL22Pon-Res cells were treated with ponatinib (500 nM) for either 1 h, 6 h, 24 h or 
48 h. These cells were washed twice and imaged live using SRS microscopy at 
identical conditions (laser power 300 mW for the tuneable pump beam, gain 2). In 
order to maintain identical settings for all the samples in triplicate, the microscope was 
only used for this particular experiment over a two week period. Individual cells were 
segmented from a field of view (n=30) at each time point using ImageJ as described 
in Section 2.2.9.3. Average ponatinib Raman signal intensity (C≡C, 2221 cm-1) was 
measured for each individual cell on ImageJ. (analyseàmeasure) The results were 
compared to the DMSO control cells using GraphPad Prism. 
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2.2.9.6 Quantifying relative ponatinib levels inside and outside lysosomes 
CML cells were treated with ponatinib (5 µM, 1 h) and labelled with Lysotracker® 
Green (50 nM, 1 h) or Lysotracker® Red (75 nM, 1 h) simultaneously. The samples 
were washed twice with serum free media and imaged live immediately using multi-
modal imaging. Optimal SRS and fluorescence settings were chosen whilst imaging 
the first sample of the day and kept constant throughout the day for quantitative 
imaging.  
Images were processed and analysed on ImageJ. For every sample, the background 
subtraction was performed first as described in Section 2.2.9.3. Individual cells were 
extracted from the image as described in Section 2.2.9.3. ImageJ analysis workflow 
for measuring relative ponatinib intensity inside and outside lysosomes is shown in 
Figure 2.2. Three images that were used for the analysis included TPF (Lysotracker), 
ponatinib (2221 cm-1) and ponatinib background subtracted. Lysosomes were 
highlighted in the Lysotracker image using the thresholding function. 
(imageàadjustàthreshold)  This was converted into a map of lysosomes in the cell. 
(editàselectionàcreate selection) The map was transferred onto the subtracted 
ponatinib image. (Ctrl+shift+E) The relative Raman intensity of ponatinib inside 
lysosomes was measured, giving the mean and the maximum ponatinib intensities. 
(analyseàmeasure) The lysosome map was then transferred onto the ponatinib 
alkyne on-resonance image (2221 cm-1), where the data inside the lysosomes was 
cleared. (Ctrl+shift+Eàeditàclear) Thresholding function was used to highlight the 
rest of the cell aside from lysosomes, which was converted into a second map. 
(imageàadjustàthresholdàeditàselectionàcreate selection) The cell map was 
transferred onto the subtracted ponatinib image. (Ctrl+shift+E) The relative ponatinib 
Raman intensity outside of the lysosomes was measured. (analyseàmeasure) This 
was repeated for n=30 cells from each sample.  




Figure 2.2 ImageJ workflow for analysing relative ponatinib intensity inside and outside 
lysosomes. 
2.2.10 Statistical analysis 
All statistical analyses were done using GraphPad Prism software. Figure 2.3 shows 
the workflow used to analyse the data. For each dataset, D'Agostino-Pearson 
normality test and Shapiro-Wilk normality test were used first to assess if the data 
follows Gaussian distribution. If two datasets of interest were compared and both 
passed the normality tests, Welch’s t-test was applied. If more than two datasets were 
compared to each other that were normally distributed, one-way ANOVA with Tukey’s 
multiple comparisons test was used. However, where two or more independent 
variables were compared two-way ANOVA with Sidak’s multiple comparisons test 
was used. In case the data was not normally distributed, the non-parametric Mann-
Whitney test was used to compare two datasets and the Kruskal-Wallis with Dunn’s 
multiple comparisons test was used to compare three or more datasets.  




Figure 2.3 The workflow used to perform statistical testing of data on GraphPad Prism 
software.  
2.2.11 Spheroid protocol 
Spheroids were generated as previously described.157 Briefly, cells were grown as a 
monolayer and seeded at 250-20,000 cells per well in an ultra-low attachment U-
bottom 96-well plate (Corning). Plates were then centrifuged at 1000 g for 10 min. 
The plates were incubated under standard cell culture conditions at 37° C, 5% CO2 in 
humidified incubators. Spheroid plates were imaged at time points stated in figure 
legends at 4× magnification in the transmitted light channel using the ImageXpress 
Micro XLS (Molecular Devices). On day seven post seeding the spheroids were 
labelled with Calcein-AM (ThermoFisher Scientific, 3.5 µM), propidium iodide 
ThermoFisher Scientific, 1 µM) and Hoechst 33342 (ThermoFisher Scientific, 1 µM) 
for 1 h in an incubator before imaging in the appropriate fluorescent channels (DAPI, 
FITC, Texas Red) using ImageXpress. 
ImageXpress was used to create a single flattened z-stack image from an eight-step 
z-stack with a 50 µm step size. A 2D maximum intensity projection was used for 
fluorescent images and a 2D minimum intensity projection for transmitted light 
images. A custom CellProfiler pipeline was used to quantify the spheroid area and 
fluorescence intensities for each spheroid.167
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Chapter 3 Optimisation of ponatinib imaging by SRS 
microscopy  
3.1 Introduction   
Drug imaging of protein kinase inhibitors (PKIs) by Raman microscopy is not a widely 
used technique, with only a few examples existing in the literature.168-171 No PKI’s 
have been imaged using standard SRS microscopy. As such, there are no ‘standard’ 
protocols and guidelines available to use when imaging by SRS microscopy. In this 
chapter, DFT calculations and LC-MS analysis were used to validate our SRS imaging 
approach for ponatinib, a PKI used for the treatment of CML. With the goal of imaging 
ponatinib in live CML cells in a quantitative manner, the SRS imaging protocol was 
optimised to achieve the most reliable and robust results from our custom-built 
microscope.172 Part of this work has been published in a peer-reviewed journal.173 
3.1.1 Protein kinase inhibitors 
The last two decades have seen a significant increase in the development of 
molecularly targeted therapies in oncology, namely small molecule protein kinase 
inhibitors.174 Protein kinases are involved in the pathogenesis of a number of 
diseases, including cancer. In 2001, imatinib was approved as the first therapeutic 
PKI by the FDA and since then a total of 52 PKIs have successfully passed clinical 
trials.175 The majority of these (46) are oncology drugs, demonstrating that kinases 
are effective targets in combatting cancer. It is therefore unsurprising that they have 
become an important drug target in the pharmaceutical industry.176,177 Up to 33% of 
drug discovery today involves protein kinases, with 175 candidates in clinical trials in 
2018.178 
3.1.2 Drug imaging of PKIs using Raman microscopy 
Although recent years have seen an unprecedented number of new drugs approved 
by the FDA, preclinical evaluation of intracellular localisation of drug candidates 
remains a challenge. Raman microscopy has been applied to the visualisation of a 
number of PKIs since 2014, demonstrating its potential as a drug imaging tool.  
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3.1.2.1 Imaging by spontaneous Raman spectroscopy 
El-Mashtoly et al. were the first to use spontaneous Raman spectroscopy to visualise 
a PKI.168 It was applied to imaging erlotinib, an Epidermal Growth Factor Receptor 
(EGFR) inhibitor that is used as a first line treatment for non-small cell lung cancer.179 
Erlotinib has an inherent alkyne moiety in its structure conjugated with an aryl ring, 
giving it a comparatively strong alkyne peak in its Raman spectrum (~2100 cm-1, 
Figure 3.1a). Intracellular erlotinib was detected in colon cancer cells (SW480), 
demonstrating that it localises in the cell periphery where EGFR are located (Figure 
3.1b). Furthermore, using Raman spectroscopy analysis of intracellular erlotinib, they 
found the intracellular metabolite of erlotinib in SW480 cells to be desmethyl-erlotinib 
(Figure 3.1a). The human plasma concentration of erlotinib and desmethyl-erlotinib 
following an oral dose of 150 mg per day, however, has been measured to be 3-5 µM 
and 0.2-0.7 µM respectively.180,181 These concentrations are below the detection limit 
of spontaneous Raman spectroscopy, which is why a higher concentration of erlotinib 
was used to treat cells in this study (~100 µM). Plasma concentrations, however, are 
not always reflective of the drug concentration inside a tumour. Patient studies have 
found in many cases that drug concentration in the tumour is lower than the reported 
plasma concentration, although the opposite also holds true.182,183 It is unlikely that 
clinically relevant intra-tumour concentrations could be imaged. 
 
 
Figure 3.1 Spontaneous Raman imaging of erlotinib. (a) Raman spectrum of erlotinib, alkyne 
peak at 2110 cm-1. (b-d) Spontaneous Raman images of SW480 cells which were treated with 
erlotinib (~100 µM, 12 h). (b) Raman image re-constructed from the C-H stretching intensity. 
(c) Raman image re-constructed from C≡C stretching intensity. (d) Overlay of panels (b) and 
(c). Adapted with permission,168 copyright Royal Society of Chemistry. 
 Optimisation of ponatinib imaging by SRS microscopy 
61 
 
Yosef et al. used spontaneous Raman spectroscopy to image sorafenib, a multikinase 
inhibitor used for the treatment of a number of cancers including kidney and liver 
cancer.171,184,185 One of the targets of sorafenib are rapidly accelerated fibrosarcoma 
(RAF) family kinases RAF-1, B-RAF, and A-RAF including the B-RAFV600E mutation, 
which is most often known in melanoma where RAF inhibitors are used to treat B-RAF 
mutant disease.186 It has also been found to be prevalent in metastatic colon and lung 
cancer patients with resistance to EGFR targeted therapy.187-189 In this study, 
sorafenib was used in the colon cancer cell line HT29, which harbours the B-RAFV600E 
mutation. The structure of sorafenib lacks any specific Raman active bands in the cell-
silent region. Therefore, a characteristic band from the fingerprint region was used to 
visualise the drug using 50 µM, 4 h treatments (Figure 3.2). Using 
immunofluorescence labelling alongside Raman, they showed sorafenib co-localises 
with the target B-RAF. The measured plasma concentration of sorafenib in metastatic 
patients after 400 mg dose was up to 13 µM, about 4-fold lower than the concentration 
required for Raman imaging in this study.190  
 
 
Figure 3.2 (a) Raman spectrum and chemical structure of sorafenib tosylate. (b-i) Raman 
imaging of HT29 cells treated with sorafenib (50 µM) for 4 h. Raman images reconstructed 
from (b) 1420–1470 cm-1 (C-H bending) and (c) 1015-1040 cm-1 (sorafenib without its tosylate). 
(d), (e) Cross-sectional Raman images along the x–z axis of the same cells. The scanning 
positions are indicated by the white line in (b). (f) Integrated Raman image of an HT29 cell. (g) 
The hierarchical clustering of the Raman data shown in (f) containing sorafenib (red). (h) 
Fluorescence image of the same cell showing B-RAF (green) and the nucleus (blue). (i) 
Overlay of sorafenib cluster from (g) (red) and (h). Sorafenib and B-RAF co-localisation in 
yellow. Adapted with permission,171 copyright Royal Society of Chemistry. 
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Neratinib, a dual TKI inhibiting EGFR and human epidermal growth factor 2 (HER2) 
irreversibly, was the first PKI imaged by spontaneous Raman spectroscopy using a 
sub-micromolar treatment concentration.169 Although neratinib possesses an 
inherently Raman active nitrile group in the cell silent region (Figure 3.3a), a strong 
Raman band in the fingerprint region at 1386 cm-1 enabled Aljakouch et al. to image 
the drug in fixed non-small cell lung cancer NCI-H1975 cells following 500 nM, 8 h 
treatment (Figure 3.3b-g). This is close to the measured neratinib plasma 
concentration (up to 257 nM).191 In addition, Aljakouch et al. found that the key 
neratinib Raman peaks shift upon cellular metabolism, giving two different metabolite 
signatures: M1 (1386à1399: 2208à2217 cm-1) and M2 (1386à1388/1402; 
2208à2217 cm-1) (Figure 4.3h). Using LC-MS, they determined the molecular weight 
of three major neratinib metabolites I (M = m/z 449.1), II (M=433.1) and III (M=461.1). 
DFT calculations were run to find out which metabolites determined by LC-MS could 
have contributed to the Raman spectra of M1 and M2. M1 was found to originate from 
metabolite I, whilst M2 likely originated from metabolite IIb and/or metabolite IIIb 
(Figure 3.3h). This work demonstrated the potential detection sensitivity of 
spontaneous Raman spectroscopy. The lack of ability to image drugs in live cells, 
however, remains, due to the slow image acquisition times of spontaneous Raman.  
 
 
Figure 3.3 (a) Raman spectrum of free neratinib. (b-g) Raman imaging of NCI-H1975 cells 
treated with neratinib (500 nM, 8 h). Raman images reconstructed from the (b) C-H 
deformation 1425-1470 cm-1 and (c) neratinib 1380-1410 cm-1 band intensities. (d) Overlay of 
(b) & (c). (e-g) Cross-section Raman images along the x, z-direction of the same cell. Scanning 
positions indicated by the white line in (b). (h) Structures of neratinib and its intracellular 
metabolites M1 and M2. Adapted with permission,169 copyright John Wiley and Sons. 
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3.1.2.2 Imaging by hyperspectral stimulated Raman scattering 
Fu et al. utilised label-free hyperspectral SRS (hSRS) microscopy to study the drug 
uptake of imatinib and nilotinib in live CML cells (Figure 3.4).170 Hyperspectral SRS 
allows imaging at multiple Raman frequencies simultaneously. The spontaneous 
Raman spectra of each drug were used to identify the major peaks for both imatinib 
and nilotinib (Figure 3.4a). The characteristic wavenumber at 1308 cm-1 was used to 
detect intracellular imatinib and nilotinib by analysing hSRS spectra following 4 h 
treatment with either of the drugs (20 µM) (Figure 3.4b,c). Both drugs were detected 
as puncta inside CML cells. Furthermore, two-photon excitation was used to measure 
fluorescent images alongside hSRS, and Lysotracker® Red dye was used to 
demonstrate drug localisation within lysosomes of the cells.  
As SRS is a concentration dependent technique, they were able to measure the 
intracellular drug concentration of imatinib and nilotinib based on a calibration curve 
generated by standard drug solutions in DMSO. Interestingly, they found a 1000-fold 
enrichment of the drugs inside lysosomes. Lysosomal drug trapping, however, 
reduces cytosolic drug availability and therefore can reduce drug efficacy. It was 
demonstrated that combination treatment with 20 µM imatinib and 50 µM chloroquine, 
a non-specific autophagy inhibitor, resulted in a tenfold decrease in the lysosomal 
imatinib enrichment, and hence an increase in the available cytosolic imatinib. This 
offers a plausible explanation to why chloroquine has been shown to have a 
sensitising effect in imatinib-based chemotherapy.129  
The measured plasma concentrations in CML patients treated with imatinib and 
nilotinib are 4 µM and 2 µM respectively.192,193 This is still lower than the concentration 
used in this experiment (20 µM), highlighting the limitation of hSRS imaging when it 
comes to using physiologically relevant drug concentrations. Overall, Fu et al. showed 
that hSRS imaging can offer unprecedented capability in label-free drug visualisation, 
and could be a valuable tool in pharmacokinetic studies. 





Figure 3.4 (a) Chemical structures and Raman spectra (700-1700 cm-1) of imatinib and 
nilotinib. 1305 cm-1 peak marked in shaded blue used for SRS imaging of both drugs. (b-d) 
Two-photon fluorescence imaging of Lysotracker® Red and SRS imaging of drug 
accumulation. BaF3/BCR-ABL1 cells were treated with: (b) 20 µM imatinib, (c) 20 µM nilotinib 
or (d) DMSO for 4 h. (i) Maximum-intensity projection of 3D SRS images at 1305 cm-1. (ii) 
Maximum-intensity projection of 3D LysoTracker® Red fluorescence images of 
BaF3/BCR-ABL1 cells treated with: (b) 20 µM imatinib, (c) 20 µM nilotinib and (d) DMSO only. 
(iii) Overlay of corresponding SRS images (green) and fluorescence images (red). Scale 
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3.2 Spontaneous Raman spectroscopy of ponatinib  
The BCR-ABL TKI ponatinib (Figure 3.5a) has an inherent alkyne moiety within its 
structure. This can be used to image the drug’s intracellular localisation without the 
addition of bulky tags such as fluorophores that could affect the biological activity of 
the drug. We therefore used this to demonstrate the utility of SRS for monitoring 
spatial and temporal drug distribution, using ponatinib as a model drug for the study. 
Initial Raman spectroscopy on powdered ponatinib enabled detection of the alkyne 
peak (2221 cm-1) within the Raman spectrum (Figure 3.5b). This peak is in the ‘cell-
silent region”, between 1800-2800 cm-1, where no inherent cellular Raman peaks are 
found.60 Imaging in this region of the Raman spectrum has the advantage of having 
minimal intracellular background, providing enhanced detection sensitivity. 
 
Figure 3.5 (a) Chemical structure of ponatinib. (b) Raman spectrum of solid ponatinib; C≡C 
peak is annotated at 2221 cm-1. Raman spectra were acquired at λex = 532 nm for 10 s using 
a 50× objective. 
3.3 Assessing levels of ponatinib metabolism in vitro by LC-MS 
Previous imaging of erlotinib and neratinib by Raman microscopy demonstrated that 
the Raman peak of interest changes upon cellular metabolism.168,169 Hence, it was 
important to consider ponatinib cellular metabolism prior to SRS imaging at a single 
wavenumber. Small molecule drugs are known to be metabolised by cytochrome 
P450 (CYP) enzymes in the body.194 CYPs are extremely versatile and catalyse a 
range of range of reactions, including carbon hydroxylation, heteroatom oxidation, 
dealkylation, epoxide formation as well as other more complex transformations.195 In 
humans, the main five hepatic CYP isoforms catalysing drug metabolism are 
CYP3A4, CYP2D6, CYP1A2, CYP2C9, CYP2E1.196 CYP3A4 is estimated to be 
responsible for the metabolism of over 50% of the drugs on the market; and it is 
involved in the metabolism of most TKIs.197  
Research on ponatinib metabolism in vivo and in human liver microsomes found the 
drug is catalysed predominantly by the CYP3A4 enzyme.198,199 The major ponatinib 
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metabolites identified in earlier studies include N-desmethyl (2) and N-oxide (3) forms 
of the drug as well as the hydroxylated (4) and dihydroxylated (5) forms 
(Figure 3.6).198,200,201 Lin et al. also found that following hydroxylation ponatinib can 
further react with glutathione (GSH) to form GSH adducts 6 and 7.198 They suggest 
these GSH adducts are formed via an intermediary epoxide formation step.  
Our target cell lines for SRS imaging were human CML cell lines KCL22 and the 
ponatinib resistant equivalent KCL22Pon-Res (cell lines described in Section 2.2.1.1). 
We used Western blot analysis to investigate CYP3A4 levels in these cell lines and 
found both cell lines expressed equal levels of CYP3A4 (Figure 3.7a). This indicated 
that intracellular metabolism of ponatinib is likely inside these CML cells. To assess 
the level of all the known metabolites in our human CML cell lines, we treated cells 
with ponatinib (5 µM, 1 h) and subsequently analysed samples by LC-MS. Ponatinib 
was found to be by far the most abundant species in the CML cells whilst only trace 
amounts of N-desmethyl (2) and dihydroxylated (5) metabolites were found (Figure 
3.7b). Considering the concentrations of these metabolites in the CML cell lines was 
very low, their presence is unlikely to affect quantitative SRS imaging of ponatinib at 
a single wavenumber. 
 
Figure 3.6 (a) Ponatinib (1) and its reported metabolites (2-7). Metabolism pathways and the 
major enzymes responsible for each metabolite are shown. CYP3A4 is responsible for 
N-desmethyl (2) and N-oxidation (3) metabolites. CYP1A1 is responsible for hydroxylation (4) 
and dihydroxylation (5). Hydroxylated metabolites (4,5) can further form adducts with 
glutathione to for GSH (6) and GSH-OH (7). Adapted with permission.198 




Figure 3.7 (a) Expression of CYP3A4 in lysates from KCL22 and KCL22Pon-Res cells. β-actin 
was used as a loading control. CYP3A4 levels were quantified from n=3 biological replicates 
and normalised to β-actin using Image Lab software. T-test was used to compare CYP3A4 
levels in KCL22 and KCL22Pon-Res cells. (b) Ponatinib and relative ponatinib metabolite levels 
measured by LC-MS. Cells were treated with ponatinib (5 µM) for 1 h prior to analysis. Mean 
values (±SEM) from n=5 biological repeats expressed relative to ponatinib. 
3.4 Predicting Raman signal intensity and frequency by DFT 
In order to account for potential Raman shifts or intensity changes due to intracellular 
metabolism of ponatinib, DFT calculations** were utilised. Theoretical Raman 
intensities have previously been calculated by DFT and expressed as IRam.60,202 
Additionally, experimental Raman intensities have been compared to the intensity of 
the alkyne resonance in the nucleoside analogue ethynyl deoxyuridine (EdU) and 
reported as relative intensity to EdU (RIE).45 Here, these two approaches were 
merged to obtain calculated RIE values (cRIE) for ponatinib as well as the metabolites 
we found present via LC-MS analysis (Table 3.1). DFT calculations have also been 
shown to predict Raman vibrational frequency shifts due to primary drug 
metabolism.169 Hence, a series of DFT calculations was carried out to determine if the 
alkyne peak in ponatinib was likely to shift in frequency in the major metabolites; and 
to confirm that acquiring SRS images at a single vibrational frequency for the alkyne 
(Figure 1b, C≡C, 2221 cm-1) would be appropriate for assessing ponatinib 




** DFT calculations performed by Marie Bluntzer. 
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Table 3.1. DFT calculated wavenumbers, intensities (IRam) and relative intensity to EdU values 
for ponatinib and its metabolites. Standard deviation for 10 lowest energy structures shown. 







EdU 2132 ± 0.74 (2120)b 693 ± 57 1.0 
ponatinib (1) 2217 ± 0.5 (2221) 14649 ±1581 21.1 ± 2.3 
ponatinib protonated 2217 ± 0.9 12135 ± 1059 17.5 ± 1.5 
N-desmethyl ponatinib (2) 2218 ± 0.5 15011 ± 1194 21.7 ± 1.7 
dihydroxylated ponatinib (5) 2218 ± 0.9 11613 ± 1136 16.8 ± 1.6 
neratinibc 
2228 ± 0.1 
2238d (2208)d 
819 ± 16 1.2 ± 0.1 
a DFT calculated values ±SD with experimentally determined values in brackets.  b Value reported by 
Tipping et al.49 c C≡N rather than C≡C. d Values reported by Aliakouch et al.169  
Ponatinib is susceptible to protonation in acidic organelles inside the cell due to the 
piperazine unit in its structure.203,204 Our DFT calculation predicted both ponatinib and 
its protonated form would have the same alkyne Raman frequency, while the cRIE 
value was slightly decreased upon protonation (Table 3.1). This confirmed that SRS 
imaging of ponatinib at a single wavenumber would be accurate across the whole cell 
environment regardless of variation in subcellular pH. In our LC-MS analysis we 
identified trace amounts of ponatinib metabolites to be its N-desmethyl (2) equivalent 
alongside the dihydroxylated (5) form (Figure 3.7b). In N-desmethyl (2) ponatinib, the 
metabolism site remains distal to the alkyne, so a large shift in IRam was not expected. 
The DFT calculation (Table 3.1) affirmed this as a similar cRIE value was found for 
the parent drug and the metabolite, and minimal alkyne Raman frequency shifts were 
predicted. Similarly, the DFT calculation for dihydroxylated ponatinib (5) did not 
predict a big Raman frequency shift, and the calculated cRIE value was only 
marginally lower (Table 3.1). Hence, the DFT calculations provided further proof that 
ponatinib metabolism is unlikely to cause significant changes in its Raman spectrum, 
validating our approach to image ponatinib at a single wavenumber using SRS 
microscopy.  
 
†† DFT calculations performed by Marie Bluntzer. 
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3.5 Imaging ponatinib in vitro using SRS microscopy  
3.5.1 Imaging ponatinib in adherent cells  
3.5.1.1 Imaging in fixed SW480 cells  
As all the CML cell lines used in the model system are non-adherent, these cells could 
not be imaged using a traditional SRS protocol previously utilised for adherent cell 
lines. In order to test and optimise the ponatinib imaging protocol by SRS, an adherent 
colorectal carcinoma cell line (SW480) was utilised first (cell line description in Section 
2.2.1.1). Fibroblast growth factor receptor 2 (FGFR2) is a member of a family of 
tyrosine kinase receptors (FGFR 1-4) and has been found to be amplified in a number 
of cancer types, including colon cancer.205,206 In addition to being a potent BCR-ABL 
inhibitor, ponatinib has been shown to be a potent inhibitor of all four FGFR’s with an 
IC50 value <20 nM, thus making the SW480 cell line relevant for investigating ponatinib 
uptake and intracellular distribution.98,191,207 
First experiments using SW480 cells included treating the cells with ponatinib for 2 h 
prior to washing and fixation (Figure 3.8). The washing step was implemented after 
the incubation period to remove any free drug from the extracellular space that had 
not been taken up by the cells. The fixed cell samples were then imaged on the 
custom-built SRS microscope. 
 
Figure 3.8 Schematic for adherent cell treatment prior to SRS imaging. (a) SW480 cells were 
plated onto fluorodishes on day zero and incubated for 48 h to allow them to adhere to the 
plates. (b) On day two SW480 cells were treated with ponatinib (concentration ranging from 
25 µM to 5 µM) for 2 h before (c) washing with PBS and fixation using glutaraldehyde. Image 
created with Biorender. 
SRS images were acquired by tuning the frequency difference between the pump and 
Stokes lasers to be resonant with intracellular proteins (CH3, 2940 cm-1) or ponatinib 
(C≡C, 2221 cm-1). False colours were applied to individual Raman spectral 
frequencies (Figure 3.9a). This process allows cellular detection without the need for 
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any additional labelling. SRS images can contain background signals from competing 
pump-probe processes such as cross-phase modulation, transient absorption and 
photothermal effects.208 Changing the pump wavelength by a few nanometres allows 
off-resonance images to be acquired (at a difference of 20-40 cm-1 from the on-




Figure 3.9 Multicolour SRS imaging of fixed SW480 cells treated with ponatinib. SW480 cells 
were treated with: (a) DMSO (0.0003%, v/v); (b) ponatinib (25 μM, 2 h); (c) ponatinib 
(10 μM, 2 h); (d) ponatinib (5 μM, 2 h) and fixed with glutaraldehyde (4%). Images were 
acquired in sequence from left to right: 2940 cm-1 (CH3, proteins); 2221 cm-1 (C≡C, ponatinib); 
2243 cm-1 (cell-silent region); 2221 cm-1 with background subtracted. Images acquired at 1024 
× 1024 pixels, 20 μs pixel dwell time, laser power 300 mW (the tuneable pump beam) with 
false colours applied to different detection wavenumbers. Scale bars: 10 μm. 
The DMSO control cells (Figure 3.9a) demonstrated that there was minimal SRS 
signal detected in the bioorthogonal region of the untreated SW480 cells at either 
2221 cm-1 (C≡C, ponatinib on resonance) or 2243 cm-1 (off-resonance). SRS imaging 
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of SW480 cells that were treated with ponatinib (25 µM, 2 h) enabled successful 
detection of ponatinib (alkyne, 2221 cm-1; off-resonance, 2243 cm-1) which distributes 
throughout the cytoplasm of the cell (Figure 3.9b). Background subtracted images 
were created by subtracting the off-resonance image from the alkyne on resonance 
image (2221 cm-1 – 2243 cm-1). In SW480 cells treated with lower ponatinib 
concentrations (10 µM or 5 µM, 2 h), a similar intracellular distribution of ponatinib 
(Figure 3.9c and 3.9d respectively) was seen compared to those treated at the higher 
concentration. However, as the ponatinib treatment concentration decreased, the 
intracellular signal also decreased, indicating reduced drug uptake by the cell, as the 
SRS signal is concentration dependent.63 No drug signal (2221 cm-1, C≡C, ponatinib 
on resonance) was detected in SW480 cells treated with ≤1 µM ponatinib (2 h). This 
means that at these treatment conditions ponatinib is no longer accumulating in the 
cells at high enough intracellular concentrations to be able to detect it by the SRS set 
up. 
3.5.1.2 Imaging ponatinib in live SW480 cells 
Once ponatinib imaging was working in fixed cells, the same protocol was tested in 
live cells. SW480 cells were treated as described in Figure 3.8, except this time the 
cells were only washed post ponatinib treatment, not fixed. Fresh media was added 
to the cells after washing, followed by live imaging on the SRS microscope.  
Once again, control cells demonstrated minimal background signals at ponatinib on 
resonance (2221 cm-1) and off resonance (2243 cm-1) wavenumbers in the cell-silent 
region of the Raman spectrum (Figure 3.10a). Ponatinib was detected in the drug 
treated live cells (Figure 3.10b and 3.10c) when both 25 µM and 10 µM concentrations 
were used for 2 h before washing. In contrast to the fixed SW480 cells (Figure 3.9), 
where ponatinib was seen diffusely throughout the cytoplasm, it was observed that 
ponatinib accumulated in live SW480 cells as distinct puncta. It is possible that a 
proportion of internalised ponatinib was re-distributed within the cells during the 
washing steps of the fixation process. As cell fixation with glutaraldehyde works by 
cross-linking proteins via their reactive side-chains, ponatinib as a small molecule 
does not necessarily get fixed in the process.209,210 This could explain why diffuse 
ponatinib signal was seen in fixed SW480 cells and ponatinib puncta were detected 
in live SW480 cells. The effect of fixing on ponatinib imaging was further investigated 
in different cell lines in Section 5.3.1. 




Figure 3.10 Ponatinib imaging in live SW480 cells. SW480 cells were treated with (a) DMSO 
(0.0003%, 2 h); (b) ponatinib (25 µM, 2 h); (c) ponatinib (10 µM, 1 h). SRS images were 
acquired in a sequence from left to right: 2940 cm-1 (CH3, proteins); 2221 cm-1 (C≡C, 
ponatinib); 2243 cm-1 (off-resonance); 2221 cm-1 with background subtracted. Images 
acquired at 1024 × 1024 pixels, 20 μs pixel dwell time, laser power 300 mW (the tuneable 
pump beam) with false colours applied to different detection wavenumbers. Scale bars: 10 μm. 
In Figure 3.10, it was also noted that the images taken of live SW480 cells treated 
with 10 µM ponatinib had a somewhat higher background at 2243 cm-1 than the fixed 
cells in Figure 3.9. In order to check if the off-resonance was perhaps still on the edge 
of the ponatinib SRS peak, a sweep of the ponatinib peak was taken between 2170– 
2270 cm-1. Across the 100 wavenumber sweep, 26 SRS images were captured 
sequentially, creating a dataset where each pixel had a range of Raman intensity 
values. An area of ponatinib intensity within SW480 cells was then highlighted and 
the intensities of this area plotted across the range of wavenumbers on Fiji. 
Figure 3.11 shows the SRS sweep, demonstrating that 2221 cm-1 is indeed the middle 
of the ponatinib peak inside cells. It also shows that 2243 cm-1 (859.0 nm on the pump 
laser), which was used on the microscope to take off-resonance images, is indeed 
still on the edge of the ponatinib peak. Taking off-resonance images at 2257 cm-1 
(858.0 nm on the pump laser), which is further away from ponatinib peak edge, would 
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Figure 3.11 SRS sweep of ponatinib peak in SW480 cells treated with ponatinib (10 µM, 2 h). 
Ponatinib on resonance (2221 cm-1) and off resonance (2243 cm-1, 2257 cm-1) peaks 
highlighted in blue.  
3.5.2 Imaging ponatinib in non-adherent CML cells 
Imaging non-adherent cells required a new experimental protocol as these cells do 
not attach to the plastic surface of the dishes they are grown in.  
3.5.2.1 Imaging ponatinib in a panel of live mouse CML cells  
CML cells were plated onto 10 cm petri dishes on day 0 and left to settle for 48 h 
before treatment with ponatinib (concentration ranging from 25 µM to 1 µM) for 2 h 
(Figure 3.12). The cells were subsequently washed with serum free media by 
centrifugation in Falcon tubes. Media was used for washing the cells rather than PBS 
as it was milder for live cells and gave better quality imaging results. Washing media 
was then removed from the Falcon tube, leaving a cell pellet with only a small amount 
of media (<500 µL). The cell pellet was then taken to the microscope room, where the 
pellet was gently re-suspended in the remaining media. An aliquot of live cells (2-5 µL 
depending on the coverslip size) was pipetted onto a microscope slide and a coverslip 
placed on top of the sample to form a single layer of cells. Cells were then immediately 
imaged on the SRS microscope.  
Ponatinib imaging was first tested in BaF3 mouse CML cell lines – BaF3-p210 and 
BaF3 p210Pon-Res (cell lines described in Section 2.2.1.1). Both BaF3-p210 and 
BaF3-p210Pon-Res cells are BCR-ABL positive, meaning these cells express the main 
clinical target of ponatinib. However, while BaF3-p210 cells are highly sensitive to 
ponatinib treatment (GI50 – 2.3 nM), BaF3-p210Pon-Res are resistant to the drug with a 
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500-fold higher dose tolerance over 48 h treatment (GI50 – 1017 nM) (GI50 values were 
determined by Alamar blue assay, details in Section 2.2.2). It was hence hypothesised 
that imaging ponatinib in BaF3 p210Pon-Res cells might be easier at higher doses 
without affecting cell viability.  
 
 
Figure 3.12 Scheme for non-adherent cell imaging using SRS microscopy. (a) CML cells were 
plated onto 10 cm Petri dishes on day zero and incubated for 48 h to allow them to settle.  (b) 
On day two CML cells were treated with ponatinib (concentration ranging from 25 µM to 1 µM) 
for 2 h. (c) Cells were subsequently washed with drug free media and (d) centrifuged in a 
Falcon tube to leave a cell pellet. (e) An aliquot of the cell pellet was pipetted onto a glass 
microscope slide and sealed with a coverslip. Image created with Biorender. 
Figure 3.13 shows sample SRS images of ponatinib in live BaF3 cells. The control 
BaF3 p210 cells that were treated with DMSO (2 h) showed virtually no signal in the 
cell silent region at 2221 cm-1 (C≡C, ponatinib peak) and 2096 cm-1 (off resonance). 
SRS imaging of BaF3 p210 cells that were treated with ponatinib (10 μM, 2 h) enabled 
successful detection of ponatinib (alkyne, 2221 cm-1; off-resonance, 2096 cm-1) in 
most of the cells in the field of view (Figure 3.13b). Ponatinib was also detected in 
BaF3 p210Pon-Res cells treated with the drug (10 µM, 2 h) (Figure 3.13c). In both cell 
lines, ponatinib was seen in cells as bright, very distinct puncta. This was in contrast 
to the SW480 cells, where ponatinib signal was also seen in the cell cytoplasm outside 
of the bright puncta.  





Figure 3.13 SRS imaging of live BaF3 cells treated with ponatinib. BaF3 p210 cells were 
treated with: (a) DMSO; (b) ponatinib (10 μM, 2 h). BaF3 p210Pon-Res cells were treated with 
(c) ponatinib (10 μM, 2 h). Images were acquired in sequence from left to right: 2940 cm-1 
(CH3, proteins); 2221 cm-1 (C≡C, ponatinib); 2096 cm-1 (off-resonance). Images acquired at 
1024 × 1024 pixels, 20 μs pixel dwell time, laser power 300 mW (the tuneable pump beam) 
with false colours applied to different detection wavenumbers. Scale bars: 10 μm. 
 
3.5.2.2 Optimising ponatinib imaging in live human CML cells 
Following successful imaging in live mouse CML cells, the next challenge was 
repeating this in live human CML cell lines whilst also optimising the conditions. For 
this purpose, KCL22 cells were utilised. This cell line has a very low GI50 value against 
ponatinib (2.4 nM) as it sensitive to the drug (GI50 values in Section 2.2.2.1). As the 
long term goal of the project was to quantitatively image ponatinib in both KCL22 and 
KCL22Pon-Res cells, optimisation was carried out in the drug sensitive cell line based 
on the hypothesis that imaging in KCL22Pon-Res cells will be less challenging due to 
this cell line having a higher tolerance against ponatinib (GI50 – 593 nM). 
The first optimisation step assessed the duration of ponatinib treatment in KCL22 
cells. Earlier imaging experiments were performed in BaF3 cells treated with ponatinib 
for 2 h (Figure 3.13). The ponatinib signal was readily detected in cells after 2 h 
treatments (Figure 3.13), indicating high uptake of the drug in concentrated puncta. 
Hence, it was hypothesised that ponatinib is taken up by the cells rapidly enough to 
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halve the treatment time to 1 h. To test this, KCL22 cells were treated with ponatinib 
(10 µM, 1 h) and imaged using SRS (Figure 3.14b). Ponatinib was successfully 
detected in KCL22 cells following the shorter treatment - bright puncta were seen in 
the cytoplasm of the cells, on average 12 puncta per cell (SD±13) in n=20 cells from 
the field of view. Interestingly, the number of ponatinib spots ranged from 2 to 52 in 
different cells, demonstrating heterogeneous uptake of the drug in KCL22 cells. While 
the mean Raman intensity inside ponatinib spots was 1947, less concentrated diffuse 
ponatinib signal seen throughout the cytoplasm was 7-fold lower, 277 in n=10 cells. 
We considered 1 h drug treatment optimal for further live cell imaging experiments.  
 
 
Figure 3.14 Imaging ponatinib uptake in KCL22 cells. KCL22 cells were treated with: (a) 
DMSO (1 h); (b) ponatinib (10 µM, 1 h); (c) ponatinib (5 µM, 1 h); (d) ponatinib (1 µM, 1 h). 
Images were acquired in sequence from left to right: 2940 cm-1 (CH3, proteins); 2221 cm-1 
(C≡C, ponatinib); 2257 cm-1 (off-resonance); 2221 cm-1 with background subtracted. Images 
acquired at 1024 × 1024 pixels, 20 μs pixel dwell time, laser power 250 mW (the tuneable 
pump beam) with false colours applied to different detection wavenumbers. Scale bars: 10 μm. 
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The second optimisation step assessed the treatment concentration in KCL22 cells. 
The goal was to determine the lowest ponatinib concentration at 1 h treatment where 
ponatinib could still be detected in live cells by SRS. KCL22 cells were treated with a 
range of ponatinib concentrations (10 µM to 1 µM), washed and imaged (Figure 
3.14b,c,d). The most intense ponatinib Raman signal was detected in KCL22 cells 
treated with 10 µM ponatinib, where mean intensity in ponatinib puncta was 1947 
(Figure 3.14b). This is indicative of higher uptake of ponatinib in these cells as SRS 
signal is concentration dependent.63 When a sweep was taken of the ponatinib peak 
using SRS, we could see the alkyne peak for intracellular ponatinib (2221 cm-1, Figure 
3.15a). Gaussian fitting was applied to measure the peak height, giving 102.7 a.u. for 
KCL22 cells treated with 10 µM ponatinib.  
Intracellular distribution of ponatinib could still be detected in KCL22 cells treated with 
a lower ponatinib concentration (5 μM, 1 h), but the Raman signal intensity in ponatinib 
puncta was reduced to 509, almost 4-fold lower than in cells treated with 10 µM 
ponatinib concentration (Figure 3.14c). When a sweep was taken of the ponatinib 
peak by SRS, we could see a peak corresponding to intracellular ponatinib 
(2221 cm-1, Figure 3.15b), but the peak height was reduced to 22.2 a.u. compared to 
10 µM treatment (102.7 a.u), indicative of reduced intracellular drug concentration. So 
the signal intensity reduction is mirrored by the reduction in peak height. As these 
sweeps were not obtained on the same day and under controlled conditions, the 
reduction in peak height is not necessarily linear. Later, in Section 3.5.3 where 
ponatinib SRS sweeps in DMSO solutions are obtained on the same day for the 
purpose of signal quantification, we show that SRS signal reduction is linear and 
correlates with peak height reduction.  
When ponatinib concentration was reduced further (1 μM, 1 h), no ponatinib was seen 
inside the cells (Figure 3.14d), and a sweep of the alkyne peak gave a flat line (Figure 
3.15c). This means that at these treatment conditions ponatinib is no longer 
accumulating in the cells at high enough intracellular concentrations to be detected 
by the SRS setup. Therefore, 5 µM ponatinib concentration is the lowest we can detect 
in KCL22 cells following short treatment, while 10 µM concentration results in higher 
uptake of ponatinib across the cell population.  




Figure 3.15 SRS sweep of ponatinib peak inside live KCL22 cells following treatment with (a) 
ponatinib (10 µM, 1 h), (b) ponatinib, (5 µM, 1 h), (c) ponatinib, (1 µM, 1 h)  where (i) inside 
cells, (ii) background intensity of media. Laser power 250 mW (the tuneable pump beam).  
 
3.5.2.3 Ponatinib uptake in CML cells 
Drugs can be taken up into the cells either by passive diffusion or active transport. 
Passive diffusion through the cell membrane does not require cells to expend energy, 
whilst active transport does. In order to test if ponatinib accumulation in cells is driven 
by active or passive transport, KCL22 cells were incubated with the drug at either 4 °C 
or 37 °C and imaged subsequently (Figure 3.16). At 4 °C, all energy requiring 
processes are halted, meaning only passive diffusion can take place, whilst at 37 °C 
both active and passive transport can be utilised by cells. 
The mean ponatinib Raman intensity was quantified per cell at both 37 °C and 4 °C 
using ImageJ (Figure 3.16b). No significant difference was found between the 
samples, demonstrating that KCL22 cells treated with ponatinib (5 µM, 1 h) at either 
37 °C or 4 °C both had equal levels of drug uptake (Figure 3.16b). This indicates that 
ponatinib accumulates in KCL22 cells by passive diffusion. Previous research by 
Lu et al. used an intracellular uptake and retention (IUR) assay with 14C-labeled 
ponatinib at 37 °C or 4 °C and found no significant difference in ponatinib IUR in CML 
cells, also concluding that ponatinib is passively transported into the cells.211 Other 
tyrosine kinase inhibitors such as sunitinib and sorafenib, have also been reported to 
enter the cells via passive diffusion.212 However, these studies did not investigate drug 
uptake mechanism via imaging, which we were able to do via SRS imaging.  
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Unlike imatinib, that is actively transported into CML cells, ponatinib transport does 
not depend on the drug-influx transporter organic cation transporter 1 (OCT-1) or the 
drug-efflux adenosine triphosphate (ATP)-binding cassette transporters (ABCB1 and 
ABCG2).211,213,214 ABCB1 and ABCG2 are also involved in the efflux of dasatinib, 
another clinically relevant BCR-ABL TKI, but dasatinib intracellular uptake is passive 
and independent of OCT-1.215,216 This highlights the heterogeneity in drug uptake and 
export mechanisms even when the drugs have an identical target, which in this case 
is BCR-ABL.  
 
Figure 3.16 KCL22 cells were treated with ponatinib (5 µM, 1 h) at (a) 37 °C or (b) 4 °C. 
Images were acquired in sequence from left to right: 2940 cm-1 (CH3, proteins); 2221 cm-1 
(C≡C, ponatinib); 2257 cm-1 (off-resonance); 2221 cm-1 with background subtracted. Images 
acquired at 1024 × 1024 pixels, 20 μs pixel dwell time, laser power 250 mW (the tuneable 
pump beam) with false colours applied to different detection wavenumbers. Scale bars: 10 μm. 
(c) Mean ponatinib Raman intensity per cell was quantified in n=10 cells, two biological repeats 
using ImageJ. The Mann-Whitney test was used to compare the samples on GraphPad Prism 
software, p=0.9042. 
 
3.5.3 Quantification of intracellular ponatinib concentrations using SRS 
As SRS has a linear concentration dependence, determining absolute intracellular 
ponatinib concentration inside CML cells was one of the major goals of the project. 
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To determine the absolute concentrations, a calibration curve of ponatinib solutions 
in DMSO was first acquired. SRS images in the range of 2176–2246 cm-1 were 
acquired for each ponatinib concentration as well as DMSO alone (n=3). 
Subsequently, the average pixel intensities of each SRS image across the range were 
calculated using ImageJ. The average pixel intensities were plotted for each 
concentration and a Gaussian fitting was applied on Origin (Figure 3.17a). The 
resulting peak was integrated, and the peak height was plotted at each concentration 
to give a ponatinib calibration curve (Figure 3.17b).  
On the same day, KCL22Pon-Res cells were treated with ponatinib (10 μM, 1 h), and 
imaged using SRS. In order to account for the noise due to day-to-day variance in the 
ponatinib on resonance SRS spectrum (C≡C, 2221 cm-1), all the Raman intensities 
below the calculated Gaussian baseline in Figure 3.17a (1000 for this dataset) were 
subtracted from the image. The final calibrated ponatinib on resonance image (Figure 
3.17c) indicates that the intracellular ponatinib concentration seen within some 
concentrated spots in the KCL22Pon-Res cells was up to 18 mM. This was an 1800-fold 
intracellular enrichment of ponatinib concentration compared to the extracellular 
concentration. Fu et al. have reported similar results for imatinib (933-fold) and 
nilotinib (2520-fold) intracellular enrichment factors in mouse CML cells using 
hyperspectral SRS imaging.170 This provides an estimation of drug concentration in 
various single points across the image, but our goal was to determine the total 
concentration in a single cell.  
To calculate the drug concentration inside a cell from a 3-dimensional SRS image, 
single cells were masked out from a z-stack of images (Figure 3.17d). Using Matlab‡‡, 
each SRS intensity per pixel inside the cell was converted to a concentration 
measurement of ponatinib by comparing the value with that from a control curve of 
drug dilutions in DMSO taken at the same settings. By converting each pixel to a 
volume measurement using the scan parameters the concentration measurements 
could also be converted to an amount of drug per voxel. By summing all the values, 
an overall drug amount per cell could be calculated. This was repeated for a total of 
10 cells. We found that KCL22Pon-Res cells had an average intracellular ponatinib 
concentration of 0.69 mM (±0.34 SD), which is 69-fold higher than the extracellular 
concentration used for treatment.  
 
‡‡ Dr Martin Lee performed the Matlab analysis. 
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However, it was noted that using the chosen laser parameters (300 mW for the 
tuneable pump beam, gain 2), our cell images had exceeded the maximum 
measurable pixel intensities in parts of the cell images, meaning we were losing 
valuable data from the top end of the concentration scale. In order to rectify this, the 
experiment was repeated with amendments to the protocol and with a second goal of 
comparing absolute ponatinib concentrations in the KCL22 and KCL22Pon-Res cell lines. 
 
Figure 3.17 Quantitative assessment of intracellular concentration of ponatinib by SRS. (a) 
Detection of decreasing concentrations of ponatinib dissolved in DMSO using SRS imaging of 
the 2221 cm-1 ponatinib alkyne peak. Laser settings: 300 mW, gain 2. SRS spectra were 
recorded across the region 2176–2246 cm-1 and the average pixel intensity was calculated for 
each image frame. A Gaussian fitting was applied to the data. (b) Calibration curve of ponatinib 
in DMSO using SRS imaging. The peak heights of the SRS peaks in (a) were plotted against 
ponatinib concentration. A linear fitting was applied to the data. R2 = 0.998. Error bars 
represent the SD across n = 3 repeats. (c) KCL22Pon-Res cells were treated with ponatinib 
(10 μM, 1 h), before SRS imaging. The colour bar corresponds to a linear ponatinib 
concentration range of 0-18 mM. (d) 3D z-stack image of a single KCL22Pon-Res cell that was 
selected from (c) to calculate intracellular ponatinib concentration using Matlab. (e) Quantified 
concentration of ponatinib in KCL22Pon-Res cells using SRS for n=10 cells. Error bar represents 
mean±SD. 
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In order to prevent any saturated pixels on the final cell images this time, test cells 
were used on the same day prior to the experiment for choosing the appropriate laser 
settings for the particular experiment. KCL22Pon-Res cells were also treated with a lower 
concentration of ponatinib (5 µM, 1 h) to prevent saturation of the drug in cells. The 
optimal laser power for the tuneable pump beam was found to be 100 mW with gain 1, 
whilst previously 300 mW with gain 2 was used. Thus a reduction to 33% laser power 
allowed the detection of ponatinib in KCL22Pon-Res cells without image saturation. 
These lower laser power settings were then used to obtain a ponatinib concentration 
curve in DMSO solutions ranging from 20 mM to 5 mM as well as DMSO alone (n=3). 
Higher concentrations of ponatinib had to be used due to the lower laser power used, 
resulting in lower peak heights (Figure 3.18a). As before, the resulting peaks were 
integrated, and the peak heights were plotted at each concentration to give a ponatinib 
calibration curve (Figure 3.18b).  
On the same day, both KCL22 and KCL22Pon-Res cells were treated with ponatinib 
(5 μM, 1 h) and imaged using SRS (Figure 3.18c). Z-stacks were taken for each cell 
line. The colour bar in Figure 3.18c corresponds to a linear ponatinib concentration 
range of 0-153 mM that corresponds to the pixel intensity scale of 0-4095. Maximum 
z-projection of an individual KCL22Pon-Res shows two individual ponatinib puncta 
(Figure 3.18d). In the brighter spot, the maximum Raman intensity was found to be 
4091, corresponding to approximately 150 mM ponatinib concentration. The average 
intensity inside that punctum was 2620 (~98 mM). This was the highest intensity 
ponatinib punctum seen across the two cell lines. The second, less bright punctum, 
had a maximum intensity of 2025 (~75 mM), with an average intensity of 1415 
(~53 mM). However, these puncta only represent the parts of the cell with high 
concentrations of ponatinib, not the whole cell.  
For calculating the concentration in whole individual cells (n=20), they were cut out 
from the z-stack images using ImageJ. These were used for quantifying ponatinib 
concentration per cell in both cell lines using Matlab§§ (Figure 3.18e). The average 
ponatinib concentration was 1.67 mM (±0.37 mM) in KCL22Pon-Res cells, 2.4 times 
higher than the estimated value from the previous protocol (0.69±0.34 mM). This was 
expected, as in the earlier protocol there were saturated pixels on the image, which 
 
§§ Dr Martin Lee performed the Matlab analysis. 
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meant data was lost from these pixels. These results highlight the importance of using 
appropriate laser settings for quantification of imaging data.  
 
Figure 3.18 Quantitative assessment of intracellular concentration of ponatinib by SRS. (a) 
Detection of decreasing concentrations of ponatinib dissolved in DMSO using SRS imaging of 
the 2221 cm-1 ponatinib alkyne peak. Laser settings: 100 mW, gain 1. SRS spectra were 
recorded across the region 2189–2257 cm-1 and the average pixel intensity was calculated for 
each image frame. A Gaussian fitting was applied to the data. (b) Calibration curve of ponatinib 
in DMSO using SRS imaging. The peak heights of the SRS peaks in (a) were plotted against 
ponatinib concentration. A linear fitting was applied to the data. R2 = 0.999. Error bars 
represent the standard deviation across n = 3 repeats. (c) KCL22 and KCL22Pon-Res cells 
treated with ponatinib (5 μM, 1 h), imaged by SRS. Scale bars: 10 µm. The colour bar 
corresponds to a linear ponatinib concentration range of 0-153 mM. (d) Z-stack maximum 
intensity projection of an individual KCL22Pon-Res cell showing two individual ponatinib puncta 
and Raman intensities inside the puncta. Scale bar: 5 µm. (e) Quantified concentration of 
ponatinib per cell in KCL22 and KCL22Pon-Res cells using SRS for n=20 cells. Concentration 
was quantified in 3D cells using Matlab. Statistical analysis was performed using GraphPad 
Prism software. Welch’s t-test was used to compare the concentration between the cell lines.  
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KCL22 cells had an average ponatinib concentration of 1.36 mM (±0.23 SD) across 
the 20 cells, 19% lower than the ponatinib concentration in KCL22Pon-Res cells 
(1.67±0.37 mM). Welch’s t-test was used on Graphpad Prism to compare the two cell 
lines. It was found KCL22Pon-Res cells have a significantly higher ponatinib 
concentration than KCL22 cells (**, p=0.004). This was counterintuitive, considering 
KCL22Pon-Res cells have a 100-fold higher GI50 to ponatinib compared to KCL22 cells. 
It is, however, consistent with reports that KCL22Pon-Res cells have developed a 
resistance mechanism that is independent of the ponatinib concentration present in 
cells.109  
The methodology used here to quantify absolute intracellular ponatinib concentration 
is not without limitations. Firstly, a calibration curve of ponatinib solutions in DMSO 
was acquired. In doing so, we have made the assumption that ponatinib SRS signal 
intensity in DMSO solution is identical to the signal intensity inside cells, which is not 
necessarily the case. There are intracellular factors that could influence SRS signal 
intensity. Cells are made of complex biomolecules, including proteins, lipids and 
nucleic acids, where intracellular pH various in different cellular compartments. The 
presence of all these factors inside cells could have an impact on ponatinib SRS 
signal intensity, but this remains an area of SRS imaging that has not been explored 
in depth. Previous studies using SRS or Raman microscopy for concentration 
quantification have also generated calibration curves in DMSO solutions.48,169,170 
In our study, we were limited by the solubility of ponatinib in DMSO, which only has a 
maximum solubility of 20 mM in DMSO. However, SRS detection sensitivity at 
optimised settings for intracellular imaging with no saturated pixels was 5 mM in 
DMSO, leaving a very limited window to mix the ponatinib solution with buffers to see 
if that would impact ponatinib SRS signal intensity. For a drug with better solubility, 
we believe it would be relevant to generate the calibration curve in a buffer if possible, 
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3.5.4 Imaging ponatinib at biologically relevant concentration 
Detection sensitivity remains the key limiting factor for utilising SRS for intracellular 
imaging as micromolar concentrations are still required to visualise target 
molecules.47,49,59,66,170 However, this is often not physiologically relevant. Our goal was 
to image ponatinib in target cells at biologically relevant concentrations using SRS. 
To do so, we chose to image in KCL22Pon-Res CML cells, which have a high tolerance 
to ponatinib (GI50=593 nM) (cell line described in Table 2.5, GI50 value in Table 2.6). 
For treatment, a ponatinib concentration close to the GI50 of the cells was chosen – 
500 nM. This concentration is also close to the measured plasma concentration of 
ponatinib, which is 145 nM following a 45 mg oral dose.199 We determined previously 
that the minimum incubation concentration that allowed intracellular detection after 
1 h treatment of cells was 5 µM. Here, we were testing the hypothesis that longer 
incubation times would result in accumulation of higher concentrations within the cells, 
which would allow treatment with a lower concentration. KCL22Pon-Res cells were 
hence treated with ponatinib (500 nM) for up to 48 h before imaging the live cells using 
SRS microscopy (Figure 3.19). Optimal set-up resulted in acquisition times of about 
45 s per image. It was necessary to use a higher laser power (300 mW for the tuneable 
pump beam, gain 2) to successfully acquire ponatinib images at this low 
concentration.  
Ponatinib Raman signal intensity (C≡C, 2221 cm-1) was analysed in individual cells 
from a field of view (n=30) at each time point using ImageJ. The results were 
compared to the DMSO control cells using GraphPad Prism (Figure 3.19d). It was 
found that there was a significant ponatinib Raman signal increase compared to the 
control cells at each time point. This is suggestive of intracellular accumulation of 
ponatinib.  
The data was further analysed by looking at the number of ponatinib puncta in the 
cells at different time points. Familiar bright ponatinib puncta were found in the cells 
from the 6 h time point onwards, while the largest number of puncta was seen in cells 
treated with ponatinib for 24 h or 48 h (Figure 3.19e). The number of ponatinib puncta 
at the 1 h time point was on average only 2 per cell. At 6 h, significantly more ponatinib 
puncta were seen in cells, averaging at 5 per cell. Additionally, the ponatinib puncta 
at 6 h had higher Raman intensities compared to those seen at 1 h (green/yellow on 
the colour bar vs blue). This is indicative of increased ponatinib concentration in the 
puncta at 6 h. The number of puncta further increased at the 24 h time point (10 per 
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cell), but there was no significant increase at the 48 h time point (11 per cell). 
Interestingly, the spread of number of ponatinib puncta per cell becomes more 
heterogeneous at the 24 h and 48 h time points compared to the 1 h and 6 h time 
points, demonstrating heterogeneity within the cell population upon ponatinib 
treatment for prolonged periods. The same trend was seen in the relative ponatinib 
concentration per cell (Figure 3.19d), where at 24 h and 48 h the drug concentration 
per cell became more heterogeneous. This demonstrates that ponatinib uptake is not 
homogeneous in the target cells as some cells are able to take up and retain higher 
concentration of ponatinib than others.  
Heterogeneous drug uptake has been reported before within tumours.182,183,217 
Ineffective drug uptake into tumours is influenced by a number of factors such as 
tumour microenvironment and vascularisation. However, this is not the case for 
heterogeneity in drug uptake in vitro, where intraclonal heterogeneity within the cell 
population has been found to influence drug uptake.218 For example, daunorubicin, a 
cytotoxic chemotherapeutic, was found to be taken up heterogeneously in vitro in 
acute myeloid leukaemia (AML) patient samples.218 This observed heterogeneity of 
drug uptake in vitro has not been studied extensively, likely due to limitations in 
imaging technology.  
Here, for the first time, SRS has been successfully used to image a drug at a 
biologically relevant dose in live cells without any additional labelling or fixation. In 
addition, thanks to the fast acquisition speeds of SRS, it was possible to image 
ponatinib in live cells. This is in contrast to the study by Aljakouch et al., where 
neratinib was imaged at nanomolar concentrations in fixed cells.169 While an average 
SRS image takes 45 s to image at optimised settings, spontaneous Raman 
microscopy is limited to fixed samples due to longer image acquisition times required 
(>30 min). This is a major advantage of SRS microscopy application to drug imaging. 




Figure 3.19 (a−c) Imaging ponatinib uptake in KCL22Pon-Res cells. KCL22Pon-Res cells were 
treated with DMSO (0.0003%, v/v) or ponatinib (500 nM) for 1, 6, 24, or 48 h (left to right). 
SRS images acquired at (a) 2940 cm-1 (CH3, proteins); (b) 2221 cm-1 (C≡C, ponatinib); (c) 
2257 cm-1 (off-resonance). Images acquired at 1024 × 1024 pixels, 20 μs pixel dwell time, 
laser power 300 mW (the tuneable pump beam), gain 2 with false colours applied to different 
detection wavenumbers. Scale bars: 10 μm. (d) Mean ponatinib intensity per cell quantified 
from 2221 cm-1 in n = 30 cells, three biological repeats. The Mann−Whitney test was used to 
compare ponatinib Raman intensity values against the DMSO control. (e) Number of ponatinib 
puncta per cell quantified from 2221 cm-1 in n=10 cells, three biological repeats. The Mann-
Whitney test was used to compare number of ponatinib puncta in cells at different time points, 
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3.6 Conclusions  
In this chapter, an SRS imaging approach for ponatinib in human CML cells was 
validated by DFT calculations and LC-MS analysis of potential ponatinib metabolites. 
The level of ponatinib metabolites found in CML cells was very low, while DFT 
calculations predicted minimal Raman shifts in their frequencies, indicating that total 
ponatinib concentration can be imaged by SRS at a single wavenumber.  
SRS imaging of ponatinib was optimised first in adherent colon cancer cells followed 
by imaging in both mouse and human CML cell lines. Optimisation included testing 
different concentrations, treatment times and imaging at different laser powers. For 
1 h treatment, it was found that the minimum ponatinib concentration required for SRS 
detection is 5 µM. Quantitative SRS imaging enabled determination of the absolute 
ponatinib concentration of both KCL22 and KCL22Pon-Res cells as 1.36 mM and 
1.67 mM respectively, demonstrating that the drug accumulates in the cells at over 
200-fold higher concentration compared to extracellular ponatinib.   
SRS imaging of ponatinib was additionally achieved through incubation at biologically 
relevant concentrations in KCL22Pon-Res cells, where a 500 nM treatment was used 
due to its proximity to the GI50 value of this cell line. Longer incubation times (6 h - 
48 h) were needed to detect intracellular ponatinib puncta at this concentration. 
However, this is the first instance where nanomolar incubation concentration of an 
analyte has allowed successful SRS imaging in live cells.
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Chapter 4 Significance of ponatinib lysosomal 
accumulation in ponatinib resistant CML cells 
4.1 Introduction 
There is currently no available information on the intracellular localisation of ponatinib 
in the context of drug resistant CML. In this chapter, we used multimodal imaging, 
immunofluorescence (IF) and fluorescence assisted cell sorting (FACS) to 
demonstrate ponatinib lysosomal accumulation and its biological significance in the 
context of CML acquired drug resistance. A combination of SRS imaging and Western 
blots were used to assess the effect of lysosomal trapping on target engagement. Part 
of this work has been published in a peer-reviewed journal.173 
4.1.1 Lysosomotropism 
The intracellular distribution of drugs is an important consideration for drug efficacy 
as it can influence drug target engagement. De Duve was the first to describe the 
principle of selective drug partitioning inside cells based on pH.219 He created the term 
lysosomotropic agents, which describes weakly basic compounds that exist in their 
unionised state in the cell cytosol (pH~7.4), enabling passive diffusion across the cell 
membrane and the lysosomal lipid bilayer (Figure 4.1a). Inside the lysosomes, which 
have acidic pH (~4.5), protonation of the base is favoured. Once the drug is ionised 
inside the lysosome, it is considered relatively membrane impermeable and cannot 
diffuse back out. This can reduce drug target engagement and has been associated 
with drug resistance.220 
Drug localisation in cells can be heavily influenced by physicochemical properties 
such as pKa (acid dissociation constant). The higher the pKa, the weaker the acid 
and conversely the stronger the base. Duvvuri et al. used a series of aminoquinoline 
(AQ) and aminoisoquinoline (AIQ) amines to study the role of pKa in lysosomal 
accumulation (Figure 4.1b).220 They showed that higher pKa correlated with increased 
lysosomal trapping. Compounds with pKa values near and above neutral (pKa=6.9-
9.0) achieved over 50 times greater lysosomal concentrations compared to those in 
the cytosol, whilst compounds with pKa values 5 and below were not detected in the 
lysosomes. The pKa alone, however, is not responsible for lysosomal trapping.  





Figure 4.1 (a) Equilibrium model of lysosomotropism. Unprotonated weak base (B) can diffuse 
through the plasma membrane and the lysosomal membrane in its unionised form. Inside the 
lysosome, the majority of the drug will be protonated (BH+) due to the low pH, rendering it 
membrane impermeable. (b) Lysosome to cytosol concentration ratios as a function of pKa 
value for model weakly basic amines in the multidrug resistant HL-60 cell line. Reproduced 
with permission,220 copyright American Chemical Society.  
Another physicochemical property affecting lysosomal accumulation levels of 
molecules in tandem with pKa is alpha (α) - it represents the lysosomal membrane 
permeability ratio for the drug in its ionised versus unionised form.221 Duvvuri et al. 
demonstrated that weak bases with a low α value, such as Lysotracker Red (LTR) 
and Quinacrine (QNC), have a pH dependent partition coefficient (Figure 4.2). For 
those compounds, the ionised base (when pH < pKa) has a significantly reduced 
partition coefficient relative to the un-ionised base (when pH > pKa). This is due to the 
fact that the basic amines in LTR and QNC are localised at the distal end of the 
molecule, with no charge distribution. In contrast, compounds with a high α value, 
such as Rhodamine 123 (R123) and Rhodamine 6G (R6G) have a pH-independent 
partitioning coefficient. The amines in R123 and R6G are next to large aromatic 
networks, enabling charge delocalisation across the molecule. As such, compounds 
with a low α get trapped in the lysosomes (QNC, LTR), whilst compounds with high α 











Figure 4.2 (a) Structures of fluorescent weakly basic compounds studied by Duvvuri et al.221 
(b) Correlation of experimental α values with the level of lysosomal accumulation. The relative 
amount of each compound in lysosomes (AmountLYSO) normalised to that in cytosol 
(AmountCYTO) plotted against α values. An average of three experiments ±SD. Reproduced 
with permission,221 copyright American Society for Biochemistry & Molecular Biology. 
4.1.2 Lysosomal drug accumulation in CML 
All the TKIs approved by the FDA for CML treatment have a weakly basic amine within 
their structure, resulting in them having pKa values ≥6 (Table 4.1).170,222,223 Imatinib, 
dasatinib, bosutinib and ponatinib all have a piperazine functional group at the tail end 
of the molecule with varying linker lengths (Figure 4.3). The piperazine amine makes 
these compounds slightly more basic than nilotinib, which has a secondary amine 
between two aromatic rings, reducing its basicity (Figure 4.3d). α values have not 
been measured for these compounds; however, considering the basic amines in 
these molecules are similarly to LTR and QNC located at the distal end of the 
molecule, they will likely have a localised charge, and are predicted have low alpha 
values. Therefore, these are all theoretically lysosomotropic drugs.  
Table 4.1 pKa-s of drugs used for CML treatment and their association with lysosomal 
accumulation.222,224-227 *n/a – not available 
CML drug pKa Lysosomal accumulation 
imatinib 8.1 √ 
bosutinib 8.0 √ 
ponatinib 7.8 n/a* 
dasatinib 6.8 √ 
nilotinib 6.0 √ 
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Hence, it is unsurprising that most of these compounds have been found to be 
associated with lysosomes by different research groups. Fu et al. used hSRS imaging 
and directly demonstrated that both imatinib and nilotinib accumulate in the 
lysosomes of CML cells (Figure 3.4b,c).170 Ruzickova et al. used indirect LC-MS 
measurements, but also found that imatinib, nilotinib and dasatinib localise in 
lysosomes of various different cancer cells.228 Burger et al. utilised the weak 
fluorescence properties of imatinib to show its lysosomal uptake in various cell 
types.229 Bosutinib has been shown to induce cell death in melanoma cells via 
lysosomal membrane permeabilisation, so it likely also accumulates in lysosomes.230 
No data has been published on ponatinib intracellular localisation.  
 
Figure 4.3 Chemical structures of TKIs used for CML treatment. (a) Ponatinib, (b) imatinib, (c) 
bosutinib, (d) nilotinib, (e) dasatinib.  
In a systematic review of TKIs approved by the FDA between 2001 and 2015, O’Brien 
and Moghaddam reviewed both measured and predicted pKa values and found that 
50% of the 30 TKIs had a pKa≥6 while only 3 had a pKa≥9.223 This highlights that a 
large proportion of clinically used TKIs are weakly basic, and could therefore be 
subject to lysosomal trapping. A number of these TKIs, such as sunitinib (pKa=8.9), 
lapatinib (pKa=7.2), gefitinib (pKa=6.9) and neratinib (pKa=7.7) have been associated 
with lysosomal accumulation.32,169,231,232 However, only sunitinib (Figure 4.4) and 
neratinib (Figure 3.3) accumulation in lysosomes could be imaged directly via 
fluorescence and Raman respectively.  
4.1.3 Role of lysosomes in drug resistance 
Lysosomal trapping has been associated with acquired TKI resistance.231 Lysosomal 
sequestering of sunitinib, a TKI approved for the treatment of renal cell carcinoma, 
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was explored in the context of acquired drug resistance by Gotink et al. (Figure 4.4).32 
They developed sunitinib resistant cell lines through continuous exposure to sunitinib 
in 786-O renal cancer cells and HT-29 colon cancer cells. Using fluorescence imaging 
of sunitinib, they demonstrated that the drug co-localises with Lysotracker Red, where 
increased lysosomal accumulation was seen in drug resistant cells (Figure 4.4b).32  
 
 
Figure 4.4 Sunitinib imaging and intracellular concentration. (a) Chemical structure of 
sunitinib. (b) Confocal images of 786-O parental (PAR) and sunitinib resistant (SUN) cells that 
were incubated with sunitinib (green) (5 µM), Lysotracker Red (red) (75 nM), and Hoechst 
(blue) (0.5 mg/mL) for 1 h. (c) Intracellular sunitinib concentration determined by LC-MS in 
786-O and HT-29 cell lines. Parental cells were incubated with sunitinib (5 µM) for 24 h while 
sunitinib resistant cells were continuously incubated with sunitinib prior to analysis. (d) 
Western blots of LAMP1 and LAMP2 in parental and sunitinib-resistant 786-O cells. Adapted 
with permission,32 copyright American Association for Cancer Research. 
In addition, they found by LC-MS analysis that the total intracellular concentration of 
sunitinib was 1.7-2.5-fold higher in drug resistant cells, 5.04 mM and 4.25 mM in 
786-O and HT-29 cells respectively compared to 2.93 mM and 1.68 mM in sunitinib 
sensitive cells (Figure 4.4c).32,233 The increased sunitinib concentration in resistant 
cells was attributed to the increased lysosomal sequestering capacity in resistant 
cells, which showed increased fluorescence signal of the drug. To investigate further, 
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they looked at lysosomal membrane protein 1 (LAMP1) and LAMP2 levels using 
Western blotting. Elevated levels of both LAMP1 and LAMP2 were found in sunitinib 
resistant cells, which is an indication of increased lysosome number and/or size 
(Figure 4.4d). However, immunofluorescence imaging of LAMP1 or LAMP2 was not 
applied to further assess LAMP levels. Gotink et al. were the first to report the 
involvement of lysosomal sequesteration in acquired TKI resistance. The HT-29 
parental and sunitinib resistant cells were further validated in an in vivo study, where 
the sunitinib resistant cells grew tumours that no longer responded to sunitinib 
treatment.234 
 
Lysosomes have also been shown to be involved in drug resistance to imatinib, where 
ABC transporter A3 (ABCA3) was found to mediate lysosomal sequestration of 
imatinib.235 Increased ABCA3 expression results in elevated lysosomal levels of 
imatinib, which has been associated with both intrinsic and acquired drug resistance 
in CML. P-glycoprotein (P-gp), another ABC transporter, can also mediate lysosomal 
sequestering, and was shown to facilitate lysosomal trapping of chemotherapeutic 
agent doxorubicin (pKa=8.3) in multidrug resistant cervical cancer.236 Therefore, 
lysosomes play an important role in cancer drug resistance. 
4.2 Lysosomal accumulation of ponatinib 
In Chapter 3, we found that ponatinib localises in concentrated puncta in the 
cytoplasm of CML cells. It was important to consider which cellular organelles these 
puncta represent, as the known target of ponatinib is the cytoplasmic tyrosine kinase 
BCR-ABL. Ponatinib, like a large population of TKIs, is a weakly basic drug with a 
pKa≥7 (pKa=7.8).224 As such, it will likely be protonated in acidic environments such 
as lysosomes. We hypothesised that ponatinib, like other TKIs used for CML 
treatment, accumulates in lysosomes or related acidic organelles inside cells. A 
multimodal imaging approach combining SRS and fluorescence imaging was used to 
investigate this.  
Both parental and ponatinib resistant KCL22 cell lines were simultaneously incubated 
with ponatinib (5 μM, 1 h) or DMSO (vehicle control, 1 h) and Lysotracker Green 
(50  nM, 1 h), a cell-permeable fluorescent dye that stains acidic organelles in live 
cells (Figure 4.5). The control cells which were treated with DMSO and stained with 
Lysotracker Green (Figure 4.5a) showed no SRS signal at 2221 cm-1 (C≡C, ponatinib 
on-resonance), indicating that the presence of the fluorophore does not increase the 
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SRS background signal. In both KCL22 and KCL22Pon-Res cells treated with ponatinib 
(Figure 4.5b,c), we could see co-localisation between the ponatinib SRS signal at 
2221 cm-1 and the two-photon fluorescence (TPF) signal shown in the merged 
images. Outside of the bright ponatinib puncta, lower levels of the drug were detected 
in the cytoplasm, which did not co-localise with the TPF signal. As the Raman signal 
of ponatinib is the highest in the puncta that co-localise with the TPF signal, it can be 
concluded that the majority of intracellular ponatinib is trapped within acidic 
organelles, most likely lysosomes, upon protonation. 
4.2.1 Increased lysosomal sequestering in ponatinib resistant cells 
As discussed in Section 4.1.3, there is evidence that increased lysosomal trapping 
plays a role in acquired resistance to TKIs.231 To investigate if this is the case in our 
CML resistance model, we used the TPF signal as a map, and quantified ponatinib 
Raman intensity inside acidic vesicles of individual cells. Quantification results 
showed increased ponatinib Raman signal in the resistant KCL22Pon-Res cells 
compared to parental KCL22 cells (Figure 4.5d,e). The mean intensity of ponatinib in 
the acidic vesicles of KCL22Pon-Res cells was 1.9-fold higher compared to parental 
KCL22 cells (Figure 4.5d), and the maximum ponatinib signal had increased 2.5-fold 
(Figure 4.5e). 	
These results were further confirmed in an identical experiment where cells were 
labelled with Lysotracker Red instead of Lysotracker Green (Appendix 2, Figure S1). 
Using Lysotracker Red as a map for assessing ponatinib levels in lysosomes gave 
similar results to Lysotracker Green – both mean and maximum ponatinib intensity 
were increased 2-fold and 2.1-fold respectively in KCL22Pon-Res cells compared to drug 
sensitive cells. This indicates that lysosomal trapping of ponatinib in KCL22Pon-Res cells 
is increased. A similar observation has previously been made in sunitinib resistant 
cells, where sunitinib fluorescence signal increased in cells with acquired drug 
resistance.32  
In addition, we noted the maximum ponatinib intensity inside lysosomes was very 
heterogeneous within the resistant cell population (Figure 4.5e). As discussed earlier 
in Section 3.5.4, heterogeneity of drug uptake in vitro has not been studied in depth. 
However, if drug uptake in CML patients is heterogeneous, it could have implications 
on treatment efficacy and drug resistance. Here, we have showed that SRS 
microscopy has the capacity to obtain information on drug uptake heterogeneity. 
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Interestingly, the ponatinib signal within the cytoplasm of the resistant cells was also 
significantly increased (Figure 4.5f). In contrast to common opinion, this demonstrates 
that lysosomal trapping in our CML drug resistance model does not lead to reduced 
ponatinib availability in the cytoplasm, which would reduce target inhibition. Ponatinib 
target inhibition is explored further in Section 4.2.3. 
 
Figure 4.5 Multimodal imaging and quantitative assessment of ponatinib uptake in KCL22 and 
KCL22Pon-Res cell lines. KCL22 cells were treated with (a) DMSO (0.0003%, v/v) or (b) ponatinib 
(5 µM, 1 h) and labelled with Lysotracker® Green (50 nM, 1 h). (c) KCL22Pon-Res cells were 
treated with (c) ponatinib (5 µM, 1 h) labelled with Lysotracker® Green (50 nM, 1 h). SRS 
images acquired at (from left to right) 2940 cm-1 (CH3, proteins); 2221 cm-1 (C≡C, ponatinib); 
2257 cm-1 (off-resonance), TPF image acquired at 861 nm (Lysotracker® Green); overlay of 
ponatinib and TPF. (d) Mean ponatinib Raman intensity, and; (e) Maximum ponatinib Raman 
intensity inside the vesicles of each individual cell quantified for KCL22 and KCL22Pon-Res cells 
that were treated with 5 µM ponatinib for 1 h, n=30 cells, 3 biological repeats. (f) Mean 
ponatinib Raman intensity quantified outside of the vesicles of individual cells, n=10, 3 
biological repeats. The Mann-Whitney test was used to compare ponatinib Raman intensity 
values. Images acquired at 1024 × 1024 pixels, 20 μs pixel dwell time, laser power 200 mW 
(the tuneable pump beam), gain 1 with false colours applied to different detection 
wavenumbers. Scale bars: 10 μm.  
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4.2.2 Chloroquine and ponatinib combination treatment 
After finding that ponatinib lysosomal accumulation was increased in ponatinib 
resistant CML, we wanted to explore if altering lysosome function with another drug 
would reduce lysosomal trapping of ponatinib. There are two potential strategies for 
inhibiting lysosome function – either inhibiting drug accumulation in the lysosomes or 
disrupting the lysosomal membrane to release its contents.237 Most drugs investigated 
for this purpose focus on inhibiting drug accumulation.  
Chloroquine (CQ), another lysosomotropic agent (pKa1=10.2, pKa2=8.4), 
accumulates in the lysosomes, where it increases lysosomal pH (Figure 4.6).170,238 
When used in combination therapy, CQ has been shown to inhibit lysosomal drug 
uptake.170 The precise mechanism by which CQ inhibits lysosome function, however, 
has not been established. Bafilomycin A1 and manzamine A both inhibit the v-ATPase 
proton pump on the lysosomal membrane (Figure 4.6).127 This prevents acidification 
of the lysosomes, leading to increased lysosomal pH. As CQ combination treatment 
with imatinib, nilotinib and dasatinib has previously been shown to increase efficacy 
of TKIs against CML stem cells, we chose CQ for our combination treatment with 
ponatinib.129 
 
Figure 4.6 Schematic showing how CQ, bafilomycin A1 and manzamine A impair lysosomes. 
CQ gets protonated inside the lysosome, mopping up protons and subsequently increasing 
lysosomal pH. Bafilomycin A1 and manzamine A inhibit v-ATPase from pumping hydrogen 
ions (H+) into the lysosomal lumen, which also increases lysosomal pH. Image created with 
Biorender. 
It was hypothesised that combination treatment with CQ would prevent the increased 
lysosomal uptake of ponatinib. Prior to multimodal imaging with SRS, both KCL22 and 
KCL22Pon-Res cells were incubated with CQ (20 μM, 2 h) before treatment with 
ponatinib (5 μM, 1 h) and labelling with Lysotracker Green (50 nM, 1 h). CQ treatment 
significantly reduced the ponatinib Raman signal in both cell lines (Figure 4.7a,b; full 
 Significance of ponatinib lysosomal accumulation 
98 
 
imaging panels shown in SI Figure S2 and Figure S3). Quantification of ponatinib 
signal inside lysosomes demonstrated that CQ treatment reduced mean ponatinib 
concentration inside the lysosomes 2.7- and 3.8-fold in the KCL22 and KCL22Pon-Res 
cells, respectively, compared to ponatinib alone (Figure 4.7c,d). Fu et al. reported 
similar results for CQ and imatinib combination treatment, which reduced lysosomal 
imatinib levels 5-fold in drug sensitive mouse CML cells.170 Our results indicate that 
CQ combination treatment does inhibit ponatinib lysosomal trapping in both ponatinib 
sensitive and ponatinib resistant cells. 
 
Figure 4.7 Multimodal imaging and quantitative assessment of CQ treatment on the vesicular 
uptake of ponatinib in KCL22 and KCL22Pon-Res cells. KCL22 and KCL22Pon-Res cells were 
treated with (a) ponatinib (5 µM, 1 h); (b) CQ (20 µM, 2 h) followed by combination treatment 
of ponatinib (5 µM, 1 h) and CQ (20 µM, 1 h). Images shown (left to right) 2221 cm-1 (C≡C, 
ponatinib); overlay TPF image at 861 nm (Lysotracker® Green) merged with 2221 cm-1. (c), 
(d) Mean ponatinib Raman intensity inside the vesicles of each individual cell quantified in (c) 
KCL22 and (d) KCL22Pon-Res cell line, n=10 cells, 3 biological repeats. The Mann-Whitney test 
was used to compare ponatinib Raman intensity values. Individual data points shown with 
error bar as mean±SD. Images acquired at 1024 × 1024 pixels, 20 μs pixel dwell time, laser 
power 200 mW (the tuneable pump beam), gain 1 with false colours applied to different 
detection wavenumbers. Scale bars: 10 μm. 
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4.2.3 Ponatinib target inhibition 
Lysosomal trapping is traditionally associated with decreasing drug-target 
engagement as it is thought to sequester the drug away from its target. Ponatinib’s 
target in CML is the cytoplasmic BCR-ABL. We wanted to investigate the effect of 
ponatinib on BCR-ABL activity via Western blotting. However, BCR-ABL activity 
cannot be measured directly because the protein is rapidly degraded and is subject 
to dephosphorylation upon cell lysis.239 CRKL is an adaptor protein that it is dependent 
on BCR-ABL for phosphorylation (Figure 4.8a). It has been shown that the phospho-
tyrosine content of CRKL can be measured quantitatively in a dose dependent 
manner as a surrogate marker of BCR-ABL activity.240 Hence, we utilised 
phosphorylation of CRKL as a standard readout of BCR-ABL activity. 
KCL22 and KCL22Pon-Res cells were both treated with either DMSO (0.0003%, drug 
vehicle) or a range of ponatinib concentrations (10 nM - 500 nM, 1 h). The effect of 
ponatinib on the phosphorylation of CRKL was measured with a phospho-CRKL 
(p-CRKL at Tyr207) antibody (Figure 4.8b,c). A reduction in p-CRKL band intensities 
represents inhibition of BCR-ABL in response to drug treatment. We found that 
ponatinib inhibited p-CRKL, and hence BCR-ABL, to a similar degree in both drug 
sensitive and drug resistant cells. This demonstrates that ponatinib target 
engagement in KCL22Pon-Res cells is not reduced despite lysosomal trapping, i.e. there 
is sufficient cytoplasmic ponatinib to inhibit CRKL phosphorylation. It also confirms a 
previously reported BCR-ABL independent resistance mechanism in this cell line.109  
 
Figure 4.8 Ponatinib inhibition of p-CRKL. (a) Schematic diagram demonstrating how 
ponatinib inhibits BCR-ABL signalling via inhibition of the tyrosine kinase domain, which in turn 
prevents phosphorylation of CRKL. Created with Biorender. (b), (c) Effect of ponatinib on the 
phosphorylation of CRKL in KCL22 and KCL22Pon-Res cells. (b) KCL22 and (c) KCL22Pon-Res 
cells were treated with (left to right) either DMSO (0.0003%, v/v) or ponatinib (10 nM, 100 nM, 
500 nM, 1 h). Western blot analysis was carried out with an antibody specific to phosphorylated 
CRKL (p-CRKLTyr207, 39 kDa). α-tubulin (50 kDa) was used as a loading control. 
 Significance of ponatinib lysosomal accumulation 
100 
 
4.2.4 Effect of chloroquine on ponatinib target engagement 
Having found that combination treatment with CQ significantly decreased lysosomal 
trapping of ponatinib in both cell lines (Figure 4.7), we were interested in its effect on 
BCR-ABL inhibition. We used Western blotting to compare the effects of CQ 
combination treatment with ponatinib only treatment on p-CRKL in KCL22 and 
KCL22Pon-Res cells. Both cell lines were treated with either ponatinib (10 nM – 500 nM, 
1 h) or a combination of CQ (20 µM, 2 h) pre-treatment followed by ponatinib (10 nM 
– 500 nM, 1 h) (Figure 4.9a,b; full blots shown in Appendix 2 Figure S4 and Figure 
S5). To compare p-CRKL inhibition level, the bands were quantified for each lane 
using ImageLab software, and normalised to α-tubulin. We found that pre-treatment 
with CQ significantly increased p-CRKL inhibition at the lowest ponatinib dose (10 nM) 
for both cell lines (Figure 4.9c,d), demonstrating that reduced lysosome trapping of 
ponatinib in the CQ treated cells increased BCR-ABL inhibition and drug target 
interaction. 
Interestingly, quantification of p-CRKL levels also revealed ponatinib only treatment 
inhibited CRKL phosphorylation more effectively in the KCL22Pon-Res cells compared 
to KCL22 ponatinib sensitive cells. This result correlates with the increased 
cytoplasmic levels of ponatinib in the resistant cells (Figure 4.5f) and supports a 
BCR-ABL independent mechanism of ponatinib resistance.109 Hence, it is not 
surprising that CQ treatment does not re-sensitise KCL22Pon-Res cells to ponatinib 
(unpublished data by the Helgason group, Figure S6). It is in contrast to the BCR-ABL 
dependent resistance mechanism reported for other TKIs used for CML treatment, 
e.g. imatinib, where combination treatment with CQ and TKI increases target 












Figure 4.9 Chloroquine effect on ponatinib target engagement. (a) KCL22 and (b) 
KCL22Pon-Res cells were treated with (left to right) either DMSO (0.0003%, v/v), ponatinib 
(10 nM, 100 nM, 500 nM, 1 h) or a combination of CQ (20 µM, 2 h) pre-treatment and ponatinib 
(10 nM, 100 nM or 500 nM, 1 h). Western blot analysis was carried out with an antibody specific 
to phosphorylated CrkL (p-CRKLTyr207, 39 kDa). α-tubulin (50 kDa) was used as a loading 
control. (c), (d) p-CrkL level was normalised to α-tubulin and DMSO values from n=3 biological 
repeats using Image LabTM Software. One-way Anova (Tukey’s multiple comparisons test) 
was used to compare ponatinib (10 nM) alone vs CQ combination treatment. Values shown 
as mean±SD. 
4.3 Investigating autophagy involvement in ponatinib localisation 
As discussed in Section 1.4 autophagy is a cellular degradation system that delivers 
cytoplasmic constituents to the lysosomes for recycling or removal. Autophagy has 
been shown to be implicated in CML drug resistance, but so far attempts to target 
autophagy in the clinic have largely failed. CQ is not just a lysosomotropic agent, it is 
also an indirect autophagy inhibitor. When lysosomal function is impaired by CQ, 
autophagy is also inhibited as lysosomes can no longer fuse with autophagosomes to 
form autolysosomes (Figure 4.10). To determine whether the inhibition of autophagy 
by CQ contributed to the reduced lysosomal accumulation of ponatinib, it was 
important to image ponatinib in cells where autophagy was inhibited directly. To that 
end, we utilised KCL22Pon-Res CRISPR-ATG7 cells. Autophagy related gene 7 (ATG7), 
a critical component of the autophagy pathway, is essential for the lipidation of LC3 
 Significance of ponatinib lysosomal accumulation 
102 
 
(LC3-II) (Figure 4.10).241,242 LC3-II attaches to the phagophore membrane, which is 
necessary for autophagosome formation. ATG7 knockdown inhibits LC3-II formation 
and subsequently also inhibits autophagy. Mitchell et al. have previously shown that 
LC3-II levels are decreased in KCL22Pon-Res CRISPR-ATG7 cells compared to 
KCL22Pon-Res CRISPR-Control cells, demonstrating that this cell line has a defect in its 
autophagy pathway.109  
 
Figure 4.10 Schematic representation of autophagy demonstrating both ATG7 involvement in 
LC3-I lipidation to LC3-II and CQ inhibition of autolysosome formation. PE-
phophatidylethylamine. Image created with Biorender. 
4.3.1 Imaging ponatinib in ATG7 knockdown CML cells 
Prior to imaging, we confirmed by Western blotting that ATG7 was knocked down in 
KCL22Pon-Res CRISPR-ATG7 cells (Figure 4.11a), and checked that both KCL22Pon-Res 
CRISPR-ATG7 (GI50=702 nM) and KCL22Pon-Res CRISPR-Control (GI50=339 nM) cells 
still retained ponatinib resistance (Table 2.6).  
For multimodal imaging, KCL22Pon-Res CRISPR-ATG7 and KCL22Pon-Res CRISPR-
Control cells were simultaneously treated with ponatinib (5 μM, 1 h) and labelled with 
Lysotracker Green (50 nM, 1 h) (Figure 4.11b,c). As previously, the TPF signal was 
used as a map to quantify relative Raman signal of ponatinib in acidic organelles of 
individual cells in both cell lines. No significant difference between the two cell lines 
was found, demonstrating that autophagy does not play a role in ponatinib 
accumulation in lysosomes (Figure 4.11d). It is therefore likely that the reduction of 
ponatinib concentration in lysosomes upon CQ combination treatment was due to the 
lysosomotropic properties of CQ, which decreased the lysosomal trapping capacity of 
ponatinib. 




Figure 4.11 Multimodal imaging and quantitative assessment of ponatinib uptake in 
KCL22Pon-Res CRISPR cell lines. (a) ATG7 (75 kDa) protein expression in KCL22Pon-Res 
CRISPR cell lines. α-tubulin (50 kDa) was used as a loading control. (b) KCL22Pon-Res CRISPR-
Ctrl and (c) KCL22Pon-Res CRISPR-ATG7 cell lines that were treated with ponatinib (5 µM, 1 h) 
and labelled with Lysotracker Green (50 nM, 1 h) simultaneously. SRS images acquired at 
(from left to right) 2940 cm-1 (CH3, proteins); 2221 cm-1 (C≡C, ponatinib); TPF image acquired 
at 861 nm (Lysotracker® Green); overlay of ponatinib and TPF. Scale bars: 10 µm. (d) Mean 
ponatinib Raman intensity at 2221 cm-1 inside the vesicles of each individual cell quantified for 
KCL22Pon-Res CRISPR-Ctrl and KCL22Pon-Res CRISPR-ATG7 cells treated with 5 µM ponatinib 
for 1 h, n=20 cells, 3 biological repeats. The Mann-Whitney test was used to compare ponatinib 
Raman intensity values. Individual data points shown with error bar as mean±SD. Images 
acquired at 1024 × 1024 pixels, 20 μs pixel dwell time, laser power 100 mW (the tuneable 
pump beam), gain 1 with false colours applied to different detection wavenumbers. Scale bars: 
10 μm. 
4.4 Lysosome biogenesis increased in ponatinib resistant CML 
After it was determined that autophagy was not involved in increased lysosomal 
accumulation of ponatinib in KCL22Pon-Res cells, it was necessary to further investigate 
the potential reasons for this increased uptake in the context of acquired drug 
resistance. Lysosomes have an important role in the cell and have previously been 
implicated in TKI drug resistance.32,231 Therefore, we decided to explore the 
importance of lysosomes in our drug resistance model.  
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4.4.1 Number of lysosomes in ponatinib resistant CML 
First, we decided to investigate the number of lysosomes in both KCL22 and 
KCL22Pon-Res cells.  To do so, we used the Lysotracker Green and Lysotracker Red 
data, which had been generated during multimodal imaging of ponatinib in lysosomes 
(Section 4.2). The number of acidic vesicles was quantified from fluorescence images 
in 30 individual cells per sample for both cell lines (Figure 4.12a,b). We found the 
number of acidic vesicles was significantly increased in KCL22Pon-Res cells compared 
to drug sensitive cells using both Lysotracker Green and Lysotracker Red labelling 
(Figure 4.12c,d). This was a first indication that the number of lysosomes is increased 
in ponatinib resistant cells upon drug treatment. However, as Lysotracker dyes label 




Figure 4.12 Assessing lysosome number in CML cells using Lysotracker Green and 
Lysotracker Red. (a), (b) Representative fluorescence image of KCL22 and KCL22Pon-Res cells 
treated with ponatinib (5 µM, 1 h) and labelled with either (a) Lysotracker® Green (50 nM, 1 
h) or (b) Lysotracker® Red (75 nM, 1 h). Scale bars: 10 μm. (c), (d) Number of acidic vesicles 
per cell quantified for both KCL22 and KCL22Pon-Res cells from the fluorescence images in n=30 
cells, 3 biological repeats. The Mann Whitney test was used to compare the number or acidic 
vesicles, **** (p<0.0001), *** (p=0.0003). Individual data points shown with error bar as 
mean±SD. 
4.4.2 LAMP1 levels in ponatinib resistant CML 
To investigate the number of lysosomes more directly, we used immunofluorescence 
to measure LAMP1 levels in our cell lines. LAMP1 and LAMP2 are the most abundant 
lysosomal transmembrane proteins, which together account for about 50% of total 
lysosomal membrane proteins.134 Therefore, measuring LAMP1 levels gives a more 
direct indication of lysosome numbers than Lysotracker labelling.  
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We imaged LAMP1 in both untreated (DMSO, 0.0003%, 1 h) and drug treated 
(ponatinib, 5 μM, 1 h) cells stained with LAMP1 antibody, where cell nuclei were 
labelled with DRAQ7 nuclear dye (Figure 4.13a,b). LAMP1 fluorescence intensity was 
quantified per cell in both KCL22 and KCL22Pon-Res cell lines (Figure 4.13c). Both 
ponatinib treated and untreated KCL22Pon-Res cells were found to have significantly 
higher levels of LAMP1 than KCL22 cells. Ponatinib treatment did not increase 
LAMP1 levels significantly in either cell line when compared to the DMSO control. 
Elevated LAMP1 levels are associated with increased lysosome number or lysosome 
size. Hence, our results indicate that ponatinib resistant CML cells have increased 
number of lysosomes and or lysosome size. Gotink et al. also reported increased 
levels of LAMP1 and LAMP2 in sunitinib resistant cell lines (Figure 4.4d).32 We 
interpreted the increased LAMP1 level as a potential indicator of increased lysosome 
biogenesis. IF images of LAMP1 could also be used to quantify the lysosome number 
and size. However, we originally set up the experiment to measure total fluorescence 
intensity per image, and the images acquired do not have high enough resolution to 
allow lysosome number to be quantified. 
 
Figure 4.13 Immunofluorescence imaging of LAMP1 in CML cells. (a) KCL22 and (b) 
KCL22Pon-Res cells were treated with either DMSO (0.0003%, v/v) or ponatinib (5 µM) for 1 h, 
fixed and stained with LAMP1 (green). Nuclei were stained with DRAQ7 (red). No antibody 
(ab) control cells were treated with DMSO (0.0003%, v/v) and stained with DRAQ7, but not 
stained with LAMP1. (c) Immunofluorescence of LAMP1 quantified in KCL22 (green) and 
KCL22Pon-Res (purple) cells. Total fluorescence intensity (TFI) of LAMP1 in individual cells of 
n=6 fields of view was quantified from 3 biological repeats. Welch’s t-test was used to compare 
LAMP1 levels. Values shown as mean±SD, **** (p<0.0001). Images acquired at 1024 × 1024 
pixels, 4 μs pixel dwell time, laser power 200 mW (the tuneable pump beam), gain 1. Scale 
bars: 10 μm. 
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4.4.3 TFEB levels in ponatinib resistant CML 
Finding increased LAMP1 levels in ponatinib resistant cells prompted us to look into 
lysosome biogenesis in our CML model. Nuclear TFEB is a master regulator of 
lysosome biogenesis (Figure 4.14).243 TFEB positively regulates the transcription of 
genes involved in all steps of lysosome biogenesis, including lysosomal proliferation, 
acidification, and exocytosis. TFEB also regulates genes involved in autophagy 
pathways. Overall, TFEB modulates processes that promote clearance of lysosomal 
substrates within cells. 
Under normal conditions, TFEB is localised in the cell cytoplasm, where it is 
phosphorylated by mTOR complex 1 (mTORC1) on the lysosomal surface.137 
Phosphorylated TFEB binds to 14-3-3 proteins which promotes its cytoplasmic 
retention. In contrast, nutrient starvation or lysosomal stress leads to TFEB 
dephosphorylation by calcineurin, which is activated by lysosomal Ca2+ release via 
muculipin 1 (MCOLN1) receptor on the lysosome surface.244 In the nucleus, TFEB 
activates coordinated lysosomal expression and regulation (CLEAR) genes, which 
triggers lysosome biogenesis (Figure 4.14).137 High nuclear TFEB localisation is 
implicated in a number of lysosome storage disorders.  
 
Figure 4.14 TFEB regulated processes. TFEB positively regulates the transcription of genes 
related to lysosome biogenesis (CLEAR). When TFEB is phosphorylated by mTORC1 it stays 
in the cytoplasm where it is sequestered by 14-3-3 proteins. Calcineurin, which is activated by 
the release of Ca2+ from the lysosomes can dephosphorylate TFEB, which drives its 
translocation into the nucleus, where it activates the transcription of genes that lead to 
increased lysosomal biogenesis and various other processes that promote cellular clearance. 
Image created with Biorender.  
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To establish whether lysosome biogenesis was differentially regulated in the resistant 
CML cells, we measured TFEB levels via immunofluorescence labelling. Both KCL22 
and KCL22Pon-Res cells were treated with DMSO (0.0003%, 1 h) or ponatinib (5 µM, 
1 h) and stained with TFEB antibody. Nuclei were stained with DRAQ7. 
Immunofluorescence imaging revealed that the majority of TFEB co-localised with 
DRAQ7 in both drug sensitive and drug resistant cells (Figure 4.15, Figure S7 for no 
antibody control images). This result indicates that both CML cell lines have high 
TFEB activity and possibly elevated levels of lysosome biogenesis. The nuclear 
localisation of TFEB in KCL22 cells shows that even drug sensitive CML cells have 
upregulated TFEB activity. 
 
Figure 4.15 Immunofluorescence imaging of nuclear TFEB in CML cells. (a), (b) KCL22  and 
(c), (d) KCL22Pon-Res cells were treated with either (a), (c) DMSO (0.0003%, v/v) or (b), (d) 
ponatinib (5 µM) for 1 h, fixed and stained with TFEB (green). Nuclei were stained with DRAQ7 
(red). (e) Immunofluorescence of nuclear TFEB quantified in KCL22 (green) and KCL22Pon-Res 
(purple) cells. Mean fluorescence intensity (MFI) in individual nuclei of n=6 fields of view was 
quantified from 3 biological repeats. The Mann-Whitney test was used to compare TFEB 
levels. Values shown as mean±SD, **** (p<0.0001). Images acquired at 1024 × 1024 pixels, 
4 μs pixel dwell time, laser power 200 mW (the tuneable pump beam), gain 1. Scale bars: 
10 μm. 
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Quantification of nuclear TFEB in individual cells demonstrated that KCL22Pon-Res cells 
had increased TFEB levels compared to KCL22 cells (Figure 4.15e), indicative of 
increased lysosome biogenesis in the resistant cells. Previous research by Mitchell 
et al. established that KCL22Pon-Res cells have increased mTORC1 levels compared 
to ponatinib sensitive KCL22 cells.109 Therefore, an mTORC1 related reduction in 
TFEB phosphorylation cannot be responsible for the increased TFEB levels in the 
nuclei of KCL22Pon-Res cells. As mentioned above, TFEB can be dephosphorylated by 
calcineurin, a serine/threonine phosphatase. Calcineurin is activated upon starvation, 
lysosomal stress or oxidative stress (Figure 4.16).245 Activation of calcineurin is 
dependent on lysosomal release of Ca2+ through MCOLN1 on the lysosome 
surface.244 Our results show increased basal level of LAMP1 (Figure 4.13c) as well 
as elevated nuclear TFEB in KCL22Pon-Res cells. It is therefore possible that lysosomal 
MCOLN1 mediated Ca2+ release is increased in ponatinib resistant cells, leading to 
elevated calcineurin dependent dephosphorylation of TFEB, which results in higher 
nuclear TFEB levels that promote lysosome biogenesis. Additional experiments would 
be required to prove this theory. This would involve exploring MCOLN1 levels, Ca2+ 
lysosomal release as well as calcineurin activity within both cell lines.  
Additionally, we found that ponatinib treatment actually decreased nuclear TFEB 
levels in both KCL22 and KCL22Pon-Res cells (Figure 4.15e). Medina et al. showed 
previously that treatment with a lysosomotropic agent, glycyl-L-phenylalanine 2-
naphthylamide (GPN), reduced Ca2+ release from lysosomes.244 As we have 
established, ponatinib is also a lysosomotropic agent, and localises in the lysosomes 
(Figure 4.5). It is plausible that ponatinib accumulation in lysosomes decreases Ca2+ 
release from lysosomes, leading to reduced calcineurin activity and consequently 
decreased TFEB nuclear localisation, which is what we saw upon ponatinib treatment 
in our cells (Figure 4.16). However, further investigation would be required to make a 
definite conclusion.  
The main take-away message from the immunofluorescence imaging of TFEB in CML 
cells was that both drug sensitive and ponatinib resistant cells KCL22Pon-Res cells had 
higher levels of nuclear TFEB compared to KCL22 cells, indicative of increased 
lysosome biogenesis. Sardiello et al. have shown that TFEB overexpression results 
in higher cellular LAMP1 levels as well as increased number of lysosomes per cell.137 
Sung et al. recently demonstrated that increased TFEB activation in glioblastoma is a 
cause of drug resistance and inhibits apoptosis.246  They showed that combination 
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treatment with melatonin and vorinostat decreased TFEB expression, increased 
apoptosis and decreased glioma stem cell tumour-sphere formation and size. TFEB 
association with drug resistance has also been shown for both ovarian cancer and 
non-small cell lung cancer.247,248  These studies positively correlate with our findings, 
and could reflect an adaptation in our ponatinib resistant CML model, which allows 
these cells to survive in the presence of ponatinib. To further assess the significance 
of elevated TFEB levels in our CML resistance model, a TFEB CRISPR knockout cell 
line could be created to determine if that would re-sensitise resistant CML cells to 
ponatinib. Additionally, transcriptome analysis could be used to investigate TFEB 
levels in drug responsive and drug resistant CML patients, as well as levels of known 
gene targets of TFEB. 
 
Figure 4.16 Model of lysosomal Ca2+ mediated regulation of TFEB. Under normal conditions, 
TFEB is phosphorylated by mTORC1 on the lysosomal surface, interacts with the 14-3-3 
proteins and remains in the cytoplasm. During nutrient starvation, lysosomal stress or oxidative 
stress, Ca2+ is released from the lysosome through the MCOLN1 receptor, establishing 
increased Ca2+ levels in the vicinity of the lysosome. Ca2+ leads to local calcineurin activation 
and TFEB dephosphorylation. Dephosphorylated TFEB translocates to the nucleus where it 
promotes transcription of lysosomal genes. Ponatinib lysosomal trapping potentially 
decreases Ca2+ release from the lysosomes. Image created with Biorender. 
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4.4.4 Lysosomal pH in ponatinib resistant CML 
Although the elevated LAMP1 and TFEB levels in ponatinib resistant CML cells were 
indicative of increased lysosome biogenesis, we still did not know how that related to 
the increased concentration of ponatinib in the lysosomes of resistant cells (Figure 
4.5d,e). TFEB has also been reported to modulate the expression of genes involved 
in lysosomal acidification.243,245 As lysosomal pH influences the equilibrium involved 
in ponatinib lysosomal accumulation, we decided to investigate the pH levels in our 
CML cell lines. To do so, we utilised Lysosensor Green, a dye whose fluorescence 
increases in acidic environments. 
Both KCL22 and KCL22Pon-Res cells were treated with DMSO (0.0003%, 1 h) or 
ponatinib (5 µM, 1 h) and simultaneously labelled with Lysosensor Green (1 µM, 1 h). 
The  live cells were immediately analysed by FACS, where Lysosensor Green 
fluorescence was measured within the cell population. We found no difference in 
Lysosensor Green fluorescence in DMSO treated samples, indicating that lysosomal 
pH is equal in KCL22 and KCL22Pon-res cells (Figure 4.17a). However, in ponatinib 
treated samples, Lysosensor Green fluorescence was increased in KCL22Pon-Res cells 
compared to KCL22 cells (Figure 4.17b). Geometric (GEO) mean values calculated 
from the histograms of three individual samples confirmed these observations (Figure 
4.17c).   
These results suggest ponatinib treatment decreases lysosomal pH in both cell lines, 
but more significantly in the drug resistant KCL22Pon-Res cells. It is possible that 
v-ATPase activity on the lysosomal membrane is increased upon ponatinib treatment, 
leading to reduced pH. If lysosomal pH is more acidic in the KCL22Pon-Res cells upon 
ponatinib treatment, it may explain why these cells have higher levels of lysosomal 
ponatinib accumulation. A lower pH likely shifts the equilibrium of ponatinib uptake 
towards increased lysosomal uptake, and increases lysosomal H+ availability. This 
would lead to increased protonation of ponatinib and trap it within the lysosomal 
lumen, resulting in increased ponatinib concentration in the lysosomes of KCL22Pon-Res 
cells.  
The impact of low pH on drug uptake into acidic vesicles has been associated with 
cancer drug resistance by previous research.249,250 Overexpression of v-ATPase that 
is responsible for lysosome acidification has been found before in drug resistant cell 
lines.251 Inhibition of the v-ATPase by bafilomycin A1 re-sensitised drug resistant renal 
cancer cells to daunomycin, doxorubicin and epirubicin.252 In these drug resistance 
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models it is assumed that lysosomal trapping leads to insufficient drug target 
engagement and consequent cell survival. In contrast, we have shown in our CML 
resistance model that increased lysosomal trapping in ponatinib resistant cells (Figure 
4.5) does not lead to reduced target engagement (Figure 4.9). Therefore, the acidic 
pH and increased lysosomal trapping of ponatinib in our CML resistance model are 
more likely to be a ‘side-effect’ of drug resistance rather than the cause of it. 
 
Figure 4.17 Estimating lysosomal pH in CML cells labelled with Lysosensor Green. (a), (b) 
Representative FACS histograms of KCL22 (green) and KCL22Pon-Res (purple) cells that were 
treated with (a) DMSO (0.0003%, v/v) or (b) ponatinib (5 µM, 1 h) and labelled with 
Lysosensor™ Green DND-189 (1 µM, 1 h). Grey and Black lines represent unlabelled KCL22 
and KCL22Pon-Res control cells respectively. (c) Geometric mean values derived from n=3 
biological repeats of FACS data using FlowJo software. One-way Anova (Tukey’s multiple 
comparisons test) was used to compare the GEO means. Values shown as mean±SD, **** 
(p<0.0001), *** (p=0.0002), ** (p=0.0096), ns (p>0.9999). 
4.5 Investigating ponatinib retention in the lysosomes 
We then asked whether ponatinib trapping in lysosomes also results in retention of 
ponatinib in lysosomes following removal of the drug from media after treatment. It 
was hypothesised that ponatinib will be retained in the lysosomes following washout. 
4.5.1 Ponatinib imaging by SRS following washout 
KCL22 and KCL22Pon-Res cells were treated with ponatinib (5 μM, 1 h), washed, and 
re-incubated in drug free media for either 0, 1, 2 or 4 h post wash before live cell 
imaging using SRS (Figure 4.18). All the samples were labelled with Lysotracker 
(50 nM, 1 h) before live cell imaging. The SRS signal of ponatinib prior to wash-out 
showed ponatinib distribution in both lysosomes and the cytoplasm of the cells (Figure 
4.18b,d, 0 h). Surprisingly, there was a rapid reduction in signal in both the KCL22 
and KCL22Pon-Res cells 1 h post wash-out (Figure 4.18b,d). Ponatinib signal inside the 
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lysosomes of individual cells (n=10) was further quantified at each time point and 
showed a significant decrease in ponatinib signal in both parental and resistant cells 
after 1 h, with a small but significant signal remaining up to 4 h post wash-out (Figure 
4.18e,f). A comparison of relative ponatinib concentrations within lysosomes between 
KCL22 and KCL22Pon-Res cells at the respective time-points showed a similar loss of 
signal in both cell lines, although the initial ponatinib signal was higher in the 
KCL22Pon-Res cells as shown previously (Figure 4.18g).  
These results demonstrated clearly that ponatinib is not retained in the lysosomes as 
we hypothesised. As we did not see major metabolism of ponatinib in either KCL22 
or KCL22Pon-Res cells from the LC-MS analysis (Figure 3.7b), however, it is unlikely 
that the rapid loss of ponatinib SRS signal following washout is due to drug 
metabolism within the lysosomes.  
TFEB is a known regulator of lysosomal exocytosis, a process during which 
lysosomes fuse with the cell membrane and release their contents into the 
extracellular environment.245,253 Zhitomirsky and Assaraf showed that lysosomal 
accumulation of a number of drugs, including sunitinib, triggered lysosomal 
translocation from the perinuclear region to the cell membrane, where lysosomal 
content, including lysosomal enzymes, were secreted into the extracellular milieu via 
lysosomal exocytosis.254 We know that TFEB is localised in the nucleus in both KCL22 
and KCL22Pon-Res cells, indicating they have activated lysosomal biogenesis and 
exocytosis pathways (Figure 4.15). Therefore, it is indirect evidence that lysosomal 
exocytosis potentially plays a role in the rapid loss of ponatinib signal in CML cells 
following treatment and drug washout. To gain more direct proof, it would be 
necessary to image lysosomal movement in CML cells both during and after treatment 
using either Lysotracker or LAMP1 labelling. Unfortunately, the CML cells are small 
in size (10-15 μm diameter) and have very large nuclei in proportion to the rest of the 
cell. For that reason, we decided it was not feasible to differentiate between lysosome 
localisation near the perinuclear region and the cell membrane.  





Figure 4.18 Multimodal imaging and quantitative assessment of ponatinib retention in 
lysosomes. KCL22 and KCL22Pon-Res cells were treated with ponatinib (5 µM, 1 h) labelled with 
Lysotracker® Green (50 nM, 1 h). The cells were imaged at (from left to right) 0 h, 1 h, 2 h or 
4 h after wash out. (a), (c) TPF images acquired at 861 nm (Lysotracker® Green). (b), (d) SRS 
images acquired at 2221 cm-1 (C≡C, ponatinib). (e), (f) Mean ponatinib Raman intensity inside 
the vesicles of each individual cell quantified for (e) KCL22 and (f) KCL22Pon-Res cells at each 
time point post treatment, n=10 cells, 3 biological repeats. The Kruskal-Wallis test with Dunn’s 
multiple comparisons test was used to compare ponatinib Raman intensity values against the 
DMSO control, **** (p<0.0001), * (p=0.0107). Individual data points shown with error bar as 
mean±SD. (g) Ponatinib Raman signal quantification for KCL22 (green) and KCL22Pon-Res 
(purple) cells at each time point. Images acquired at 1024 × 1024 pixels, 20 μs pixel dwell 
time, laser power 200 mW (the tuneable pump beam), gain 1 with false colours applied to 
different detection wavenumbers. Scale bars: 10 μm. 
An additional factor that may contribute to ponatinib signal loss from the lysosomes is 
ponatinib diffusion out of the lysosomes following washout (Figure 4.19). Removing 
ponatinib from the media after drug treatment changes the drug uptake equilibrium in 
the cell. Although we believe ponatinib is trapped in the lysosomes in its protonated 
form, we do not know what proportion of the drug is protonated within the lysosomes. 
It is possible that at these very high local concentrations of ponatinib the v-ATPase 
proton pumps can get saturated, where not all of lysosomal ponatinib will get 
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protonated. In this case, following washout, the deprotonated drug would be able to 
diffuse back out of the lysosome, into the cytoplasm, and out of the cell as the new 
drug uptake equilibrium is reached.  
Although we did not determine the exact mechanism of ponatinib transport out of the 
CML cells following washout, SRS imaging showed that it is a dynamic process where 
lysosomes play an important role. SRS has the temporal imaging capability to allow 
live cell visualisation in real time to study drug uptake and efflux. Tipping has 
demonstrated this previously using SRS imaging for Raman-tagged anisomycin, 
where following washout anisomycin Raman signal disappearance was seen in real 
time.255 Alternatively, drug uptake and efflux can be monitored by fluorescence 
microscopy. In contrast to Raman tags, photostability is a concern for the majority of 
fluorophores, and has made it challenging to apply fluorescence microscopy for 
quantitative temporal drug imaging.256,257 In the current study, we were limited by the 
fact that CML cells are non-adherent, which experimentally prevented us from using 
SRS imaging to further study ponatinib lysosomal uptake and transport in real time.  
 
Figure 4.19 Schematic representation of ponatinib (P) accumulation in the cell via passive 
diffusion. Ponatinib treatment actives v-ATPase pumps, forcing more protons into the 
lysosomal lumen to enable lysosomal trapping of ponatinib (PH+).  However, after washout (1-
4 h after), external ponatinib is removed from the media, causing intracellular ponatinib to 
diffuse back out of the cytoplasm as well as the lysosome of the cell to reach a new equilibrium.  
4.6 Conclusions 
In this chapter, SRS imaging was applied to determine ponatinib intracellular 
localisation and explore its biological significance in the context of ponatinib resistant 
CML. We demonstrated that ponatinib localises in the lysosomes of both parental and 
drug resistant CML cells, while both ponatinib lysosomal and cytoplasmic 
accumulation were found to be increased in ponatinib resistant cells. In addition, 
lysosome number was found to be elevated in ponatinib resistant cells by Lysotracker 
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imaging, and further confirmed by LAMP1 immunofluorescence measurements. In 
untreated cells, lysosomal pH was equal in both ponatinib sensitive and resistant cell 
lines, but ponatinib treatment increased lysosomal acidity more in drug resistant cells. 
Together, these results demonstrate that lysosomal uptake of ponatinib is 
differentially regulated in our ponatinib resistant CML model. Subsequently to 
publishing our findings, Englinger et al. reported ponatinib localisation in lipid droplets 
within lung cancer cells using ponatinib fluorescence to visualise the drug.258 
Considering they used a completely different cell model compared to us, it is possible 
that ponatinib intracellular localisation differs in lung cancer cells. As ponatinib is not 
a highly fluorescent molecule, intracellular visualisation required the use of 10 μM 
concentrations, which is higher than we used for SRS imaging.  
Interestingly, we did not find ponatinib retention in the lysosomes following drug 
washout. This is postulated to be a result of lysosomal exocytosis and or diffusion of 
ponatinib out of the lysosomes to re-establish equilibrium after drug removal from the 
media. Further experiments would be required to prove this using real time SRS 
imaging.  
Combination treatment with chloroquine, a nonspecific autophagy inhibitor that acts 
as a lysosomotropic agent, decreased ponatinib lysosomal sequestering significantly 
in both cell lines, and consequently increased target engagement. Using an 
autophagy knockdown cell line, we found that autophagy does not play a role in 
ponatinib lysosomal trapping. Therefore, CQ likely reduces lysosomal uptake of 
ponatinib due to its lysosomotropic properties, which decrease the ability of ponatinib 
to accumulate in the lysosomes. However, CQ combination treatment does not re-
sensitise cells to ponatinib due to BCR-ABL independent resistance mechanism in 
this CML model. These results highlight that although lysosomal trapping can 
influence drug uptake and target engagement, it does not always have an effect on 
cell viability. This is an important consideration for other BCR-ABL independent 
resistance mechanisms where target inhibition is no longer sufficient to induce cell 
death. In addition, it applies to other cancers where TKI independent resistance 
mechanisms occur, such as non-small cell lung cancer where treatment with EGFR 
targeted therapy leads to EGFR independent acquired resistance.259 To improve 
future treatment of cancers with target independent resistance mechanisms, it is 
important to identify the underlying causes of these resistance mechanisms, and 
target them with new treatments.  
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While investigating lysosome biogenesis in our CML model, we found a significant 
increase in nuclear TFEB, a master regulator of lysosome biogenesis and autophagy, 
in the ponatinib resistant cells. Recently, Sung et al. demonstrated that elevated TFEB 
activation in glioblastoma is a cause of drug resistance and inhibits apoptosis, where 
TFEB targeting increased cell death.246 This is potentially something that could also 
be investigated in the context of ponatinib resistant CML. Mitchell et al. have shown 
that mTORC1 is overexpressed in ponatinib resistant CML and mTORC inhibition with 
NVP-BEZ235, an inhibitor of mTORC1, mTORC2 and all PI3K isoforms, was effective 
in inducing cell death in vitro, in vivo and in TKI-resistant primary CML cells.109 The 
relationship between TFEB and mTOR in CML has not been extensively studied and 
how both TFEB and mTOR can be constitutively activated in ponatinib resistant CML 
is unknown. Recent reports in other cell models, however, have identified TFEB 
mediated endocytosis as a critical process leading to activation of mTORC1 and 
autophagic function.260,261 Therefore, further exploration of TFEB role in ponatinib 
resistant CML would potentially be interesting to determine if TFEB could be a 
potential drug target in CML.  
In summary, we determined intracellular localisation of ponatinib for the first time 
using SRS, demonstrating that acquired drug resistance can influence drug uptake 
and localisation in CML, which in turn has an effect on target engagement. However, 
lysosomal accumulation of ponatinib did not influence cell viability in this BCR-ABL 
independent CML model. We therefore propose that lysosomal uptake of ponatinib in 
drug resistant CML is rather a side effect of drug resistance than the primary cause.
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Chapter 5 Spheroid imaging  
5.1 Introduction 
Previous chapters focused on applying SRS drug imaging in two dimensions using a 
monolayer of cells. However, many cancers form solid tumours in patients. It is 
therefore also important to study drug efficacy in three-dimensional (3D) cancer 
models. Most such research has traditionally been done in vivo using animal models, 
but more recently cancer spheroids have emerged as an additional option for pre-
clinical drug evaluation. In this chapter, SRS utility is tested for drug imaging in cancer 
spheroids.  
5.1.1 Use of spheroids in drug development  
Conventional drug discovery screens utilise 2D cell culture where adherent cells are 
grown in monolayers.262 Although it provides a simple and effective tool for pre-clinical 
drug screens, 2D cell culture fails to mimic the complex physiology of the in vivo 
tumour microenvironment (TME), lacking cell–cell and cell–matrix interactions that are 
present in tumours.150 In contrast, 3D cell culture systems exhibit physiologically 
relevant cell-cell and cell-matrix interactions, gene expression, heterogeneity as well 
as structural complexity characteristic to tumours (Table 5.1).142 Compared to 2D 
culture, spheroids represent a more accurate in vitro model for pre-clinical drug 
testing.  
To progress from the pre-clinical drug screening phase to the clinical phase, drug 
activity has to be shown in vivo first. However, in vivo models have drawbacks 
including ethical considerations, high cost, and they are not high throughput. In 
addition, there are physiological differences between animals and humans, which 
sometimes fail to accurately represent human disease and can later lead to issues 
such as drug toxicity in clinical trials. 3D spheroids possess close to all the important 
characteristics of in vivo tumours (Table 5.1), but due to lack of vasculature in 
spheroids, drug penetration in spheroids is not exactly similar to in vivo tumours. 
Therefore, spheroids likely cannot replace the use of in vivo models, but they can help 
reduce the number of animals used by trialling active compounds that are then tested 
in vivo, and represent an important tool that can be used alongside 2D and in vivo 
models during pre-clinical drug evaluation.  
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Drug screens comparing 2D and 3D cultures have shown drastic differences in 
sensitivity.263,264 Spheroids are typically more resistant to drug treatment compared to 
2D culture.265 More importantly, 3D cultures have now been shown to accurately 
predict patient responses to chemotherapy, and mimic intra- and interpatient 
heterogeneity to drug response.266,267 This highlights the importance of using 3D 
models in pre-clinical drug screening.   
Table 5.1 Key features of 2D cell culture, spheroids and in vivo tumours. Adapted with 
permission,150 copyright Elsevier.  




Spatial restriction of cells P O O 
Concentration gradient of O2, nutrients, metabolic 
waste 
O P P 
Hypoxic core O P P 
Proliferative, quiescent & necrotic zones O P P 
Heterogeneous clonal subpopulations P P P 
Cancer stem cell niche O P P 
Gene expression profile Different Similar Similar 
 
5.1.2 Drug imaging in spheroids 
Spheroids are not only useful for drug sensitivity studies; they can also be used to 
better understand uptake, penetration and metabolism of drugs in 3D. However, the 
biggest challenge for drug imaging in 3D is penetration depth of imaging techniques.  
Confocal fluorescence microscopy has been applied to imaging doxorubicin, an 
inherently fluorescent cytotoxic drug routinely used for the treatment of both solid 
tumours and haematological malignancies, but it was only able to detect the 
fluorescence up to 50 µm in depth (Figure 5.1a).31,268,269 At 100 µm depth, the real 
degree of doxorubicin penetration could no longer be determined.31 In confocal 
microscopy, the same lens is used to excite the sample and to collect the emitted 
photons from the sample, where the pinhole system removes out-of-focus light and 
enables optical sectioning.270 However, the light scattering from the sample degrades 
fluorescence signal and leads to exponential decay in emitted photons from the 
sample with increasing imaging depth.  





Figure 5.1 Comparison of confocal imaging and LSFM imaging of doxorubicin in a pancreatic 
tumour spheroid. (a) Confocal imaging of spheroid with a diameter of ~600 μm that was 
incubated with doxorubicin (20 μM, 3 h) prior to imaging. Images from left to right: Maximum 
intensity projection (MIP) of the z-stack; spheroid section at ∼5 μm depth; spheroid section 
∼50 μm depth and optical section at ∼100 μm depth. (b) LSFM imaging of spheroid with a 
diameter of ~600 μm that was incubated with doxorubicin (20 μM, 3 h) prior to imaging. Images 
acquired from left to right: MIP of the z-stack; spheroid sections at ~58 μm; ~110 μm and 
~190 μm (middle of spheroid). (c), (d) LSFM imaging of spheroid (diameter ~1 mm) that was 
incubated with doxorubicin (20 μM, 4 h) (red) and labelled with Hoechst 33342 (blue). (d) 
Spheroid section at 403 µm depth. Scale bars: 100 μm. Reproduced with permission.31 
In contrast, light sheet fluorescence microscopy (LSFM) uses a separate illumination 
lens and detection lens, which are placed perpendicular to each other. As no pinhole 
is used, more photons from the sample are detected. This gives LSFM superior 
imaging depth compared to confocal fluorescence microscopy.31 Lazzari et al. 
demonstrated that LSFM can be used to image doxorubicin uptake in spheroids with 
a diameter of 600 µm, where doxorubicin was successfully detected at up 190 µm 
depth (Figure 5.1b).31 To further demonstrate the imaging depth and 3D 
reconstruction of LSFM, they imaged doxorubicin in 1 mm diameter spheroids 
(Figure 5.1c). Diffuse doxorubicin signal could be detected in the middle of the 
spheroid at 403 µm depth (Figure 5.1d), but clear distinction of doxorubicin in the cell 
nuclei was not possible as a consequence of strong scattering phenomena this deep 
in the spheroid.  
MALDI imaging mass spectrometry (MALDI-IMS) has also been applied to imaging 
drug uptake in spheroids.271 In contrast to fluorescence, MALDI imaging is done on 
sections through the spheroid to allow penetration of the drug to be measured, not on 
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the whole spheroid at once. Although MALDI-IMS has become a widely used tool in 
pre-clinical drug screening,272 especially for tissue imaging, it is limited by low spatial 
resolution of approximately 20 µm. Hence, to gain meaningful information about drug 
uptake and metabolism in different spheroid sections, large spheroids (ideally ≥ 
500 µm in diameter) have to be imaged. In addition, MALDI-IMS protocol is relatively 
complex, requiring sectioning of frozen spheroids prior to imaging as well as choosing 
an appropriate matrix for detecting the small molecule of interest.153,273,274  
LaBonia et al. successfully imaged irinotecan and its active metabolite in colon cancer 
spheroids using MALDI-IMS.275 Irinotecan is a prodrug that is metabolised by 
carboxylesterase in the body into its active metabolite SN-38, which is a 
topoisomerase I inhibitor (Figure 5.2a).276 It is widely used to treat colon, pancreatic 
and lung cancer.277 LaBonia et al. used a novel 3D printed fluidic device that provided 
a continuous drug flow of irinotecan (50 µM) over 24-h treatment period. This drug 
treatment method was applied to large spheroids with a diameter of approximately 
1 mm. Subsequent MALDI-IMS imaging revealed the prodrug of irinotecan localised 
in the centre of the tumour spheroid, while the active metabolite SN-38 primarily 
localised on the edge of the spheroid (Figure 5.2b). As the outer rim of the spheroid 
contains the proliferating cells, the metabolism of the prodrug into the active 
metabolite was likely in that area of the spheroid. This study perfectly illustrates the 
relevance of imaging drugs in spheroids by giving spatial information on both the drug 



















Figure 5.2 MALDI-IMS imaging of irinotecan in HCT-116 spheroids. (a) Metabolic reaction of 
irinotecan prodrug into its active metabolite, SN-38. (b) Imaging of irinotecan (left) and SN-38 
(center). Merged image (right) shows that the active metabolite (SN-38) is localised to the 
periphery of the spheroid while the prodrug (irinotecan) localises to the core. Reproduced with 
permission,275 copyright John Wiley & Sons. 
5.2 Optimising spheroid growth 
Unlike in previous chapters, where human CML cell lines KCL22 and KCL22Pon-Res 
were successfully used to image ponatinib in 2D, the goal in this chapter was to use 
SRS to image in 3D. In order to do that, we needed to optimise spheroid growth using 
these cell lines.  
5.2.1 Growing spheroids from CML non-adherent cells 
Not all leukaemia cell lines form spheroids and they are not routinely grown in 3D. 
However, a few examples exist where acute myeloid leukaemia (AML) and acute 
lymphoblastic leukaemia (ALL) cells have been shown to form spheroids.278,279 As 
discussed in Section 1.6.1 the U-bottom ULA plate method has been shown to allow 
rapid formation of consistently sized uniform spheroids and is amenable to HTS.280 
Therefore, we also chose to utilise this method for spheroid growth optimisation.157 
KCL22 and KCL22Pon-Res cell lines were seeded onto a U-bottom ULA 96-well plate at 
various seeding densities (250 to 6,000 cells per well in 200 µL media). The spheroid 
formation was initiated by centrifugation of the plates at 1000 g for 10 min. Spheroids 
were grown for seven days and imaged using the ImageXpress. Example of the ULA 
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96-well plate with CML spheroids on day 7 is shown in Figure 5.3, demonstrating that 
a single spheroid per well is generated using this method.     
 
Figure 5.3 U-bottom ULA 96-well plate with CML spheroids. KCL22 and KCL22Pon-Res cells 
were seeded at various densities (250-6,000 cells) on day 0 with or without matrigel (MG). 
Phase contrast image of the plate was recorded on day 7 post seeding using ImageXpress. 
Scale bar: 1 mm. 
Transmitted light images were acquired on ImageXpress for each well on day 2, day 
4 and day 7 post seeding to measure spheroid growth over time (Figure 5.4a,b). Both 
KCL22 and KCL22Pon-Res spheroids grew over seven days. Spheroid size was 
measured based on the spheroid area using Cellprofiler. On day 2 and day 4 post 
seeding it is visible that seeding density is proportional to spheroid size, but by day 7 
the spheroids at higher seeding density (2,000-6,000 cells per well) have reached a 
plateau and are almost equal in size (Figure 5.4c,d). However, when looking at each 
seeding density separately, all the spheroids grew visibly between day 2 and day 4 
as well as day 4 and day 7 (Figure 5.4 e,f). These trends were similar in both KCL22 











Figure 5.4 CML spheroid growth. KCL22 and KCL22Pon-Res cells were seeded at various 
densities on day 0 (250-6,000 cells per well) and imaged using ImageXpress on day 2, day 4 
and day 7. Sample spheroid images of (a) KCL22 and (b) KCL22Pon-Res shown for 2,000 cells 
per well. Scale bars: 500 μm. (c), (e) KCL22 and (d), (f) KCL22Pon-Res spheroid sizes (µm2) 
measured from n=2-8 spheroids per seeding density. Values shown as mean±SD. 
Next, spheroid size between KCL22 and KCL22Pon-Res cells was compared using the 
imaging data from day 7 (Figure 5.5a). Morphologically, both KCL22 and KCL22Pon-Res 
spheroids look relatively similar, but the KCL22Pon-Res cell line formed significantly 
smaller spheroids than KCL22 cell line at each seeding density (Figure 5.5b). This 
could indicate that KCL22Pon-Res cells proliferate slower in 3D. Although proliferation 
rates were never directly compared between the cell lines in 2D, it was observed 
during passaging of cells that KCL22 cells proliferated faster. This could explain the 
smaller spheroid size in 3D as well, since identical number of cells were seeded for 
both cell lines.  However, sometimes spheroid size can be smaller due to more tightly 








Figure 5.5 Comparison of spheroid size between KCL22 and KCL22Pon-Res cell lines. (a) 
Representative spheroid images taken on day 7 after seeding for (i) KCL22 and (ii) 
KCL22Pon-Res cell line at various seeding densities (250-6,000 cells per well). Scale bars: 
500 μm. (b) Spheroid size measured from ImageXpress images using CellProfiler on day 7. 
Two-way ANOVA (Sidak’s multiple comparisons test) was used to compare spheroid sizes 
from n=2-8 spheroids per seeding density. Values shown as mean±SD, **** (p<0.0001), *** 
(p=0.0003), ** (p=0.0094), * (p=0.0133).  
To characterise the spheroids further, on day 7 after seeding, the spheroids were 
labelled with Hoechst (blue), Calcein AM (green) and propidium iodide (PI, red). 
Hoechst labels cell nuclei by binding to the minor groove of DNA.281 Calcein-
acetoxymethylester (Calcein-AM) is a non-fluorescent cell permeable compound that 
is used as a live cell marker.282 Inside live cells, esterases convert Calcein AM into 
Calcein, which is fluorescent. Propidium iodide (PI) is a dead cell dye that binds to the 
DNA of dead cells.283 As it is membrane impermeable, PI does not label the DNA of 
live cells. 
The spheroids were labelled with all three fluorophores simultaneously and single 
images per well were acquired in each channel on the ImageXpress Micro (IXM) 
automated HCS platform subsequently. Sample images of Calcein AM and PI labelled 
KCL22 and KCL22Pon-Res spheroids at different seeding densities are shown in Figure 
5.6a-d. Using the Hoechst fluorescent signal as a whole spheroid map (images not 
shown), Calcein AM and PI MFI was quantified in individual spheroids (Figure 5.6e,f). 
Calcein fluorescence slightly decreased with increasing spheroid size in both cell 
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lines, indicating that although the spheroid size is increasing the number of viable 
cells is not increasing proportionally. There was no significant difference between the 
KCL22 and KCL22Pon-Res cell lines. PI staining was normalised to spheroid size to 
account for the difference in KCL22 and KCL22Pon-Res measured spheroid sizes. PI 
staining increased with increasing spheroid size, indicative of the increasing size of 
the dead cell core in the spheroids, which can also be seen from the images (Figure 
5.6c,d,f). In the larger spheroids (2,000-6,000 cells per well at seeding) the area of 
dead cells is taking up the majority of the spheroid volume. PI staining was lower in 
KCL22Pon-Res spheroids compared to KCL22 spheroids at most seeding densities, 
reflective of the smaller dead cell core in these spheroids.  
 
 
Figure 5.6 Propidium iodide (PI) and Calcein AM staining in CML spheroids. KCL22 and 
KCL22Pon-Res cells seeded at various densities on day 0 were grown for seven days to form 
spheroids. Spheroids were labelled with (a), (b) Calcein AM and (c), (d) PI for 1 h on day 7. 
Scale bars: 500 μm. MFI of (e) Calcein AM and (f) PI was measured for each spheroid and PI 
intensity was normalised to spheroid size. Two-way ANOVA (Sidak’s multiple comparisons 
test) was used to compare fluorescence intensity from a minimum of n=2-8 spheroids per 
seeding density. Values shown as mean±SD, *** (p=0.0004), ** (p=0.0033), * (p=0.0176). 
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The effect of matrigel on CML spheroid growth was also tested during the optimisation 
stage. Matrigel is a gelatinous protein mixture derived from mouse tumour cells and 
commercialised as Matrigel.284-286 It is a sterile reconstituted basement membrane 
preparation that primarily consists of laminin, collagen IV, entactin as well as various 
proteases, growth factors and proteins; and forms a 3D gel at 37 °C.285 Matrigel 
mimics the ECM of tumours and is routinely used for a variety of in vitro, in vivo and 
ex vivo experiments, where it promotes cell morphogenesis, differentiation and 
tumour growth. It has also been shown to aid spheroid formation in 3D cell 
culture.157,280  
KCL22 and KCL22Pon-Res cells were seeded in the presence or absence of matrigel 
and grown for seven days. Spheroids were imaged on day 2, day 4 and day 7 post 
seeding and the spheroid size was measured on each day. It was noted that on day 
2 and day 4 both KCL22 and KCL22Pon-Res spheroids grown in the presence of matrigel 
were more compact and smaller in size (Figure 5.7a,b). Ivascu and Kubbies reported 
a similar case, where matrigel enabled tighter spheroid formation in a breast cancer 
cell line MDA-MB-231, which otherwise did not form spheroids at all.157 However, in 
our experiment, by day 7 the CML spheroids grown with no matrigel were the same 
size as the spheroids grown in matrigel, and upon visual observation both displayed 
similar morphology.  
For SRS imaging, it was a requirement to be able to move the spheroids out of the U-
bottom well of the ULA plate as the plate cannot be imaged directly. This type of 
spheroid transfer is usually done by careful pipetting. Spheroid transfer was tested 
both on day 4 and day 7. Unfortunately, when the CML spheroid transfer was 
attempted for either cell line grown with or without matrigel, the spheroid structure fell 
apart. Therefore, the KCL22 and KCL22Pon-Res cell lines had formed cell aggregates 
in 3D rather than true spheroids. This is not unusual and been reported for a number 
other cell lines grown in ULA plates.157,280 In addition, CML cells do not normally form 
cell-cell contacts. It is possible that matrigel did have some effect on CML spheroid 
formation in the first few days and acted to physically compact the spheroids, but this 
effect did not result in actual spheroid formation over seven days.  
 
 





Figure 5.7 Matrigel (MG) effect on CML spheroid size. (a) KCL22 and (b) KCL22Pon-Res 
spheroids were seeded with 2.5% MG or without MG on day 0 at various densities (250-6,000 
cells per well) and spheroid size was measured on day 2, day 4 and day 7 post seeding. 
Representative spheroid images shown at 2,000 cells per well seeding density for both (a) 
KCL22 and (b) KCL22Pon-Res on day 2, day 4 and day 7. Scale bars: 500 μm. Two-way ANOVA 
(Sidak’s multiple comparisons test) was used to compare spheroid sizes from a minimum of 
n=2-8 spheroids per seeding density. Values shown as mean±SD, **** (p<0.0001), *** 
(p=0.0002). * (p=0.0146).  
5.2.2 Growing spheroids from T47D adherent cells 
As the goal of this chapter was utilisation of SRS imaging on spheroids and the CML 
cell lines of interest did not form tight spheroids, another cell line was chosen for 3D 
imaging purposes. T47D, an adherent breast cancer cell line that is known to form 
tight spheroids in ULA plates, was picked as an alternative.148,157,163  
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5.2.2.1 Testing spheroid growth conditions 
T47D cells were initially seeded at 2,000 cells per well with or without matrigel and 
grown for seven days. Spheroid growth was imaged on day 2, day 4 and day 7 using 
the ImageXpress (Figure 5.8a,b). The transmitted light images clearly show that T47D 
spheroids only formed when there was no added matrigel in the wells. Spheroid size 
was measured on each day the spheroids were imaged, and showed that T47D 
spheroids grow in size between both day 2 and day 4 as well as day 4 and day 7 
(Figure 5.8c). The average spheroid diameter on day 7 was estimated to be 530 µm. 
To confirm the T47D spheroids have tight cell-cell contacts they were transferred onto 
an imaging slide by pipetting, after which the spheroid structure remained intact.  
 
Figure 5.8 Matrigel (MG) effect on T47D spheroid growth. T47D cells were seeded at 2,000 
cells per well on day 0 (a) without MG or (b) with 2.5% MG and the spheroid formation was 
imaged on day 2, day 4 and day 7. Scale bars: 500 μm (b) T47D cells did not form spheroids 
in the presence of MG. (c) T47D spheroid size was measured on day 2, day 4 and day 7 from 
(a). One-way ANOVA (Tukey’s multiple comparisons test) was used to compare spheroid size 
on different days from n=31 spheroids. Values shown as mean±SD, **** (p<0.0001).  
5.2.2.2 Optimising spheroid size 
The effect of seeding density on T47D spheroid size and composition was tested next. 
T47D cells were seeded at different seeding densities (2,000-6,000 cells per well) on 
day 0, grown for seven days to forms spheroids, and labelled with Hoechst, Calcein 
AM and PI on day 7 before imaging on the ImageXpress. Spheroid size increased 
with increasing seeding density (Figure 5.9a-d). The average diameters of spheroids 
seeded at 2,000, 4,000 and 6,000 cells per well were estimated to be 540 µm, 590 µm 
and 650 µm respectively. Calcein AM staining slightly decreased with spheroid size 
for T47D cells, demonstrating that larger spheroids don’t necessarily have higher 
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number of viable cells (Figure 5.9e). In contrast to the CML cell aggregates, where 
the Calcein AM staining was equal throughout the spheroid, T47D spheroids have a 
clear viable edge with higher intensity Calcein AM fluorescence. This is more distinct 
in the larger spheroids (4,000 and 6,000 cells per well).  
 
 
Figure 5.9 Seeding density effect on T47D spheroid size and composition. T47D cells were 
seeded at (a) 2,000 (b) 4000 or (c) 6,000 cells per well on day 0 and grown for seven days to 
form spheroids. Spheroids were labelled with Calcein AM (3.5 μM) and PI (1 μM) for 1 h on 
day 7 and imaged on the ImageXpress. Scale bars: 500 μm. (d) Spheroid size was measured 
from the phase contrast images for a minimum of n=18 spheroids per seeding density. (e) MFI 
from Calcein AM images. (f) MFI from PI images normalised to spheroid size. Minimum of 
n=16 spheroids per seeding density were analysed. One-way ANOVA (Tukey’s multiple 
comparisons test) was used to compare spheroid size, Calcein AM and PI fluorescence from 
n=16-24 spheroids per seeding density. Values shown as mean±SD, **** (p<0.0001), *** 
(p=0.0003), ** (p=0.0022). 
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PI staining showed that the dead cells are concentrated within the core of these 
spheroids (Figure 5.9a-c). PI fluorescence intensity increased with spheroid size, 
indicative of an increasing dead cell core size in spheroids with larger diameter (Figure 
5.9f). Overall, the labelling confirmed that T47D cells have formed spheroids with a 
distinct viable outer layer and a dead cell core. This is consistent with previously 
reported data, where T47D spheroids were shown to have a hypoxic core by labelling 
with an anti-pimonidazole antibody, which is a hypoxia marker.287 In addition, it has 
been demonstrated previously that T47D spheroids have up-regulated hypoxia and 
low-nutrition related genes in 3D culture compared to 2D. 
In an attempt to see if we can grow larger T47D spheroids, which would be compatible 
for comparison imaging with MALDI, and up to 1 mm diameter, another experiment 
was conducted with higher seeding densities. T47D cells were seeded at 6,000, 
10,000 and 20,000 cells per well on day zero, grown for seven days, and labelled with 
Hoechst, Calcein AM and PI before imaging on the ImageXpress. As seen earlier, 
spheroid size measurements demonstrated that increasing seeding density resulted 
in increased size (Figure 5.10a-d). The average diameters of spheroids seeded at 
6,000, 10,000 and 20,000 cells per well were estimated to be 660 µm, 810 µm and 
960 µm respectively.  
In correlation with previous imaging, Calcein AM staining slightly decreased with 
increasing spheroid size while PI staining intensity increased in line with spheroid size 
(Figure 5.10e,f). However, at 20,000 cells per well seeding density, the spheroid no 
longer consisted of just a simple viable edge and a dead core (Figure 5.10c). It now 
appeared to have an outer proliferating edge as well as an inner ring of live cells as 
well as two separate dead cell regions within the spheroid core. This demonstrates 
that although it is possible to grow T47D spheroids with close to 1 mm diameter, the 
internal spheroid structure at that size becomes more complex and needs to be 










Figure 5.10 Growing larger T47D spheroids. T47D cells were seeded at (a) 6,000 (b) 10,000 
or (c) 20,000 cells per well on day 0 and grown for seven days to form spheroids. Spheroids 
were labelled with Calcein AM (3.5 μM) and PI (1 μM) for 1 h on day 7 and imaged on the 
ImageXpress. Scale bars: 500 μm. (d) Spheroid size was measured from the phase contrast 
images for a minimum of n=18 spheroids per seeding density. (e) MFI from Calcein AM images 
normalised to spheroid size. (f) MFI from PI images normalised to spheroid size. Minimum of 
n=16 spheroids per seeding density were analysed. One-way ANOVA (Tukey’s multiple 
comparisons test) was used to compare spheroid size, Calcein AM fluorescence and PI 
fluorescence from n=16-23 spheroids per seeding density. Values shown as mean±SD, 
**** (p<0.0001). 
During T47D spheroid growth, spheroid contraction between day 0 and the first few 
days of spheroid growth was noticed when observing the ULA plate on a benchtop 
microscope. To investigate this further, transmitted light images of T47D spheroids 
plated at different seeding densities (6,000, 10,000, 20,000 cells per well) were 
acquired on day 1, 2, 3, 6 and 7 post seeding (Figure 5.11a-c). Spheroid size was 
quantified on each day at the three different seeding densities (Figure 5.11d). 
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Between day 1 and day 2 (24 h – 48 h post seeding) the spheroid size decreased for 
all three seeding densities, confirming the spheroid contraction effect seen on the 
benchtop microscope. Between day 2 and day 3 (48 h – 72 h post seeding) spheroid 
size remained constant for the smallest seeding density (6,000 cells per well), while 
the spheroids size continued to decrease for spheroids with larger seeding density 
(10,000 and 20,000 cells per well). During those first three days, the spheroids 
contracted, resulting in spheroid size decreasing. It is possible that during that time 
strong cell-cell contacts were formed. To prove this, it would be necessary to fix and 
stain the spheroids with a cell-cell adhesion marker such as E-cadherin, and to 
measure the strength of the adhesions. 
 
Figure 5.11 T47D spheroid size changes between day 1 and day 7. T47D cells were seeded 
at (a) 6,000, (b) 10,000 or (c) 20,000 cells per well on day 0 and the spheroid formation was 
imaged between day 1 and day 7 using the ImageXpress. Scale bars: 500 μm. (d) Spheroid 
size was measured from the phase contrast images for a minimum of n=17-23 spheroids per 
seeding density. Values shown as mean±SD. 
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Between day 3 and day 6 spheroid size increased for all the seeding densities and 
the same was true between day 6 and day 7. These results demonstrate that while 
higher seeding density leads to larger spheroid size, it also takes longer for the 
spheroids to form and compact. From a drug screen perspective, if inhibitors were 
added to the spheroids, these should be added after day 3 when the spheroids have 
fully formed. Wenzel et al. used T47D spheroids for a HCS of 1120 drug molecules 
and they chose to drug the spheroids on day 4 post seeding.287 
5.3 Imaging ponatinib in 2D T47D cells 
Before SRS imaging could be attempted in the T47D spheroids, it was necessary to 
check that ponatinib can be imaged in T47D cells in 2D cell culture first. T47D cells 
were treated with DMSO or ponatinib, washed and imaged live using SRS microscopy 
as described earlier in Section 3.5.1. Control cells showed close to no background 
signals at ponatinib on resonance (2221 cm-1) and off resonance (2257 cm-1) 
wavenumbers in the cell-silent region of the Raman spectrum (Figure 5.12a). 
Ponatinib was detected in the drug treated live cells (Figure 5.12b) where 5 µM 
ponatinib was added for 1 h before washing. Both diffuse cytoplasmic signal of 
ponatinib as well as ponatinib puncta were clearly visible.  
An SRS sweep of the ponatinib peak was taken as described in Section 3.5.1.2. 
Across the sweep between 2189 – 2257 cm-1 wavenumbers, 17 SRS images were 
captured sequentially for both the control cells and the ponatinib treated cells. The 
SRS sweep of the control cells showed that there was no peak present when cells 
were not treated with ponatinib (Figure 5.12c), while a ponatinib peak can be detected 
in the SRS sweep of T47D cells that were treated with the drug (Figure 5.12d). This 












Figure 5.12 Ponatinib imaging in live T47D cells. T47D cells were treated with (a) DMSO 
(0.0003%, 2 h); (b) ponatinib (5 µM, 1 h). SRS images were acquired in a sequence from left 
to right: 2940 cm-1 (CH3, proteins); 2221 cm-1 (C≡C, ponatinib); 2257 cm-1 (off-resonance); 
2221 cm-1 with background subtracted. Images acquired at 1024 × 1024 pixels, 20 μs pixel 
dwell time, laser power 250 mW (the tuneable pump beam), gain 1 with false colours applied 
to different detection wavenumbers. Scale bars: 10 μm. (c), (d) SRS sweep of ponatinib peak 
in T47D cells treated with (c) DMSO (0.0003%, 2 h); (d) ponatinib (5 µM, 1 h). 
5.3.1 The influence of fixing on imaging ponatinib in T47D cells 
When ponatinib was imaged in SW480 cells in Chapter 3 (Section 3.5.1), we noticed 
that fixing of cells after drug treatment negatively influenced ponatinib imaging using 
SRS. In fixed cells, only a diffuse cytoplasmic ponatinib signal was seen in 
comparison to bright ponatinib puncta in live SW480 cells. To look into this further, we 
compared live imaging and two different fixing agents, paraformaldehyde (PFA) and 
glutaraldehyde (GA), in T47D cells (Figure 5.13). In live T47D cells ponatinib puncta, 
which are likely localised in acidic organelles such as lysosomes, are clearly visible 
by SRS imaging (Figure 5.13a). When the cells were treated under identical 
conditions, but fixed with PFA, no ponatinib puncta were detected in the cells, and 
only a faint cytoplasmic signal could be seen (Figure 5.13b). The same results were 
obtained when a different fixative, GA, was used (Figure 5.13c).  
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To gain further proof that significant proportion of ponatinib is washed out of the cell 
during the fixing protocol, the same experiment was conducted in an ovarian cell line, 
ES2.  As expected, ponatinib puncta were visible in live ES2 cells (Figure 5.14a) while 
no puncta were seen in fixed ES2 cells (Figure 5.14b). These results are consistent 
with the SRS imaging data obtained for the SW480 cell line previously. Similarly, 
ponatinib signal was never detected in CML cell lines when they were fixed (data not 
shown). These results illustrate that fixing influences ponatinib cellular localisation. It 
is therefore an important consideration to think about the impact of fixation when 
looking at drug distribution using other imaging modalities as well. Most clinical tissue 
specimens are stored as formalin-fixed paraffin-embedded (FFPE) samples, which 
have a long lifetime and can be stored at room temperature.288 However, MALDI 
imaging of drugs generally requires frozen, rather that fixed tissue sections.275,289,290 
It is thought drug molecules are likely to be washed away, at least in part, during the 
traditional fixation process.288 Our results indicate that the same principle applies for 
SRS imaging. Hence, spheroid imaging is carried out on live samples.  
 
 
Figure 5.13 The effect of fixing on ponatinib SRS imaging in T47D cells. T47D cells were 
treated with ponatinib (5 µM, 1 h) and (a) imaged live or (b) fixed with PFA (4%); (c) fixed with 
glutaraldehyde (4%) and imaged subsequently. SRS images were acquired in a sequence 
from left to right: 2940 cm-1 (CH3, proteins); 2221 cm-1 (C≡C, ponatinib); 2257 cm-1 (off-
resonance); 2221 cm-1 with background subtracted. Images acquired at 1024 × 1024 pixels, 
20 μs pixel dwell time, laser power 250 mW (the tuneable pump beam), gain 1 with false 
colours applied to different detection wavenumbers. Scale bars: 10 μm. 





Figure 5.14 The effect of fixing on ponatinib SRS imaging in ES2 cells. ES2 cells were treated 
with ponatinib (5 µM, 1 h) and (a) imaged live or (b) fixed with PFA (4%) and imaged 
subsequently. SRS images were acquired in a sequence from left to right: 2940 cm-1 (CH3, 
proteins); 2221 cm-1 (C≡C, ponatinib); 2257 cm-1 (off-resonance); 2221 cm-1 with background 
subtracted. Images acquired at 1024 × 1024 pixels, 20 μs pixel dwell time, laser power 
250 mW (the tuneable pump beam) with false colours applied to different detection 
wavenumbers. Scale bars: 10 μm. 
5.4 SRS imaging of live T47D spheroids   
Initial SRS imaging of live T47D spheroids was carried out to assess imaging depth 
capabilities of our SRS microscope. A T47D spheroid established from seeding 6,000 
cells per well, was labelled after seven days with Hoechst, Calcein AM and PI, and 
visualised using multimodal imaging (Figure 5.15). This T47D spheroid had an 
estimated diameter of about 650 µm. Images were acquired at 5 µm, 18 µm, 37µm, 
100 µm and 200 µm depth from the top of the spheroid (Figure 5.15a-d). SRS images 
were taken at the protein stretch (CH3, 2940 cm-1). Fluorescence images of cell nuclei 
(Hoechst, blue), live cells (Calcein AM, green) and dead cells (PI, red) were recorded 
simultaneously.  
SRS images taken at 5 μm and 18 μm depth show bright signal within the spheroid, 
where all the cells throughout the field of view can clearly be seen (Figure 5.15a,b) 
SRS signal loss was already seen at 37 µm depth as the middle of the spheroid looked 
darker, and the signal almost completely disappeared at 100 µm depth (Figure 
5.15c,d). The next image was acquired at 200 µm depth (image not shown), where 
no SRS signal was detected. These results are in agreement with the literature where 
Weia et al. previously imaged spheroids using SRS and reported an imaging depth of 
120 µm in tumour spheroids without tissue clearing.291  
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Calcein AM staining from 18 µm depth onwards was only bright around the edge of 
the spheroid, similar to the images acquired on the ImageXpress. However, the 
multiphoton microscope is giving much better image resolution, enabling visualisation 
of individual cells within the spheroid.  
Unfortunately, the Calcein AM green fluorescence was bleeding through into the red 
channel on the multiphoton microscope. Hence, the red channel also appears to have 
an intensely stained outer edge, but that is not true PI fluorescence. Actual PI staining 
is visible on the images acquired deeper inside the spheroid at 37 µm and 100 µm 
depth, where the dead cell core is clearly stained (Figure 5.15c,d). This demonstrates 
that although SRS signal and Hoechst fluorescence signal are reduced at 100 μm due 
to depth penetration limitations, cells are still present in the core of the spheroid.  
 
Figure 5.15 Multimodal imaging of T47D spheroid. T47D cells were seeded at 6,000 cells per 
well and grown for seven days to form a spheroid. On day 7 the spheroid was labelled with 
Hoechst (1 μM), Calcein AM (3.5 µM), PI (1 μM) for 1 h and imaged live at various depths (a) 
5 µm; (b) 18 µm; (c) 37 µm; (d) 100 µm. Images were acquired from left to right: Hoechst; 
Calcein AM; PI; SRS 2940 cm-1 (CH3, protein).  Images acquired at 1024 × 1024 pixels, 20 μs 
pixel dwell time, laser power 250 mW (the tuneable pump beam) with false colours applied to 
different detection wavenumbers. Scale bars: 50 μm. 
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To test reproducibility of both spheroid formation and SRS imaging depth, another 
T47D spheroid at 6,000 cells per well seeding density was formed over seven days, 
labelled with aforementioned fluorescent dyes and imaged using the multiphoton 
microscope (Figure 5.16). The estimated diameter of the spheroid was 660 µm, which 
is only 10 µm (±2%) larger than the diameter of the previous T47D spheroid seeded 
at 6,000 cells per well; proving that our spheroid growth protocol produces spheroids 
with consistent sizing from independent experiments.  
For this T47D spheroid, smaller step-sizes were taken for the z-stack during 
multimodal imaging to better estimate the SRS imaging depth. Images were acquired 
at 15 µm, 30 µm, 60 µm, 100 µm, 130 µm and 200 µm depth from the top of the 
spheroid (Figure 5.16a-e). As before, the SRS signal was significantly reduced by 
100 µm depth, but some protein signal was still detected at 130 µm depth (Figure 
5.18d,e). No signal was detected at 200 µm depth (image not shown).  
Both 6,000 cells per well spheroids from independent experiments looked similar in 
size on the multiphoton images. These spheroids filled the whole field of view of the 
microscope, with only edges of the spheroid slightly out of the field of view (Figure 
5.16 & Figure 5.16). If the goal is to image the whole spheroid in one field of view, 
4,000 well seeding density should be used in the future with seven day spheroid 
growth as it generates spheroids with about 10% smaller diameter (590 µm vs 
650 µm).  




Figure 5.16 Multimodal imaging of T47D spheroid. T47D cells were seeded at 6,000 cells per 
well and grown for seven days to form a spheroid. On day 7 the spheroid was labelled with 
Hoechst (1 μM), Calcein AM (3.5 µM), PI (1 μM) for 1 h and imaged live at various depths (a) 
15 µm; (b) 30 µm; (c) 60 µm; (d) 100 µm; (e) 130 µm. Images were acquired from left to right: 
Hoechst; Calcein AM; PI; SRS 2940 cm-1 (CH3, protein).  Images acquired at 1024 × 1024 
pixels, 20 μs pixel dwell time, laser power 250 mW (the tuneable pump beam) with false 
colours applied to different detection wavenumbers. Scale bars: 50 μm. 
As we saw from the ImageXpress images, seeding 10,000 cells per well generated 
T47D spheroids with close to 1 mm diameter (~960 µm) and a more complex internal 
structure (Figure 5.10c). One of these larger spheroids was imaged on the 
multiphoton to compare and contrast it to the smaller (~650-660 µm) T47D spheroids 
(Figure 5.15 & Figure 5.16). Images were acquired at 15 µm, 30 µm, 60 µm, 100 µm, 
130 µm and 200 µm depth from the top of the spheroid (Figure 5.17a-e). It was clear 
from the images that this spheroid did not fit into a single field of view on the 
multiphoton microscope due to its larger size. It would be necessary to acquire 
multiple images at each depth to obtain a full spheroid picture, increasing imaging 
 Spheroid imaging 
140 
 
time per spheroid as well as making image analysis more complex. In terms of 
imaging depth, SRS signal intensity was similar to the spheroids imaged earlier, 
where we could detect the spheroid protein signal up to 130 µm depth (Figure 5.17e). 
PI staining demonstrated that the bigger T47D spheroid (~960 µm diameter) had more 
dead cells in the core compared to the smaller T47D spheroids (~650-660 µm 
diameter), indicative of higher level of dead cells (Figure 5.17c-e vs Figure 5.16c-e). 
 
Figure 5.17 Multimodal imaging of T47D spheroid. T47D cells were seeded at 20,000 cells 
per well and grown for seven days to form a spheroid. On day 7 the spheroid was labelled with 
Hoechst (1 μM), Calcein AM (3.5 µM), PI (1 μM) for 1 h and imaged live at various depths (a) 
15 µm; (b) 30 µm; (c) 60 µm; (d) 100 µm; (e) 130 µm. Images were acquired from left to right: 
Hoechst; Calcein AM; PI; SRS 2940 cm-1 (CH3, protein).  Images acquired at 1024 × 1024 
pixels, 20 μs pixel dwell time, laser power 250 mW (the tuneable pump beam) with false 
colours applied to different detection wavenumbers. Scale bars: 50 μm. 
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To get a better view of the whole spheroid, z-stacks of each of the T47D spheroids 
were obtained using SRS imaging (Figure 5.18). Between a 103 and 133 SRS images 
were acquired and used to reconstruct 3D images of each spheroid (Figure 5.18a-c). 
It is possible to see that the two spheroids seeded at 6,000 cells per well fit into the 
field of view, while the spheroid seeded at 20,000 cells per well does not. As a result, 
we can see the morphology of the smaller spheroids much more clearly with 
protruding bumps of cells visible on the surface. High-resolution images of the 
superficial morphology of spheroids are usually taken using scanning electron 
microscopy (SEM).150,268,292 However, SEM requires samples to be fixed and 
dehydrated with or without gold coating prior to imaging. In contrast, SRS imaging 
allowed us to image spheroids live with no extensive sample preparation protocol.  
 
Figure 5.18 3D SRS imaging of live T47D spheroids. T47D cells were seeded at (a), (b) 6,000 
or (c) 20,000 cells per well and grown for seven days to form spheroids. Z-stack images of live 
T47D spheroids were acquired using SRS at 2940 cm-1 (CH3, proteins). (a) 103 images 
acquired at 2 µm step size. (b) 130 images acquired at 2 µm step size. (c) 133 images acquired 
at 2 µm step size. All the images acquired at 512 × 512 pixels, (a) 4 μs pixel dwell time (b), (c) 
10 μs pixel dwell time, laser power 250 mW (the tuneable pump beam). Scale bars: 100 μm.  
 Spheroid imaging 
142 
 
These initial SRS images acquired in spheroids highlight that depth penetration is a 
major limitation for SRS imaging just as it is for fluorescence based imaging. For both 
fluorescence and SRS imaging the imaging depth depends on the attenuation 
coefficient of the tissue, which has two major contributing factors, the amount of 
scattering and the amount of absorbance from the sample.293  Scattering is mostly a 
product of the tissue itself and varies with tissue type - lung tissue is subject to high 
level of scattering while skin is not. In addition, scattering is wavelength dependent, 
where higher wavelength light scatters less and is generally better for imaging deeper 
into the sample. Absorption of light by the sample, however, also influences imaging 
depth. As absorption is a function of all the different chromophores in the tissue, 
including water, haemoglobin, melanin and fat amongst others, it is a complicated 
factor to predict. These properties of tissues vary from tissue to tissue, person to 
person and even time to time. Therefore, defining absolute imaging depths for either 
fluorescence or SRS imaging would not be accurate.  
Here, we used two-photon fluorescence microscopy to visualise the fluorophores 
within the spheroid. Two-photon excitation generates fluorescence from both the focal 
plane and from outside the focal plane, where out-of-focus fluorescence increases as 
the focus is pushed deeper into the sample.294 The depth limit of two-photon excitation 
is generally limited by the amount of background fluorescence produced from outside 
the focal plane. Takasaki et al. recently explored TPF depth penetration in mouse 
brain cortex using GCaMP6 green fluorescence.294 They found that two photon depth 
limit was approximately 450 μm in the mouse cortex. Depth penetration in tissue can 
be increased using red-shifted fluorophores, which allows for longer wavelength 
excitation light to be used.  This helps to reduce both scattering and absorbance of 
the excitation and emission light. Tischbirek et al. have shown that TPF imaging with 
a red fluorophore enabled mouse brain cortex imaging up to 900 μm in depth.295  
In SRS imaging, the depth penetration is dependent on additional factors, which 
reduce imaging depth in comparison to TPF. For SRS to occur two different 
wavelength lasers need to be focussed by an objective at the same point in the tissue 
and the photons that arrive need to be overlapped both spatially and temporally.  This 
will be complicated by both the optical properties of the tissue which vary with 
wavelength, as well as due to chromatic aberrations within the optical elements of the 
microscope itself.  Another limiting factor in SRS is that it is a homodyne technique, 
where the signal is carried at the same wavelength as the excitation wavelength, 
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meaning that it is necessary to collect both the stimulated photons as well as the 
normal photons to allow for a measurement to be taken. Therefore, it us unsurprising 
that the maximum depth penetration for mouse brain tissue using SRS has been 
measured as 205 μm, significantly less than TPF.296 
The fact that SRS imaging in 3D is limited by depth penetration, is clearly visible on 
the side view images of the spheroids, where the signal intensity decreases 
exponentially deeper inside the spheroid and eventually disappears completely 
(Figure 5.18a-c). In addition, it appears that SRS imaging depth is lower in the larger, 
thicker spheroid (Figure 5.18c) compared to the smaller, thinner spheroids (Figure 
5.18a,b). Others have previously also applied SRS imaging to tissue. Wei et al. 
detected terbafine in mouse ear tissue at about 100 μm depth and Saar et al. imaged 
deuterated ibuprofen at about 15 μm depth.47,70 Additionally, Chiu et al. imaged 
deuterated solvent penetration into human nail plate using SRS, and detected 
deuterated water up to 100 μm depth.71 They also investigated the effect of tissue 
thickness on SRS penetration depth using three nails samples from three different 
individuals with varying thickness, where signal was normalised to CH2 intensity on 
the nail surface. The CH2 signal profile across the nail was found to be similar for the 
three samples examined. More recently, however, Hill et al. investigated SRS 
penetration depth in brain tissue slices with varying thickness (250 µm - 2 mm).296 
They found that maximum imaging depth was reduced in thicker samples, where the 
maximum imaging depth for 250 μm sample was 205 μm, while for 2 mm sample it 
was 130 μm. These were the reported depth limits using transmissive imaging mode, 
which we also used for the spheroid imaging. In contrast, when Hill et al. used epi 
detection, slightly improved signal to noise ratio and imaging depth were achieved in 
the thicker, 2 mm samples. Overall, our early data on SRS application to imaging 
spheroids is in good agreement with previously published data on tissues and 
spheroids.  
To enhance the depth penetration when using SRS, tissue clearing protocols have 
also been developed. Weia et al. used 8 M urea with 0.2% Triton X-100 for spheroid 
and tissue clearing, reporting 10-fold increase in SRS depth-penetration upon clearing 
the samples.291 However, this protocol requires days to weeks to complete depending 
on the sample type. Li et al. tested a number of tissue clearing agents on brain tissue 
samples to improve the clearing protocol and found that using formamide solutions at 
gradient concentrations for 30 min in total yielded the best results, increasing SRS 
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imaging depth up to 500 µm.297 As we have shown that the ponatinib SRS signal in 
2D cell culture disappears upon cell fixation (Section 5.3.1), we believe a tissue 
clearing protocol would likely have similar effects when imaging ponatinib in 
spheroids.  
5.4.1 SRS imaging of ponatinib in live T47D spheroids 
Initial ponatinib imaging in a live T47D spheroid was attempted using SRS 
microscopy. A T47D spheroid was seeded at 6,000 cells per well and grown for seven 
days. At this time the mature spheroid was treated with ponatinib (10 µM, 1 h) in the 
U-bottom ULA plate. Following treatment, SRS images of the live spheroid were 
acquired immediately after transferring the spheroid to a slide. Ponatinib was detected 
at both 20 µm and 70 µm depth, but the off-resonance images showed significantly 
higher background than we have previously seen during 2D SRS imaging of ponatinib 
(Figure 5.19a,b). The three-dimensional spheroid sample has overall more ‘bulk’ than 
a 2D sample, leading to increased background signals from competing pump-probe 
processes such as cross-phase modulation, transient absorption and photothermal 
effects.63 Background subtraction does indicate that ponatinib is present in the 
spheroid – at 20 µm depth ponatinib uptake appears homogeneous across the section 
(Figure 5.19a). In contrast, at 70 µm depth on the subtracted image, the ponatinib 
signal only appears on the edges of the spheroid. However, at 70 µm depth the same 
is also seen on the protein image due to SRS signal loss as a result of light scattering 
deeper in the spheroid.   
To look at ponatinib uptake in the spheroid in more detail, we zoomed into an area of 
the spheroid at both imaging depths (Figure 5.19c,d). At 20 µm depth, a few ponatinib 
puncta were identified from the on resonance image (2221 cm-1) where the 
corresponding off-resonance image did not have puncta present (Figure 5.19c). Upon 
close examination it was also possible to point out individual ponatinib puncta with 
low background signal at 70 µm depth (Figure 5.19d). These early results show that 
despite higher background in the off-resonance area in 3D imaging, it is still possible 
to detect ponatinib uptake in spheroids. However, it certainly makes it harder to 
confidently distinguish between true ponatinib signal and background artefacts. It is 
noteworthy, that much higher laser power was required to detect ponatinib in 3D 
(350 mW at 20 µm, 500 mW at 70 µm) compared to 2D imaging (200-250 mW).  
 




Figure 5.19 SRS imaging of ponatinib in a live T47D spheroid. T47D spheroid was seeded at 
6,000 cells per well, grown for seven days, and incubated with ponatinib (10 µM, 1 h) on day 
7. SRS images of the spheroid acquired at (a) 20 µm and (b) 70 µm depth (from left to right) 
2940 cm-1 (CH3, proteins); 2221 cm-1 (C≡C, ponatinib); 2257 cm-1 (off-resonance); 2221 cm-1 
with background subtracted. (c) Zoomed in to the red square from (a), red arrows pointing at 
ponatinib spots with low background. (d) Zoomed in to the red square from (b), red arrows 
pointing at ponatinib spots with low background. Images acquired at 1024 × 1024 pixels, 20 μs 
pixel dwell time, laser power 250 mW (the tuneable pump beam) for CH3, 350 mW for ponatinib 
in (a) and 500 mW for ponatinib in (b). False colours applied to different detection 
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5.5 Conclusions  
In this chapter, spheroid growth was optimised using a U-shaped ULA plate method. 
We found that CML cell lines KCL22 and KCL22Pon-Res only form cell aggregates in 
ULA plates. In contrast, the breast cancer cell line T47D formed tight spheroids with 
strong cell-cell contacts. T47D spheroids were characterised by size as well as live 
and dead cell dyes, demonstrating that they have a proliferative edge and a dead cell 
core after seven days of growing.  
Prior to SRS imaging of spheroids, ponatinib was imaged in 2D cell culture using 
T47D cells. Ponatinib could successfully be detected in live T47D cells, but when cells 
were fixed ponatinib signal disappeared inside cells. We believe this is likely due to 
the drug being washed out of the cell during the fixing protocol since ponatinib is not 
covalently bound to its target. As we have shown the majority of ponatinib localises 
within acidic organelles – fixing can influence organelle pH, and subsequently lead to 
re-distribution of ponatinib during fixing and the associated wash steps.  
The T47D spheroids were imaged using the multiphoton microscope. It was 
determined that the SRS imaging depth penetration is around 130 µm on our 
microscope. Initial SRS images of ponatinib in a T47D spheroid were also acquired, 
where ponatinib puncta were detected at 20 µm depth and 70 µm depth inside the 
spheroid. However, it was clear that SRS off-resonance background is a lot higher 
when imaging at depth, reducing the signal-to-noise ratio and making it more difficult 
to differentiate true ponatinib signal from background artefacts. For this type of drug 
imaging hSRS would be a more advantageous technique, as it would allow imaging 
on and off the ponatinib SRS peak significantly faster. An alternative option for 
reducing background signal would be the use of frequency modulated SRS (FM-
SRS).208 In contrast to normal SRS, where amplitude modulation is used with on-and-
off laser, FM-SRS modulates the laser frequency from on-resonance to off-
resonance, and gives a final image where wavelength independent competing 
background processes have already been removed. Rigneault et al. have also 
explored other avenues for reducing SRS background signals, such as using 
stimulated Raman gain and opposite loss detection (SRGOLD), where SRG and SRL 
are both measured.298 Theoretically, SRGOLD can double the signal intensity 
acquired as SRG and SRL signal are added up, without increasing background 
signals.299 Unfortunately, unsymmetric parasitic background signals cannot be 
removed by SRGOLD imaging. These advanced SRS imaging techniques could be 
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applied to drug imaging to improve signal to noise ratio, which is especially prominent 
in 3D SRS imaging.  
Although others have used clearing techniques to improve SRS imaging depth, we 
believe this would not be the best option for drug imaging in 3D. We found that fixing 
protocol washes away significant proportion of ponatinib from the cell, reducing 
detectable drug signal with SRS, and altering drug localisation. Clearing protocol 
would likely have a similar effect on ponatinib as well as other drugs. Therefore, using 
clearing techniques for drug imaging with SRS in 3D is probably not the best approach 
for improving imaging depth. A more suitable option would be sectioning of frozen 
spheroids, as is done for MALDI imaging of drugs. Imaging serial sections of drug 
treated spheroids rather than the whole spheroid would help overcome the depth 
penetration issues for SRS imaging. Additionally, it would hopefully improve SNR for 
imaging ponatinib in spheroids, giving less background off resonance. It is not known, 
however, if freezing the sample will influence the SRS signal – this would have to be 
investigated.   
In summary, preliminary data was acquired in this chapter to take drug imaging with 
SRS microscopy from 2D to 3D. Although drug signal was successfully detected in a 
spheroid for the first time using SRS microscopy, it was accompanied by high 
background signal. The two major limitations for SRS drug imaging in 3D were found 
to be depth penetration and significant level of background signals from competing 
pump-probe processes.  
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Chapter 6 Future perspectives 
In this thesis SRS was successfully used for label-free imaging of ponatinib in 2D and 
3D. A wide range of SRS applications that are beneficial for improving our 
understanding of intracellular drug behaviour were demonstrated throughout the 
chapters. While visualising intracellular drug uptake and distribution to improve the 
pre-clinical drug discovery process is still a challenge for scientists, SRS imaging 
provides a potential solution that allows quantitative drug imaging at sub-cellular 
resolution in live cells.  
We explored ponatinib localisation in a BCR-ABL independent CML resistance model, 
where increased lysosomal uptake of ponatinib was found in ponatinib resistant cells 
compared to drug sensitive cells. Lysosomal uptake was not, however, found to be 
the cause of drug resistance. Unlike imatinib resistance, which has been studied 
extensively, not much is published on ponatinib resistance mechanisms. In contrast 
to CML resistance to 1st and 2nd generation TKIs, where BCR-ABL mutations are 
prevalent in patients, mutations are rarely the cause of ponatinib resistance.300 Certain 
compound mutations, where multiple mutations occur within the same BCR-ABL 
clone, have been found to decrease sensitivity to ponatinib.301 Deininger et al., 
however, used next generation sequencing on 267 heavily pre-treated CP-CML 
patients, and found that compound mutations do not confer primary and/or secondary 
resistance to ponatinib in CML patients.302 Instead, BCR-ABL independent resistance 
mechanisms seem to be the cause of ponatinib resistance. Research on BCR-ABL 
independent ponatinib resistance models has identified mTOR and Axl as potential 
new drug targets.109,303 Therefore, both our results and literature on ponatinib 
resistance are in agreement that BCR-ABL independent resistance mechanisms 
warrant novel treatment approaches to be investigated to improve the treatment of 
CML patients who have become resistant to BCR-ABL inhibition.  
Although in this project we focused ponatinib imaging on drug resistant CML, as a 
multikinase inhibitor, it has various other cellular targets in addition to BCR-ABL. As 
such, ponatinib has been explored as a treatment option for other cancers in various 
clinical trials, including lung cancer, gastrointestinal tumours, glioblastoma as well as 
other haematological malignancies.304 In these trials, ponatinib targets have included 
FGFRs, RET, KIT and FLT3 amongst others. So far these trials have not led to 
successful approval of ponatinib use in non-haematological cancers, but many are 
  Future perspectives 
  149 
 
still ongoing. This presents additional opportunities for studying ponatinib localisation 
in other cancer types using SRS imaging with our established protocols.  
Our work on ponatinib imaging demonstrated the quantitative nature of SRS imaging 
and allowed us to quantify the absolute ponatinib concentration within individual cells 
for the first time. The methodology for using SRS for absolute drug concentration 
determination, however, could be improved further in the future. First of all, more 
biologically relevant solvent could be used for acquiring the concentration curve. 
Additionally, the potential influence of varying pH on SRS signal intensity could be 
explored experimentally. This would help ensure that when drugs localise in acidic 
compartments inside cells it does not affect their Raman signal.  
Investigating intracellular drug metabolism by SRS alone is not very efficient, because 
Raman shifts are not easily observable in SRS. Hyperspectral SRS would be a more 
sensitive technique for detecting Raman shifts. As we did not have access to hSRS, 
we used DFT measurements to assess the likelihood of Raman shifts and intensity 
changes of known ponatinib metabolites, and measured ponatinib metabolite levels 
in our cell lines of interest using LC-MS. We demonstrated that the combined use of 
DFT, LC-MS and SRS enables drug metabolism to be investigated alongside drug 
localisation inside cells, which cannot be achieved by mass spectrometry techniques 
alone.  
Although MALDI is the gold standard for label-free drug imaging and investigating 
drug metabolism simultaneously, it is limited by its poor resolution, which is 20-
100 μm.23 In contrast, SRS has a spatial resolution of about 300 nm and allows drug 
imaging with subcellular resolution.61 For both techniques, the detection sensitivity 
varies from drug to drug.23,305 MALDI is the more powerful tool for detecting drug 
metabolites while SRS has superior resolution. As such, we envisage that combining 
MALDI and SRS, especially for drug imaging in spheroids and tumours, would enable 
superior information on drug metabolism and cellular localisation to be captured 
compared to using either technique alone. Randall et al. have recently demonstrated 
the utility of MALDI and SRS tandem imaging in a in a patient-derived xenograft model 
of glioblastoma, where tumour slices with 12 μm thickness were imaged.289 MALDI 
was used for erlotinib detection and SRS for protein, lipid and heme imaging alongside 
standard histology staining. They found that SRS imaging provided detailed spatial 
and chemical information that could not be provided by standard histology. This could 
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be taken a step further by using SRS for drug imaging in tumours, which so far has 
not been reported.  
SRS, like all imaging modalities, has its limitations, including detection sensitivity, 
depth penetration as well as parasitic background signals. Although we successfully 
managed to image ponatinib in CML cells following 500 nM treatment concentration, 
it still required accumulation of the drug at approximately 1 mM local concentration 
inside the cell. Hyperspectral SRS would allow detection of on and off resonance 
images simultaneously. This would increase image acquisition speeds and would 
likely improve detection sensitivity. Previous research by Fu et al. reported the 
detection sensitivity of hSRS as 1-2 mM, however, they were imaging drugs within 
the fingerprint region of the Raman spectrum.170 Imaging in the ‘cell silent’ region 
would likely improve the detection sensitivity of hSRS. More recently, Zong et al. 
showed that SRS detection sensitivity can also be increased by plasmon-enhanced 
SRS (PESRS), where single molecule detection of adenine on gold nanoparticles was 
demonstrated.306  
SRS detection sensitivity can be enhanced by the addition of Raman active tags as 
well. As ponatinib was inherently Raman active it did not require labelling, but not all 
drugs have a Raman active moiety within the ‘cell silent’ region. To allow wider 
application of SRS imaging to other drugs, addition of Raman active tags could be 
considered. This has been demonstrated before by Tipping et al., where BADY tag 
was successfully incorporated in a small molecule anisomycin, enabling its 
intracellular visualisation.49 However, addition of a Raman tag to a drug could perturb 
the molecules’ bioactivity, and care must be taken to prevent that from happening. 
Traditional Raman tags that significantly increase the Raman activity of the molecule 
of interest such as BADY are usually very lipophilic. Hence, Raman tags could 
influence the logP of the drug molecule and affect the molecule’s localisation within 
the cell. Future development of Raman tags for drug imaging purposes will therefore 
likely focus on the synthesis of Raman active tags with more drug-like 
physicochemical properties.  
The other major limitation of SRS imaging is depth penetration. We found that depth 
penetration in spheroids was approximately 130 μm when visualising the protein 
stretch. Our results are in agreement with previous SRS spheroid imaging by Weia 
et al., who also reported 120 μm depth penetration with SRS.291 Depth penetration is 
dependent on both tissue type and sample thickness. When SRS imaging was 
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compared for 1 mm thick samples, Hill et al. found that depth penetration for brain, 
kidney, liver and lung were 185 μm, 165 μm, 170 μm and 70 μm respectively.296 It is 
therefore unsurprising that most small molecule detection using SRS imaging in 3D, 
including spheroids, tissue slices, nail and in vivo imaging, has been done around or 
below 100 μm depth.46,70,71 Same holds true for CARS imaging of deuterated 
compounds in skin.307,308 Although we could detect ponatinib puncta at 70 μm depth 
in spheroids using SRS, imaging in 3D significantly increased SRS background 
signals, which made it more difficult to differentiate true ponatinib signal from 
background artefacts. This highlights that drug imaging in vivo using SRS is going to 
be challenging. We think in the near future, 3D drug imaging using SRS will be more 
likely achievable in spheroid and/or tissue slices similarly to MALDI, which will remove 
depth penetration issues whilst still allowing heterogeneity in drug uptake to be 
visualised with superior resolution in comparison to MALDI.  
Application of advanced SRS modalities, such as FM-SRS and SRGOLD to drug 
imaging, could improve depth penetration and reduce SRS background, but has yet 
to be explored. Depth penetration could also be improved by advanced data 
processing. Hill et al. showed 24% (40 μm) increase in SRS depth penetration by 
using a convolution neural networks based denoising algorithm.296  It is hence still 
possible that in vivo drug imaging using SRS microscopy will be feasible in the future. 
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Appendices 
Appendix 1 Common abbreviations 
2D  2-dimensional 
3D  3-dimensional 
A.U.  arbitrary units 
ABC  ATP-binding cassette  
ABCA3  ATP-binding cassette sub-family A member 3 
abl  Ableson leukemia virus 
AIQ  aminoisoquinoline 
AM  acetoxymethylester 
AML  acute myeloid leukaemia 
AOM  acousto-optic modulator 
AP  accelerated phase 
AQ  aminoquinoline 
ATG5  autophagy-related gene 5 
ATG7  autophagy-related gene 7 
ATP  adenosine triphosphate 
BADY  bisaryldiyne 
bcr  breakpoint cluster region 
BP   blast phase 
BSA  bovine serum albumin 
Carbow carbon rainbow 
CARS  coherent anti-Stokes scattering 
CLEAR coordinated lysosomal expression and regulation 
CML  chronic myeloid leukaemia 
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CNS  central nervous system 
CQ  chloroquine 
cRIE  calculated relative intensity to EdU 
CYP  cytochrome P450  
Da   Dalton 
DFT  density functional theory 
DMEM  Dulbecco's modified Eagle's medium 
DMSO  dimethyl sulfoxide 
ECM  extracellular matrix 
EdU  5’-Ethynyl-2’-deoxyuridine 
EGFR  epidermal growth factor receptor  
EOM  electro-optic modulator 
ER  endoplasmic reticulum 
FACS  fluorescence assisted cell sorting  
FDA  U.S. Food and Drug Administration 
FGFR  fibroblast growth factor receptor 
FM-SRS frequency modulated SRS 
GA  glutaraldehyde 
GI50  growth inhibitory 50% 
GPN  glycyl-L-phenylalanine 2-naphthylamide 
GSH  glutathione  
HCA  hierarchical cluster analysis 
HCQ  hydroxychloroquine 
HCS  high content screening  
HDM  hanging droplet method 
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HER2  human epidermal growth factor receptor 2 
hSRS  hyperspectral stimulated Raman scattering  
IF  immunofluorescence  
IR   infrared 
IUR  intracellular uptake and retention  
LAMP1 lysosomal-associated membrane protein 1 
LC3  microtubule-associated protein 1 light chain 3 
LC-MS  liquid chromatography mass spectrometry  
LSC  leukemic stem cells 
LSFM  light sheet fluorescence microscopy 
LTR  lysotracker red  
MALDI  matrix assisted laser desorption ionisation 
MALDI-IMS MALDI imaging mass spectrometry 
MCOLN1 mucolipin-1  
MCR  multivariate curve resolution 
MFI  mean fluorescence intensity  
MIP   maximum intensity projection 
MRI   magnetic resonance imaging  
MS  mass spectrometry  
mTOR  mammalian target of rapamycin  
mTORC1 mTOR complex 1  
OCT1  organic cation transporter 1  
PA  polylactic acid 
PE  phosphatidylethanolamine 
PESRS plasmon enhanced SRS 
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PET  positron emission tomography 
PFA  paraformaldehyde  
PG  propylene glycol 
PGA  polyglycolic acid 
PGE  polyethylene glycol 
P-gp  P-glycoprotein 
Ph  Philadelphia chromosome 
PhDY  phenyldiyne 
PI  propidium iodide 
PI3K  phosphoinositide 3-kinase  
PKI  protein kinase inhibitor  
poly-HEMA poly(2-hydroxyethyl methacrylate) 
QNC  quinacrine 
R&D  research and development 
R123  rhodamine 123 
R6G  rhodamine 6G 
RAF  rapidly accelerated fibrosarcoma  
RIE  relative intensity to EdU  
ROS  reactive oxygen species 
RPMI   Roswell Park Memorial Institute medium 
RT  room temperature  
SD  standard deviation 
SEM  standard error of the mean  
SERS  surface enhanced Raman scattering 
SIMS  secondary ion mass spectrometry 
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SRG  stimulated Raman gain 
SRGOLD stimulated Raman gain and opposite loss detection 
SRL  stimulated Raman loss 
SRS  stimulated Raman scattering  
TFEB  transcription factor EB 
TFI  total fluorescence intensity  
TH  terbafine hydrochloride  
TKI  tyrosine kinase inhibitor  
TME  tumour microenvironment 
TPF  two photon fluorescence  
ULA  ultra-low attachment 
ULK  Unc-51 like kinase 
v-ATPase vacuolar H+ ATPase  
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Appendix 2 Supplementary figures 
 
Figure S1 KCL22 and KCL22Pon-Res cells that were treated with 5 µM ponatinib (1 h) and 
labelled with Lysotracker Red (75 nM, 1 h) and imaged live. (a) Mean ponatinib Raman 
intensity, and; (b) Maximum ponatinib Raman intensity inside the vesicles of each individual 
cell were quantified for n=30 cells, 3 biological repeats. The Mann-Whitney test was used to 
compare ponatinib Raman intensity values. 
 
 
Figure S2 Multimodal imaging and quantitative assessment of ponatinib uptake in KCL22 cells 
following CQ combination treatment. KCL22 cells were treated with (a) DMSO (0.0003%, v/v), 
(b) ponatinib (5 µM, 1 h) or (c) chloroquine (20 µM, 2 h) followed by combination treatment of 
ponatinib (5 µM, 1 h) and chloroquine (20 µM, 1 h). All the samples were labelled with 
Lysotracker® Green (50 nM, 1 h). SRS images acquired at (from left to right) 2940 cm-1 (CH3, 
proteins); 2221 cm-1 (C≡C, ponatinib); 2257 cm-1 (off-resonance), TPF image acquired at 861 
nm (Lysotracker® Green); overlay of ponatinib and TPF. Images acquired at 1024 × 1024 
pixels, 20 μs pixel dwell time, laser power p200 gain 1 with false colours applied to different 
detection wavenumbers. Scale bars: 10 μm.  
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Figure S3 Multimodal imaging and quantitative assessment of ponatinib uptake in KCL22 cells 
following CQ combination treatment. KCL22 cells were treated with (a) DMSO (0.0003%, v/v), 
(b) ponatinib (5 µM, 1 h) or (c) chloroquine (20 µM, 2 h) followed by combination treatment of 
ponatinib (5 µM, 1 h) and chloroquine (20 µM, 1 h). All the samples were labelled with 
Lysotracker® Green (50 nM, 1 h). SRS images acquired at (from left to right) 2940 cm-1 (CH3, 
proteins); 2221 cm-1 (C≡C, ponatinib); 2257 cm-1 (off-resonance), TPF image acquired at 861 
nm (Lysotracker® Green); overlay of ponatinib and TPF. Images acquired at 1024 × 1024 
pixels, 20 μs pixel dwell time, laser power p200 gain 1 with false colours applied to different 
detection wavenumbers. Scale bars: 10 μm. 
 
 
Figure S4 Full Western blots shown for KCL22 cell lysates that were probed for (a) p-CRKL 
(39 kDa) and (b) α-tubulin (50 kDa). Standard ladder has been annotated. 
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Figure S5 Full Western blots shown for KCL22Pon-Res cell lysates that were probed for (a) 
p-CRKL (39 kDa) and (b) α-tubulin (50 kDa). Standard ladder has been annotated. 
 
Figure S6. Measuring apoptosis and relative colony number in KCL22Pon-Res cells using 
various inhibitors.*** KCL22Pon-Res cells were cultured with 10 μM CQ , 150 nM dasatinib (Das), 
100 nM ponatinib (Pon), 100 nM NVP-BEZ235 (BEZ235) or a combination of two drugs for 
72 h. (a) Apoptosis was measured by staining the cells with annexin V and 7-Amino-
Actinomycin D and analysed by FACS. Error bars ± SD, n=3 biological repeats. (b)  Number 
or colonies was measured following 72 h of drug treatment using colony formation assay. 
Statistical analysis was performed by using paired t-test. Annotation above a bar refers to 






*** Unpublished data acquired by the Helgason group, The University of Glasgow.  
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Figure S7 No antibody control images for IF imaging of nuclear TFEB in CML cells. (a) KCL22 
and (b) KCL22Pon-Res no antibody control cells were treated with DMSO (0.0003%, v/v) for 1 h. 
Cell nuclei were stained with DRAQ7, but cells were not stained with TFEB. Images acquired 
at 1024 × 1024 pixels, 4 μs pixel dwell time, laser power p200 gain 1. Scale bars: 10 μm. 
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ABSTRACT: Stimulated Raman scattering (SRS) microscopy represents a powerful method for imaging label-free drug
distribution with high resolution. SRS was applied to image label-free ponatinib with high sensitivity and specificity in live
human chronic myeloid leukemia (CML) cell lines. This was achieved at biologically relevant, nanomolar concentrations,
allowing determination of ponatinib uptake and sequestration into lysosomes during the development of acquired drug
resistance and an improved understanding of target engagement.
■ INTRODUCTION
Despite the identification of an unprecedented number of
potential new drug targets over the past two decades, and an
accompanying intense investment in the generation of NCEs
with improved potency and selectivity, currently only 1 in 10
clinical candidates progresses to regulatory approval.1 This
major loss in investment by drug developers can be analyzed
from the viewpoint of the physicochemical properties of drug
candidates,2 but these studies do not provide clear indicators
for how to reduce attrition rates.3 Some of the highest pipeline
attrition rates are seen in the development of chemo-
therapeutics.4 As a plethora of new, targeted chemotherapeu-
tics enter the clinic and, with the development of resistance to
these agents, alternative approaches are urgently required to
optimize their development and use. A shift toward
determining critical information through the use of relevant
cell-based assays at an earlier stage in the pipeline5 could result
in a much cheaper and more effective development process.6
Stimulated Raman scattering (SRS) microscopy generates
image contrast using the Raman active vibrational frequency of
a given chemical bond, providing information on the
biochemical composition of tissues and allowing label-free
visualization for a number of biomedical applications including
drug interactions.7,8 SRS is distinguished by a number of key
features:
(1) Fast acquisition speeds (orders of magnitude faster than
those achieved with spontaneous Raman), good photo-
stability, and a lack of phototoxicity, which together
allow real-time imaging.
(2) A linear relationship between signal intensity and
chemical concentration, which enables quantitative
imaging.
(3) Multiple acquisition wavelengths, which allows drug
distribution within cells to be mapped onto subcellular
features providing intracellular registration.
(4) Multimodal imaging (SRS and fluorescence), which
allows image overlay with cell- or tissue-specific
markers.9,10
Combined, these characteristics ensure that SRS imaging
provides a unique platform to understand drug distribution
within individual cells, thus distinguishing it from other
technologies, such as whole-body autoradiography and liquid
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chromatography−mass spectrometry (LC-MS), that are
typically used to monitor drug distribution.11,12
Raman imaging was initially developed as a label-free
technique for visualization of biomolecules including lipids
and proteins, and more recently the development of alkynes
(CC) as nonlinear vibrational tags for imaging small
biomolecules using SRS microscopy has extended the
applicability of this approach.13,14 Alkynes are both chemically
and Raman spectroscopically biorthogonal as they do not react
with endogenous biomolecules and do not exist inside cells.
The CC stretching motion can hence be detected in the
Raman “cellular-silent” region (1800−2800 cm−1). This also
presents an optimal region for drug imaging, as there is
minimal contribution from endogenous cellular biomolecules,
thus improving detection sensitivity.8,15 In this study, we utilize
the advantages of an alkyne-based imaging approach to assess
label-free drug uptake and distribution in cellular models of
resistance using ponatinib (1),16 a tyrosine kinase inhibitor
with regulatory approval for the treatment of chronic myeloid
leukemia.
■ RESULTS AND DISCUSSION
Ponatinib (1) has an inherent alkyne moiety in its structure
providing the potential for imaging its cellular localization in
the Raman “cellular-silent” region (Figure 1a,b), without the
addition of bulky tags such as fluorophores, which can
negatively impact on the biological activity of drugs. In SRS,
two synchronized lasers, the pump and the Stokes beam are
used to excite a specific molecular vibration (Figure 1c). To
visualize a chemical bond of interest, the frequency difference
between the pump beam and the Stokes beam is tuned to
match the chosen vibration (ωυ), allowing stimulated Raman
scattering to take place in addition to the inherently weak
spontaneous Raman scattering.
Predicting the Intensity and Frequency of Raman
Signals by DFT. Density functional theory (DFT) calcu-
lations have previously been used to predict theoretical Raman
intensities (IRam),
8,15 while experimentally observed Raman
intensities have been compared with the intensity of the alkyne
resonance in the nucleoside analogue ethynyl deoxyuridine
(EdU) to give relative intensity to EdU (RIE) values.17 We
have combined these two approaches to give a series of
calculated RIE values (cRIE) to facilitate comparison of the
predicted intensity values for signals in the “cellular-silent”
region. DFT calculations have also, very recently been used to
predict the changes in Raman vibrational frequencies that
result from primary drug metabolism.18 Thus, we have used a
series of DFT calculations to establish whether the acquisition
of SRS images at a single vibrational frequency for the alkyne
(Figure 1b, CC, 2221 cm−1) would provide an accurate
assessment of the ponatinib concentration within a cell
(Supporting Information (SI), Table S1).
The piperidine unit in ponatinib means that it is susceptible
to lysosomal trapping through protonation.19,20 However, in
our DFT calculations, both the parent drug and its protonated
counterpart were predicted to have very similar frequencies for
the alkyne resonance, with a slight decrease in cRIE value upon
protonation (SI, Table S1). Hence, it was determined that SRS
imaging at a single wavenumber would allow assessment of
ponatinib concentrations across the whole cell environment,
independent of subcellular variations in pH. Previous studies
have identified the primary metabolites of ponatinib as its N-
oxide and N-desmethyl analogues, together with dihydroxy-
lated forms.21−23 As the chemical perturbations in these two
major metabolites is distal to the alkyne vibrational motif, a
large change in IRam is not expected. This conclusion was
confirmed by DFT calculations (SI, Table S1), which show
similar cRIE values to the parent drug, with only minimal shifts
in the predicted Raman frequencies for the alkyne absorption.
The formation of these metabolites has been shown to be
catalyzed predominantly by the P450 enzyme CYP3A4.23,24
Western blot analysis confirmed expression of CYP3A4 protein
in both KCL22 and KCL22Pon‑Res cells (Figure 2a). However,
we identified ponatinib as the predominant peak by LC-MS
analysis with only trace amounts of the N-desmethyl and
Figure 1. (a) Chemical structure of ponatinib; (b) Raman spectrum
of solid ponatinib. The following peak has been annotated: 2221 cm−1
(CC, ponatinib). Raman spectra were acquired at λex = 532 nm for
10 s using a 50× objective. (c) Energy level diagram showing the
working principle of SRS microscopy.
Figure 2. (a) Expression of CYP3A4 in lysates from KCL22 and
KCL22Pon‑Res cells. β-actin was used as a loading control. (b)
Ponatinib and ponatinib metabolites identified by LC-MS. Cells were
treated with ponatinib for 1 h prior to analysis. Mean values from five
biological repeats expressed relative to ponatinib.
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dihydroxylated metabolites present in the CML cells (Figure
2b).
Thus, given the relatively low concentrations of these
metabolites in the CML cell lines, and the minimal shifts in
their predicted Raman frequencies, their presence is not
expected to affect SRS imaging of the intracellular distribution
of ponatinib. This conclusion is in sharp contrast to recent
imaging studies conducted on neratinib using Raman
microscopy, where metabolism directly affects the Raman
active motif in the drug and significant vibrational shifts are
observed.18
Applications of SRS Imaging of Intracellular Drug
Concentrations. With the validity of imaging the alkyne in
ponatinib by Raman to assess its intracellular distribution
established, we conducted a series of experiments to
demonstrate the utility of this approach experimentally. CML
results from expression of the constitutively active tyrosine
kinase BCR-ABL and treatment with TKIs, such as ponatinib,
which target BCR-ABL, have been successful in providing
improved life expectancy, although resistance prevents long-
term durable responses in many patients.25 There is currently
no information on the subcellular distribution and uptake of
Figure 3. (a−c) Imaging ponatinib uptake in KCL22Pon‑Res cells. KCL22Pon‑Res cells were treated with DMSO (0.0003%, v/v) or ponatinib (500
nM) for 1, 6, 24, or 48 h (left to right). SRS images acquired at (a) 2940 cm−1 (CH3, proteins); (b) 2221 cm
−1 (CC, ponatinib); (c) 2257 cm−1
(off-resonance). Images acquired at 1024 × 1024 pixels, 20 μs pixel dwell time, laser power p300, gain 2 with false colors applied to different
detection wavenumbers. Scale bars: 10 μm. (d) Mean ponatinib intensity per cell quantified from 2221 cm−1 in n = 30 cells, three biological
repeats. The Mann−Whitney test was used to compare ponatinib Raman intensity values against the DMSO control.
Figure 4. Multimodal imaging and quantitative assessment of ponatinib uptake in KCL22 and KCL22Pon‑Res cell lines. KCL22 cells were treated
with (a) DMSO (0.0003%, v/v) or (b) ponatinib (5 μM, 1 h). KCL22 Pon‑Res cells were treated with (c) ponatinib (5 μM ponatinib, 1 h). SRS
images acquired at (from left to right) 2940 cm−1 (CH3, proteins), 2221 cm
−1 (CC, ponatinib), 2257 cm−1 (off-resonance), TPF image acquired
at 861 nm (Lysotracker Green), overlay of ponatinib and TPF. (d) Mean ponatinib Raman intensity. (e) Maximum ponatinib Raman intensity
inside the vesicles of each individual cell quantified for KCL22 and KCL22Pon‑Res cells that were treated with 5 μM ponatinib for 1 h, n = 30 cells,
three biological repeats. (f) Mean ponatinib Raman intensity quantified outside of the vesicles of individual cells, n = 10, three biological repeats.
Images acquired at 1024 × 1024 pixels, 20 μs pixel dwell time, laser power p200 gain 1 with false colors applied to different detection wavenumbers.
Scale bars: 10 μm. The Mann−Whitney test was used to compare ponatinib Raman intensity values, ***p < 0.0001.
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TKIs in the context of drug resistance, and here we
demonstrate the utility of SRS for label-free live cell imaging
of ponatinib in a model of ponatinib resistance.
1. Direct Imaging of Ponatinib at Biologically Relevant
Doses. In a recent study, spontaneous Raman imaging of the
intense fingerprint peak for the TKI neratinib (1386 cm−1)
allowed visualization of the drug following incubation at
nanomolar concentrations; however, this process requires
extended acquisition times (>30 min) using fixed cells.18 In
contrast, SRS microscopy enables up to video-rate imaging
speed, allowing live cell imaging. Hyperspectral SRS imaging,
which enables drug signals in the fingerprint region to be
extracted from the cellular signals, can also been used to follow
drug uptake into cells, although as yet this requires incubation
with micromolar concentrations of analyte and successful
imaging is dependent on 1000-fold enrichment of drugs into
lysosomes.9 The detection sensitivity is the major limitation of
intracellular imaging using SRS, with the micromolar
concentrations required to detect the molecule of interest
often not being physiologically relevant.9,10,13,14,26 To
determine whether we could use SRS to visualize ponatinib
at biologically active concentrations, we chose a concentration
of ponatinib (500 nM), which is close to the GI50 for human
KCL22Pon‑Res CML cells (SI, Table S2). The KCL22Pon‑Res cells
are a ponatinib-resistant cell line that was generated to
understand the drivers of resistance to ponatinib, as resistance
to ponatinib is a recognized clinical problem.27
Cells were treated with ponatinib (500 nM) for up to 48 h
prior to live cell imaging using a custom built SRS
microscope,28 where optimal setup resulted in acquisition
speeds of around 45 s per image. Images were acquired by
tuning the frequency difference between the pump and Stokes
lasers to be resonant with ponatinib (CC, 2221 cm−1, SI,
Figure S1) or intracellular proteins (CH3, 2940 cm
−1) to
provide cellular registration (Figure 3a,b). SRS images can
contain background signals from competing pump−probe
processes such as cross-phase modulation, transient absorp-
tion, and photothermal effects.29 When the signal-to-noise (S/
N) ratio of the SRS image of the drug is low, these background
artifacts can be subtracted to remove the unwanted processes
from the image. This can be achieved by changing the pump
wavelength by a few nanometers, which allows off-resonance
images to be acquired (at a difference of 10−30 cm−1 from the
on-resonance image). This difference image can be used to
distinguish true SRS signals from these artifacts (Figure 3c).30
When imaging with drug concentrations over 5 μM, the SRS
S/N is sufficiently high that subtraction is not necessary to
visualize ponatinib within the cell (see Figure 4a−c).
We analyzed the ponatinib Raman signal intensity (CC,
2221 cm−1) per cell in a population (n = 30) at each time point
and compared it to the values of DMSO treated control cells.
At each time point, there was a significant increase in Raman
signal compared to the control cells, indicating intracellular
accumulation of ponatinib (Figure 3d). Ponatinib puncta
formed in the cells from 6 h onward, with the largest number
of puncta in cells at 24 and 48 h (Figure 3d). This
demonstrates that SRS can be used to image live cells treated
with biologically relevant doses without the need for any
additional labeling or fixation. Many TKIs, including ponatinib
(Figure 1b), have strong Raman bands in the cellular
fingerprint region, and if one of these bands is sufficiently
strong, it can also be used for visualization, as has been
demonstrated for neratinib using spontaneous Raman.18
2. Determination of the Intracellular Localization of
Ponatinib. As ponatinib was concentrated in puncta in the
cytoplasm of the cells, it was important to consider which
cellular organelles these were, as the known target of ponatinib
is the cytoplasmic tyrosine kinase BCR-ABL. Knowing that
ponatinib is a weakly basic drug with a pKa value greater than
eight (pKa1 = 11.4, pKa2 = 8.0)
31 and hence is likely to be
protonated in acidic environments, we predicted that it would
accumulate in lysosomes or related acidic organelles in the cell.
A multimodal imaging approach was used to explore this. Cells
were simultaneously incubated with ponatinib (5 μM, 1 h) or
DMSO (vehicle control, 1 h) and Lysotracker Green (50 nM,
1 h), a cell-permeable fluorescent dye that stains acidic
organelles in live cells (Figure 4). Cells treated with DMSO
and stained with Lysotracker Green (Figure 4a) showed no
SRS signal at 2221 cm−1 (CC, ponatinib on-resonance),
indicating that the presence of the fluorophore does not give a
background SRS signal. In cells treated with ponatinib (Figure
4b,c), we could see colocalization between the SRS signal at
2221 cm−1 and the two-photon fluorescence (TPF) signal
shown in the merged images, with evidence of lower levels of
ponatinib in the cytoplasm, which did not colocalize with the
TPF signal. This demonstrates that the majority of ponatinib is
trapped within acidic organelles, most likely lysosomes, upon
protonation.
There is evidence that lysosomal trapping plays a role in
resistance to TKIs by sequestering them away from their
intracellular targets and thereby reducing target engagement.32
Using the TPF signal as a map, the ponatinib Raman intensity
was quantified in individual cells which showed an increased
ponatinib Raman signal in the resistant KCL22Pon‑Res cells
compared to parental KCL22 cells (Figure 4d,e). The mean
intensity of ponatinib was increased 1.9-fold in the
KCL22Pon‑Res cells compared to parental KCL22 cells (Figure
4d), and the maximum ponatinib signal had increased 2.5-fold
(Figure 4e). There was also a significant increase in the
ponatinib signal within the cytoplasm of the resistant cells
(Figure 4f).
To determine whether differences in lysosomal pH in the
cell lines could be contributing to the increased accumulation
of ponatinib in the KCL22Pon‑Res cells we used Lysosensor
Green, a dye whose fluorescence increases in acidic environ-
ments. There was no significant difference in Lysosensor Green
signal between the KCL22 and KCL22Pon‑Res cells (SI, Figure
S2a,b). However, we did see an increase in expression of the
lysosomal marker LAMP1 in the KCL22Pon‑Res cells (SI, Figure
S2c,d), indicative of increased lysosome number or lysosome
size. To establish whether lysosome biogenesis was differ-
entially regulated in the resistant cells at a transcriptional level,
we looked at nuclear transcription factor EB (TFEB), which is
a master regulator of lysosome biogenesis.33 There was a
significant increase in nuclear TFEB in the KCL22Pon‑Res cells
(SI, Figure S2e,f), indicative of increased lysosome biogenesis
in the resistant cells. This may reflect adaptation of the
resistant cells to allow them to respond to lysosomal stress.
3. Using SRS Imaging to Enhance Target Engagement
Studies. To investigate the importance of lysosomal trapping
on ponatinib−target engagement, we used chloroquine (CQ),
which is a nonspecific autophagy inhibitor that acts as a
lysosomotropic agent, increasing lysosomal pH and ultimately
preventing fusion of autophagosomes and lysosomes. It was
hypothesized that chloroquine treatment could be used to
prevent the increased lysosomal uptake of ponatinib. Pretreat-
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ment of KCL22 and KCL22Pon‑Res cells with CQ (20 μM, 2 h)
prior to treatment with ponatinib (5 μM, 1 h) significantly
reduced the ponatinib Raman signal in both cell lines (Figure
5b−e)
Quantification of ponatinib signal inside lysosomes demon-
strated that CQ treatment reduced mean ponatinib concen-
tration in the lysosomes 2.7- and 3.8-fold in the KCL22 and
KCL22Pon‑Res cells, respectively, compared to ponatinib alone
(Figure 5c,d). To determine whether the inhibition of
autophagy by CQ also contributed to the reduced lysosomal
accumulation of ponatinib, we used KCL22Pon‑Res CRISPR-
ATG7 knockout cells. ATG7 is a critical autophagy regulator
and KCL22Pon‑Res CRISPR-ATG7 cells have a defect in the
autophagy pathway. KCL22Pon‑Res CRISPR-ATG7 and
KCL22Pon‑Res CRISPR-Control cells were simultaneously
treated with ponatinib (5 μM, 1 h) and labeled with
Lysotracker (50 nM, 1 h) before live imaging using SRS (SI,
Figure S3). Quantification of relative concentrations of
ponatinib by Raman intensity in individual cells of both cell
lines demonstrated no significant difference between the cell
lines, demonstrating that autophagy does not play a role in
ponatinib accumulation in lysosomes. Therefore, reduction of
ponatinib concentration in lysosomes upon CQ combination
treatment was likely due to the lysosomotropic properties of
CQ, which decreased the ability of ponatinib to accumulate in
the lysosomes.
Having found that CQ treatment significantly decreased
lysosomal trapping of ponatinib in both cell lines, we looked at
how this affected BCR-ABL inhibition. BCR-ABL is a cytosolic
tyrosine kinase and phosphorylation of CRKL (Tyr207), a
direct BCR-ABL substrate, was used as a surrogate for BCR-
ABL activity. Pretreatment with CQ significantly increased p-
CRKL inhibition at the lowest 10 nM ponatinib dose (Figure
5e,f, and SI, Figure S4). Thus, the reduced lysosome trapping
of ponatinib in the CQ treated cells increased BCR-ABL
inhibition. Interestingly, we saw a greater inhibition of pCRKL
phosphorylation in the KCL22Pon‑Res cells than in KCL22
ponatinib sensitive cells which correlates with the increased
cytoplasmic levels of ponatinib in the resistant cells (Figure 4f)
and supports a BCR-ABL independent mechanism of
ponatinib resistance.26 This is in contrast to the BCR-ABL
dependent resistance to other basic TKIs such as imatinib that
are used in the treatment of CML, where CQ can increase
target engagement with combined CQ and TKI treatments
resulting in enhanced efficacy.9,34
■ CONCLUSIONS
This study demonstrates the benefits of SRS microscopy in
providing real-time measurements of drug distribution in live
cells with high sensitivity and resolution. Use of SRS
microscopy has allowed label-free imaging of the TKI
ponatinib at biologically relevant concentrations and provided
Figure 5. Multimodal imaging and quantitative assessment of the effect of chloroquine treatment on the vesicular uptake of ponatinib. KCL22 and
KCL22Pon‑Res cells were treated with (a) ponatinib (5 μM, 1 h), (b) chloroquine (20 μM, 2 h) followed by combination treatment of ponatinib (5
μM, 1 h) and chloroquine (20 μM, 1 h). Images shown (left to right) 2221 cm−1 (CC, ponatinib), overlay TPF image at 861 nm (Lysotracker
Green) merged with 2221 cm−1. (c,d) Mean ponatinib Raman intensity inside the vesicles of each individual cell quantified in (c) KCL22 and (d)
KCL22Pon‑Res cell line, n = 10 cells, three biological repeats. Images acquired at 1024 × 1024 pixels, 20 μs pixel dwell time with false colors applied
to different detection wavenumbers. Scale bars: 10 μm. (e,f) p-CRKL level quantification from Western blots where KCL22 and KCL22Pon‑Res cells
were treated with (left to right) either DMSO (0.0003%, v/v), ponatinib (10, 100, 500 nM, 1 h), or a combination of chloroquine (20 μM, 2 h)
pretreatment and ponatinib (10, 100, or 500 nM, 1 h). p-CRKL level was quantified against α-tubulin control and normalized to DMSO using
Image Lab Software. One-Way ANOVA (Tukey’s multiple comparisons test) was used to compare ponatinib (10 nM) alone vs CQ combination
treatment.
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insight into changes in uptake and sequestration of drug that
has occurred during the development of acquired drug
resistance. We show that tuning the pump wavelength to the
alkyne stretch within ponatinib allows SRS imaging within the
Raman cellular-silent region following treatment with nano-
molar concentrations of ponatinib. Although imaging within
the cell silent region increases sensitivity, the recent
demonstration that Raman imaging of drugs may also be
achieved in the fingerprint region when the drug is enriched in
subcellular locales, opens up the possibility of label-free
imaging for a wider number of drug candidates and
metabolites.9,16 Furthermore, the addition of small alkyne
tags or deuterium substitutions to enable SRS imaging of drugs
and small molecules in the cellular-silent region with increased
sensitivity, further extends the potential for this technology to
provide read-outs of drug kinetics and mechanism of
action.10,17,35,36 Combined with DFT calculations and LC-
MS measurements, SRS imaging could be transformative to the
drug discovery pipeline by providing important information on
drug localization, mechanism of action, and target engagement.
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